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Heme is an essential cofactor in most organisms, this includes bacteria and mammals. 
The coproporphyrin-dependent heme biosynthesis pathway is specific to Gram 
positive bacteria and was only discovered in 2015. Before this discovery Gram positive 
bacteria were assumed to synthesise heme using the same heme synthesis pathway 
as mammals. As a result, the enzymes within this pathway have not been fully 
characterised and provide novel targets for antibiotics. 
 
Experiments were completed to investigate the protein-protein interactions between 
HemH and HemQ, two consecutive enzymes in the pathway as they are covalently 
linked in P. acnes. This used SEC and showed that truncations for the P. acnes HemH-
Q protein (HemHL and HemQS) interacted 1:1 whereas other non-covalently linked 
HemH and HemQ proteins didn’t have observable protein-protein interactions. 
 
Kinetic investigation of the wildtype B. subtilis and S. aureus HemH proteins with their 
endogenous substrate (coproporphyrin) was completed as previous kinetic analysis of 
B. subtilis HemH used analogues of protoporphyrin IX in the kinetic assays. A 
combination of spectroscopic techniques were utilised and they show that the two 
proteins are very active and behave in a broadly similar way to each other. Stopped 
flow fluorescence spectroscopy proved a useful tool for in depth kinetic investigation 
into the enzymatic mechanism of coproporphyrin ferrochelatase. Rates constants for 
enzyme/porphyrin isomerisation, metal chelation and binding constants for substrate 
binding were estimated using this technique. 
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Finally, functionally important B. subtilis HemH active site mutants (K87A, H88A, 
E264A/Q) were characterised using similar techniques described for wildtype 
characterisation. K87A/H88A and E264A/Q are on the non-conserved and conserved 
active site face, respectively. This shows that whilst K87A, E264A/Q are relatively 
inactive they are capable of binding coproporphyrin and activity is diminished after 
binding. H88A has activity comparable to wildtype with weakened coproporphyrin 
binding and better at iron binding and chelation. This research could provide details 
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ABC Ammonium bicarbonate 
ACN Acetonitrile 
AFM                                   Atomic force microscopy 
AhbA/B/C/D Alternative heme biosynthesis A/B/C/D 
ALA    δ-aminolevulinic acid 
ALAS δ-aminolevulinic acid synthase 
APS              Ammonium persulphate 
AUC                                   Analytical ultracentrifugation 
B. megaterium           Bacillus megaterium 
B. subtilis   Bacillus subtilis 
bFC             Bacillus subtilis ferrochelatase 
BLAST   Basic local alignment search tool 
BN-PAGE   Blue native polyacrylamide gel electrophoresis 
CD              Circular dichroism spectroscopy 
CgDC    Coproporphyrinogen III decarboxylase 
CgDH    Coproporphyrinogen III dehydrogenase 
CgOX    Coproporphyrinogen III oxidase 
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CHAPS                       3-[(cholamidopropyl)dimethylammonio]-1-   
                                           propanesulfonate hydrate  
 
ChDC              Coproheme decarboxylase 
CoA              Coenzyme A 
Copro    Coproporphyrin III 
Copro’gen   Coproporphyrinogen III 
Coproheme   Fe-coproporphyrin III 
CpFC    Coproporphyrin ferrochelatase 
CPIII    Coproporphyrin III 
CPO              Coproporphyrinogen oxidase 
CV              Column volumes 
D. vulgaris Desulfovibrio vulgaris 
DDSH 12, 18-didecarboxysirohydrochlorin 
DIX Deuteroporphyrin IX   
EDTA Ethylenediaminetetraacetic acid 
FAD                       Flavin adenine dinucleotide 
FC                                 Ferrochelatase 
FI             Fluorescence intensity 
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FMN             Flavin mononucleotide 
GluT             Glutamyl-tRNAGlu 
GluTR             Glutamyl-tRNA reductase 
GluTS              Glutamyl-tRNA synthetase 
GSA              Glutamate-1-semialdehyde  
GSAM             Glutamate-1-semialdehyde aminomutase 
H. sapiens   Homo sapiens 
HDX-MS   Hydrogen-deuterium exchange mass spectrometry 
hFC                                 Homo sapiens ferrochelatase 
HMB              1-hydroxymethylbilane 
HMBS              Hydroxymethylbilane synthase 
IAA              Iodoacetamide 
IEX              Ion exchange chromatography 
IMAC    Immobilised metal affinity chromatography 
IPTG    Isopropyl β-D-1-thiogalactopyranoside 
KLD              Kinase, ligase, Dpn1 
L. monocytogenes  Listeria monocytogenes 
 
LC              Liquid chromatography 
M. barkeri                       Methosarcina barkeri  
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MST                                    Microscale thermophoresis 
M. tuberculosis  Mycobacterium tuberculosis  
MPIX              Mesoporphyrin IX 
NAD              Nicotinamide adenine dinucleotide 
NADP              Nicotinamide adenine dinucleotide phosphate 
NirDL/G/H/J   Nitrate reductase DL/G/H/J  
N-MeMP   N-methyl mesoporphyrin  
OEP              Octylethylporphyrin 
P. acnes             Propionibacterium acnes 
PAA              Peracetic acid 
PBG                        Porphobilinogen 
PBGD              Porphobilinogen deaminase 
PBGS              Porphobilinogen synthase 
PBS    Phosphate buffered saline 
PC2    Precorrin 2 
PCDH              Precorrin dehydrogenase 
PCR                        Polymerase chain reaction 
 
PgDH1/2   Porphobilinogen dehydrogenase 1/2      
PgOX                                 Porphobilinogen oxidase 
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PpFC                       Protoporphyrin ferrochelatase  
PPO              Protoporphyrinogen oxidase 
Proto              Protoporphyrin IX 
Proto’gen   Protoporphyrinogen  
R. spheroides  Rhodobacter spheroides 
RR              Resonance Raman 
S. aureus             Staphyloccocus aureus 
S. cerevisiae   Saccharomyces cerevisae 
SAM                        S-adenosyl methionine 
SAXS                                  Small- angle X-ray scattering 
SDS              Sodium dodecyl sulphate 
SDS-PAGE   Sodium dodecyl sulphate polyacrylamide gel                
                                            electrophoresis 
SEC    Size exclusion chromatography 
SEC-MALS                         Size exclusion chromatography – multiple angle light 
                                            scattering 
SH    Siroheme 
SiHC              Sirohydrochlorin 
SPR                                    Surface plasmon resonance 
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SUMT             SAM-dependent uroporphyrinogen methyltransferase     
TCEP                                 Tris(2-carboxyethyl) phosphine hydrochloride 
TEMED             N, N, N′,N′-tetramethylethylene-diamine 
Tm              Thermal melting point 
Uro’gen    Uroporphyrinogen III 
UROD              Uroporphyrinogen III decarboxylase 
UROS               Uroporphyrinogen III synthase 

































1.1 Tetrapyrroles and heme 
Tetrapyrroles are chains of four covalently linked pyrroles. They can be linear or cyclic 
such as hydroxymethylbilane (HMB) and uroporphyrinogen III (uro’gen), respectively. 
A specific class of cyclic tetrapyrroles are called porphyrins. Porphyrins are derived 
from the parent compound porphine (figure 1.1). Substitution of the hydrogen at 
positions 1-8 give rise to the different porphyrin compounds. Examples include 
coproporphyrin III (Copro or CPIII) which contains 4 methyl and 4 propionyl groups at 
positions 1-8 and protoporphyrin IX (Proto or PPIX) containing 4 methyl, 2 vinyl and 2 
propionyl groups at positions 1-8  (Falk, 1964). 
 
Tetrapyrrole synthesis diverges at the last common precursor, uroporphyrinogen III.  
Uroporphyrinogen can be converted into a number of different products through a 
series of different enzymatic steps. These tetrapyrrole products include heme, 





Figure 1.1 - Porphyrin structures 
The parent porphyrin compound porphine contains hydrogens at potential substitution 
positions 1-8 (red). Coproporphyrin III and protoporphyrin IX are examples of porphyrins where 
positions 1-8 have been substituted with methyl, vinyl and propionyl groups. 
 
Heme is a prosthetic group or cofactor of proteins involved in a wide range of biological 
processes; this includes gene regulation, cell signalling and oxygen transport. Heme 
is one of the most important tetrapyrroles and as a result it is found in a variety of 
proteins, the most commonly known examples are hemoglobin, myoglobin, 
cytochrome P450, peroxidases and catalases (Munro et al., 2009, Falk, 1964). 
  
1.2 Heme biosynthesis 
 Heme biosynthesis occurs through three routes: the protoporphyrin-dependent 
(canonical or classic) route taken by Gram negative bacteria and eukaryotes, the 
coproporphyrin-dependent (non-canonical or intermediate) pathway utilised by Gram 
positive bacteria and the siroheme-dependent (alternative) pathway used by sulphate 
reducing bacteria and archaea (figure 1.2). The coproporphyrin-dependent pathway is 
the most recently discovered pathway and so investigating the enzymes in this 
pathway could lead to the production of novel antibiotics specifically targeted against 
Gram positive bacteria (Layer et al., 2010, Storbeck et al., 2010, Dailey et al., 2015). 
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Figure 1.2 - Simple scheme of the three different heme biosynthetic pathways 
The pathway from δ-aminolevulinic acid to uroporphyrinogen III is conserved in the three heme 
biosynthetic pathways. After the formation of uroporphyrinogen, the siroheme-dependent 
pathway diverts away from the conserved pathway and forms heme using different enzymes 
and substrates. Uroporphyrinogen is decarboxylated to form coproporphyrinogen and the 
protoporphyrin-dependent and coproporphyrin-dependent pathways diverge at 
coproporphyrinogen and synthesise heme using different enzymatic steps. Abbreviations: 
ALA (δ-aminolevulinic acid), URO’GEN (uroporphyrinogen III), COPRO’GEN 
(coproporphyrinogen III). 
 
1.2.1 Conserved pathway  
1.2.1.1 Formation of δ-aminolevulinic acid (ALA) 
 
Figure 1.3 – Overall heme biosynthesis pathway 
The green box highlights the current section of interest, the formation of ALA. ALA is through 
two pathways: the Shemin pathway and the C5 pathway. The Shemin pathway utilises glycine 
and the C5 pathway uses glutamate. 
 
All natural tetrapyrroles are synthesised from a common precursor δ-aminolevulinic 
acid (ALA) and this is formed in two different unrelated ways, the Shemin (C4) pathway 
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and the C5 pathway (figure 1.3). The route taken to form ALA is dependent on the 
organism (Layer et al., 2010). Mammals, fungi and α-proteobacteria produce ALA 
through the condensation of succinyl-CoA (coenzyme A) and glycine, catalysed by the 
homodimeric, pyridoxal phosphate-dependent enzyme δ-aminolevulinic acid synthase 
(ALAS, HemAC4). This is the Shemin pathway (Choi et al., 2004, Layer et al., 2010).  
The Shemin pathway was proposed in 1952, and the involvement of glycine and 
succinyl-CoA in heme biosynthesis was discovered in 1945 and 1952, respectively. 
These results identified δ-aminolevulinic acid as a potential precursor for heme 
synthesis (Shemin and Kumin, 1952, Shemin and Rittenberg, 1945)(figure 1.4).  
 
Figure 1.4- Enzyme mechanism of ALAS 
The mechanism starts with the formation of a glycine-PLP imine which becomes deprotonated 
(1). This is followed by a Claisen-like condensation reaction with succinyl CoA (2) and 
decarboxylation (3). The molecule undergoes tautomerization (4) and transamination to give 
ALA(5). 
 
The C5 pathway is found in plants, archaea and most bacteria (Layer et al., 2010). It 
was discovered in the 1970s after it was shown that glycine was not used in heme 
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biosynthesis in chlorophyll-synthesising tissues (figure 1.5).  Further studies indicated 
that glutamyl-tRNA provided the carbon and nitrogen source needed for heme 
biosynthesis in these tissues (Layer et al., 2010, Huang et al., 1984). The C5 pathway 
begins with glutamyl-tRNAGlu (GluT) which is produced via glutamyl-tRNA synthetase 
(GluTS) (Heinemann et al., 2008). Glutamyl-tRNA is reduced by glutamyl-tRNA 
reductase (GluTR, HemAC5) to form the reaction intermediate glutamate-1-
semialdehyde (GSA) (Kannangara and Gough, 1978, Beale et al., 1975). Glutamate-
1-semialdehyde is quickly converted to δ-aminolevulinic acid by glutamate-1-
semialdehyde aminomutase (GSAM, HemL) in a pyridoxal phosphate-dependent 
transamination reaction (Layer et al., 2010, Heinemann et al., 2008). After the 
formation of δ-aminolevulinic acid, the subsequent steps in heme biosynthesis are 
conserved across the majority of heme-synthesising organisms until the synthesis of 
the first cyclic intermediate uroporphyrinogen III (Heinemann et al., 2008).  
 
Figure 1.5 - Formation of ALA (δ-aminolevulinic acid) 
Two different pathways to form the tetrapyrrole intermediate δ-aminolevulinic acid (red), the 
Shemin pathway (orange) and the C5 pathway (blue) Abbreviations: ALAS (δ-aminolevulinic 
acid synthase), ALA (δ-aminolevulinic acid), GSAM (glutamate-1-semialdehyde 




1.2.1.2 Formation of uroporphyrinogen III (Uro’gen) 
 
 
Figure 1.6– Overall heme biosynthesis pathway 
The green box highlights the current section of interest, the conserved pathway, This pathway 
is conserved for all tetrapyrroles synthesis pathways and the main branch starts after the 
formation of ALA and ends in the formation of URO’GEN. In the conserved pathway δ-
aminolevulinic acid is converted to uroporphyrinogen through a series of conserved enzymatic 
steps. Two molecules of δ-aminolevulinic acid are asymmetrically condensed to produce 
porphobilinogen and four molecules of porphobilinogen are covalently linked to form 
hydroxymethylbilane. Hydroxymethylbilane undergoes isomerisation and circularisation to 
produce uroporphyrinogen. Abbreviations: ALA (δ-aminolevulinic acid), PBGS 
(porphobilinogen synthase), PBG (porphobilinogen) PBGD (porphobilinogen deaminase), 




After the formation of ALA the main branch of the conserved pathway begins, this is 
common to all tetrapyrrole biosynthesis pathways and ends after the formation of 
uroporphyrinogen III (figure 1.6). To start, two δ-aminolevulinic acid molecules are 
asymmetrically condensed to produce porphobilinogen, in a reaction catalysed by 
porphobilinogen synthase (HemB, PBGS figure 1.7) (Bevan et al., 1980). The activity 
of porphobilinogen synthase is controlled by an allosteric mechanism. Different 
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multimeric states of porphobilinogen synthase indicate whether the enzyme is active 
or inactive. In an octameric state porphobilinogen synthase is active, the octamer 
dissociates to form dimers, the N-terminal arm domains of the dimers re-orientate so 
that the inactive hexamer can assemble. There are allosteric sites on the hexamer and 
octamer that stabilise each of the conformations (Jaffe and Lawrence, 2012). In human 
porphobilinogen synthase, zinc is required for catalysis and the magnesium binds 
allosterically. Of the porphobilinogen synthase sequences available 50% are predicted 
to require zinc for catalysis and 90% bind magnesium allosterically (Bollivar et al., 
2004, Layer et al., 2010, Bevan et al., 1980).  
 
Figure 1.7- PBGS enzyme mechanism 
The enzymatic mechanism for PBGS is shown. Firstly, two ALA molecules are bound to the 
PBGS by two imine linkages through lysine residues (1). There is nucleophilic addition of 
amine group from one ALA molecule to the iminium ion of the other (2). The molecule is 
cyclised (3) and detaches from a PBGS lysine residue (4). The second lysine residue is 
eliminated (5) and tautomerization of the porphobilinogen molecule occurs (6) 
 
The next conserved step in heme biosynthesis includes the covalent linkage of four 
molecules of porphobilinogen through the action of porphobilinogen deaminase 
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(PBGD, HemC), also known as hydroxymethylbilane synthase (HMBS). 
Polymerisation of porphobilinogen forms the linear molecule 1-hydroxymethylbilane 
(HMB or pre-uroporphyrinogen). Porphobilinogen deaminase contains a 
dipyrromethane cofactor (two linked porphobilinogen molecules), which acts a 
platform for the incoming porphobilinogen molecules; it keeps the substrate in the 
active site and allows the construction of hydroxymethylbilane (Jordan and Warren, 
1987, Warren and Jordan, 1988, Hart et al., 1987) (figure 1.8).  Ring A of the 
tetrapyrrole ring is formed first followed by rings B, C and D before the product is 
released (Jordan and Warren, 1987).  
 
Figure 1.8- Porphobilinogen deaminase (PBGD) enzyme mechanism 
The PBGD mechanism involves sequential electrophilic aromatic substitution. 
Porphobilinogen loses ammonia forming a cation (1) and the cation is conjugated to the 
dipyrromethane cofactor in PBGD (2). Another porphobilinogen cation is added to the chain 
to give a tetrapyrrole and this is repeated twice more yielding a hexapyrrole (3). To detach the 
molecule from the dipyrromethene cofactor the second pyrrole is protonated (4) and the 




Following the release of hydroxymethylbilane from porphobilinogen deaminase, 
uroporphyrinogen III synthase (UROS, HemD) cyclises hydroxymethylbilane to 
uroporphyrinogen III.  Uroporphyrinogen III synthase converts hydroxymethylbilane to 
uroporphyrinogen III in two stages; it circularises hydroxymethylbilane and catalyses 
ring closure by bonding the carbons either side of ring D (C16 and C20) forming a 
spirocyclic pyrrolenine intermediate. Then cleavage of the C15-16 bond and formation 
of a C15-C19 bond causes an intermolecular rearrangement in D ring allowing the D 
ring to flip and produce the type III porphyrinogen, uroporphyrinogen III (figure 1.9) 
(Crockett et al., 1991, Mathews et al., 2001). This conserved pathway is shown in 
figure 1.5. Without the intervention of uroporphyrinogen III synthase, 1-
hydroxymethylbilane would spontaneously cyclise and form a non-physiological 
compound uroporphyrinogen I which can oxidise to uroporphyrin I, a toxic molecule 




Figure 1.9 – UROS enzymatic mechanism 
The enzymatic mechanism for UROS is shown. HMB must rearrange (0) before it is protonated 
forming a cation (1), this generates a spirocyclic intermediate. Ring is reopened to form an 
acyclic cation (2), the ring is then closed to using the opposite side of the pyrrole ring giving 
uroporphyrinogen III (3) 
 
Uroporphyrinogen III is the first cyclic heme precursor and is common to all 
tetrapyrroles.  Uroporphyrinogen III is the last universal precursor for all tetrapyrroles. 
After this point there are specialised enzymatic pathways that lead to formation of 
specific molecules such as heme, chlorophyll, coenzyme F430, siroheme and 
cobalamin (Tanaka and Tanaka, 2007).  
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Figure 1.10 - Enzymatic and non-enzymatic pathways involving uroporphyrinogen III 
The enzymatic pathway shows circularisation and isomerisation of HMB and to 
uroporphyrinogen III using the UROS enzyme. In the non-enzymatic pathway HMB is still 
circularised but isomerisation of ring D doesn’t occur, this forms uroporphyrinogen I and 
uroporphyrinogen I is oxidised to produce uroporphyrin I, a toxic molecule. Abbreviations: 
HMB (1-hydroxymethylbilane), UROS (uroporphyrinogen III synthase). 
 
1.2.2 Siroheme-dependent pathway the route to heme via siroheme 
The siroheme-dependent biosynthesis pathway is the first of the three pathways to 
separate from the others, it was observed in heme-synthesising archaea and sulfate-
reducing bacteria such as Desulfovibrio vulgaris (D. vulgaris) and Methanosarcina 
barkeri (M. barkeri). This pathway follows the conserved heme biosynthesis pathway 
until the formation of uroporphyrinogen III.  At uroporphyrinogen III the siroheme-
dependent pathway deviates from the main pathway (figure 1.11).  
 
The siroheme-dependent pathway (figure 1.12) was studied using labelled methionine 
experiments, this revealed potential pathway intermediates (Ishida et al., 1998, 
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Bollivar et al., 1995). These experiments showed that methyl groups donated by S-
adenosyl methionine (SAM) can be transferred onto uroporphyrinogen III at positions 
2 and 7 to produce precorrin-2 (PC2). Other potential pathway intermediates that 
containing the methyl groups donated by SAM were sirohydrochlorin (SiHC), 12, 18-
didecarboxysirohydrochlorin (DDSH), coproporphyrin III and protoporphyrin IX. Using 
these intermediates, the sequence of enzymatic reactions in the siroheme-dependent 
heme biosynthesis pathway was predicted (Ishida et al., 1998).   
 
Figure 1.11 – Overall heme biosynthesis 
The green box highlights the current section of interest, the siroheme dependent pathway. 
Uro’gen is the last common precursor for tetrapyrrole biosynthesis and ends in the formation 
of heme. The siroheme dependent pathway shares a pathway intermediate with the 
coproporphyrin-dependent pathway, coproheme 
 
The complete siroheme-dependent biosynthetic route was established when 
screening for heme biosynthetic enzymes in archaea and sulfate-reducing bacteria. 
Archaea and sulfate-reducing bacteria contained the heme biosynthetic enzymes 
required to produce uroporphyrinogen but no identifiable enzymes in the 
protoporphyrin-dependent pathway. These organisms cannot synthesise heme d but 
do contain genes similar to those encoding enzymes found in the heme d biosynthetic 
pathway. The function of these putative heme biosynthetic enzymes were studied 
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using potential intermediary molecules. From these experiments the siroheme-
dependent pathway was determined (Panek and O'Brian, 2002, Raux et al., 2003).  
 
Figure 1.12– Siroheme-dependent heme biosynthesis pathway 
Uroporphyrinogen III is converted to precorrin-2 through the methylation of rings A and B on 
uroporphyrinogen, this is catalysed by a SAM-dependent methyltransferase. Precorrin-2 is 
oxidised to form sirohydrochlorin and iron metalation of sirohydrochlorin forms siroheme.  
Siroheme is decarboxylated by AhbA/B to form 12, 18-didecarboxysiroheme after, 
deacetylation of 12,18-didecarboxysiroheme forms coproheme. Finally, oxidative 
decarboxylation of coproheme by AhbD forms heme. Abbreviations: URO’GEN 
(uroporphyrinogen III), SUMT (SAM (S-adenosyl methionine)-dependent uroporphyrinogen 
methyltransferase), PC2 (precorrin-2), PCDH (precorrin-2 dehydrogenase), SiHC 
(sirohydrochlorin), FC (ferrochelatase), SH (siroheme), AhbA/B (alternative heme 
biosynthesis A and B), DDSH (12, 18-didecarboxysiroheme), AhbC (alternative heme 
biosynthesis C) and AhbD (alternative heme biosynthesis D). 
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1.2.2.1 Formation of heme via siroheme 
Siroheme is an iron-containing isobacteriochlorin that is incorporated into sulphite and 
nitrite reductases as a prosthetic group (Bali et al., 2014). Three enzymatic steps are 
required to convert uroporphyrinogen into siroheme (SH). The enzymes required are 
dependent on the organism. In some cases, only one enzyme is required to catalyse 
all three enzymatic steps, however in others three separate enzymes are required, 
one for each step. Conversion of uroporphyrinogen into siroheme is shown in figure 
1.12 (Bali et al., 2014, Raux et al., 1999, Raux et al., 2003). 
 
The formation of heme through the siroheme-dependent heme biosynthetic pathway 
begins with the methylation of uroporphyrinogen rings A and B. The addition of the 
methyl groups onto uroporphyrinogen III is catalysed by a SAM-dependent 
uroporphyrinogen methyltransferase (SUMT), this produces precorrin-2 (Bali et al., 
2014, Kuhner et al., 2014). Precorrin-2 is a precursor for siroheme, cobalamin, heme 
d1 and cofactor F430.  There are two routes for cobalamin synthesis from precorrin-2, 
in an aerobic environment precorrin-2 can be converted to precorrin-3 by Cob1 and 
through several more enzymatic steps cobalamin is produced (Bali et al., 2014, Raux 
et al., 2003). In an anaerobic environment precorrin-2 is oxidised to sirohydrochlorin 
(SiHC) using a precorrin-2 dehydrogenase (PCDH), the next step towards the 
formation of SH. In cobalamin synthesis, SiHC can be chelated with cobalt using the 
CbiK and CbiX enzymes, diverting the pathways towards cobalamin production rather 
than siroheme formation (Warren et al., 2002). To direct the pathway towards 
siroheme and ultimately heme synthesis, iron is inserted into sirohydrochlorin by a 
ferrochelatase (FC) forming siroheme.  
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There are three enzyme catalysed reactions in this part of the siroheme pathway, a 
SAM-dependent uroporphyrinogen methyltransferase, precorrin-2 dehydrogenase 
and ferrochelatase. In Bacillus megaterium (B. megaterium) three separate enzymes 
are required: SirA, the SAM-dependent uroporphyrinogen methyltransferase, SirC, the 
precorrin-2 dehydrogenase and SirB the ferrochelatase whereas Saccharomyces 
cerevisiae (S. cerevisiae) only requires two enzymes Met1p and Met8p; Met8p 
contains both dehydrogenase and chelatase activity (Raux et al., 2003, Raux et al., 
1999). In E. coli, one enzyme, CysG, catalyses all three steps, it contains two subunits 
CysGA and CysGB, CysGA has methyltransferase activity and CysGB has 
dehydrogenase and ferrochelatase activity (Warren et al., 1994).  
 
1.2.2.2 Formation of heme from siroheme 
After the formation of siroheme, there are three more enzymatic steps to form heme. 
The first is the decarboxylation of siroheme creating the intermediate 12,18-
didecarboxysiroheme (DDSH), the acetate side chains on rings C and D of siroheme 
are converted to methyl groups, the enzymes AhbA and AhbB (alternative heme 
biosynthesis) catalyse these reactions.  Acetyl groups on rings A and B of 12,18-
didecarboxysiroheme are removed by AhbC, forming Fe-coproporphyrin III 
(coproheme) (Bali et al., 2014, Kuhner et al., 2014). Coproheme is also an 
intermediate of the coproporphyrin-dependent heme biosynthesis pathway; this 
pathway is discussed later (section 1.4). The final step in the alternative heme 
biosynthesis pathway is the oxidative decarboxylation of the propionate side chains 
on rings A and B.  AhbD catalyses the conversion of coproheme to protoheme (heme) 
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(Bali et al., 2014, Kuhner et al., 2014). In denitrifying bacteria the homologous 
enzymes are NirDL, NirG, NirH and NirJ these nitrite reductase enzymes are involved 
in the biosynthesis of heme d (Kuhner et al., 2014). NirD and NirL are often fused 
together and in combination with NirG and NirH they convert siroheme to 12,18-
didecarboxysiroheme (as with AhbA and AhbB). If NirD or NirH is only present mono 
decarboxylation occurs and when NirDL or NirG and NirH are present there is a 
mixture of mono decarboxylation or fully decarboxylated product (Bali et al., 2011). 
NirJ is responsible for removing the propionate side chains on rings A and B of 12,18-
didecarboxysiroheme producing dihydro-heme d1 (Dailey et al., 2017, Bali et al., 2011)   
 
1.2.3 The protoporphyrin-dependent pathway of heme biosynthesis 
found in Gram negative bacteria and eukaryotes 
The protoporphyrin-dependent pathway of heme biosynthesis from uroporphyrinogen 
to heme (protoheme) includes four enzymatic steps (figure 1.13).  These involve side 
chain modification, oxidation and the insertion of iron. The first step is the sequential 
decarboxylation (starting from ring D) of the acetyl groups on each of the four rings to 
form coproporphyrinogen III (copro’gen)(Jackson et al., 1976). This decarboxylation is 





Figure 1.13 – Overall heme biosynthesis 
The green box highlights the current section of interest, the protoporphyrin-dependent 
pathway. Uro’gen is the last common precursor for tetrapyrrole biosynthesis and this pathway 
ends in the formation of heme. 
 
Human uroporphyrinogen III decarboxylase was crystallised in 1997 and a mechanism 
of action was proposed (Phillips et al., 1997, Whitby et al., 1998). UROD side chains 
D82 and Y159 are assumed to be protonated; uroporphyrinogen binds so that ring D 
is in hydrogen bonding distance to D82. Y159 protonates the pyrrole group causing 
an electronic rearrangement. The electronic rearrangement causes a release of 
carbon dioxide and the formation of a methylene intermediate. The methylene 
intermediate is protonated by D82 and Y159 removes a proton from the pyrrole ring to 
restore the ring to its original configuration (Martins et al., 2001).  
 
Coproporphyrinogen III oxidase (CPO) can decarboxylate coproporphyrinogen to 
protoporphyrinogen IX. There are two types of CPO: oxygen-dependent (HemF also 
known as CgDC (coproporphyrinogen decarboxylase)) and oxygen-independent 
(HemN also known as CgDH (coproporphyrinogen dehydrogenase)) (Layer et al., 
2010, Breckau et al., 2003). They both decarboxylate the propionate group on rings A 
and B to vinyl groups using a terminal electron acceptor. However they are structurally 
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unrelated and do not use the same mechanism (see figure 1.14 for CgDH mechanism) 
(Seehra et al., 1983). 
 
Figure 1.14 – Radical SAM mechanism of CgDH 
An electron is transferred from the 4Fe-4S cluster to the sulphonium of SAM and this causes 
cleavage of SAM to methionine and a 5’-deoxyadenosyl radical (1,2). The radical abstracts 
hydrogen from the β-C in the propionate group creating a radical (3). Carbon dioxide is 
eliminated and electron transfer to the electron acceptor results in the formation of a vinyl 
group (4), this is repeated three more times to give protoporphyrinogen (5). 
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Coproporphyrinogen decarboxylase uses oxygen as a terminal electron acceptor and 
is mainly found in eukaryotes but is present in some species of bacteria (Layer et al., 
2002, Troup et al., 1994). It sequentially decarboxylates ring A of coproporphyrinogen 
to form harderoporphyrinogen and then decarboxylates ring B to form 
protoporphyrinogen (Breckau et al., 2003). Coproporphyrinogen dehydrogenase is 
mainly found in microbes and requires an alternative terminal electron acceptor.  It is 
a radical SAM (S-adenosyl methionine) enzyme that contains a 4Fe-4S cluster; this is 
coordinated by a three cysteine motif (CxxxCxxC) and a nearby SAM molecule. The 
mechanism of action for this enzyme involves the transfer of an electron from the iron 
cluster to SAM resulting in the cleavage of SAM to methionine and a 5’-deoxyadenosyl 
radical. This radical reacts with the propionate side chains of rings A and B on 
coproporphyrinogen converting them to vinyl groups producing protoporphyrinogen 
(Layer et al. 2003). Conversion of coproporphyrinogen to protoporphyrinogen requires 
NAD+ or NADP+, magnesium and SAM (S-adenosyl methionine) (Tait, 1972, Troup 
et al., 1994, Layer et al., 2002). In some cases both CPOs can be found in one 
organism, for example in Rhodobacter spheroides (R. spheroides), an organism which 
is very versatile, it can synthesise several different tetrapyrrole molecules (heme, 
chlorophyll and vitamin B12) and can survive in aerobic and anaerobic conditions 
(Seehra et al., 1983, Aizawa, 2014).  
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Figure 1.15 - Formation of protoheme through the canonical pathway 
Protoheme is synthesised from uroporphyrinogen in a four-step reaction, uroporphyrinogen is 
decarboxylated to produce coproporphyrinogen which is subsequently decarboxylated again 
to produce protoporphyrinogen. Protoporphyrinogen is oxidised to protoporphyrin IX and 
ferrous iron is inserted into protoporphyrin IX, producing the metalated porphyrin, protoheme. 
Abbreviations: URO’GEN (uroporphyrinogen III), UROD (uroporphyrinogen decarboxylase) 
CgDC (coproporphyrinogen decarboxylase), CgDH (coproporphyrinogen dehydrogenase), 
COPRO’GEN (coproporphyrinogen III), PgDH1/2 (protoporphyrinogen dehydrogenase 1 and 
2), PgOX (protoporphyrinogen oxidase), PpFC (protoporphyrin ferrochelatase), PROTO’GEN 
(protoporphyrinogen IX), PROTO (protoporphyrin IX). 
 
Protoporphyrinogen IX oxidase, catalyses the six-electron oxidation needed to convert 
protoporphyrinogen to protoporphyrin IX. There are oxygen-dependent (also known 
as HemY or PgOX (protoporphyrinogen oxidase)) and oxygen-independent (also 
known as HemG or PgDH1 (protoporphyrinogen dehydrogenase)) variants of 
protoporphyrinogen IX oxidase.  
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The oxygen-dependent protoporphyrinogen IX oxidase (HemY) is present in 
eukaryotes and bacteria. Initially, these were thought to be found as both soluble and 
membrane or membrane bound proteins, but this was before the discovery of the 
coproporphyrin-dependent pathway. The soluble protoporphyrinogen oxidases 
present in Actinobacteria and Firmicutes are in fact coproporphyrinogen oxidases 
(CgOX) and are capable of oxidising coproporphyrinogen to coproporphyrin and 
protoporphyrinogen to protoporphyrin. In humans protoporphyrinogen oxidase is 
located  in the inner mitochondrial membrane and membrane bound 
protoporphyrinogen IX oxidases  are found in  bacterial species such as Myxococcus 
and Aquifex (Boynton et al., 2011, Dailey et al., 2017, Dailey et al., 2015, Lobo et al., 
2015, Dailey and Dailey, 1996). The oxygen-dependent enzyme uses molecular 
oxygen as the terminal electron acceptor and frequently contains, as a cofactor, flavin 
adenine dinucleotide (FAD) or flavin mononucleotide (FMN). Flavin molecules are 
frequently involved in redox reactions such the conversion of protoporphyrinogen to 
protoporphyrin (Fagan et al., 2010). 
 
The oxygen-independent protoporphyrinogen IX oxidase or protoporphyrinogen 
dehydrogenase 1 (PgDH1) requires alternative electron acceptors to oxygen, such as 
fumarate, nitrate and menaquinone (Boynton et al., 2009, Jacobs and Jacobs, 1976). 
Protoporphyrinogen dehydrogenase 1 uses menaquinone and provides a route for 
heme biosynthesis in anaerobic Gram negative bacteria (Boynton et al., 2009). 
Sequence analysis revealed that protoporphyrinogen dehydrogenase 1 is part of 




Another protoporphyrinogen IX oxidase is HemJ (also known as PgDH2 
(protoporphyrinogen dehydrogenase 2); HemJ was discovered as it clustered with 
uroporphyrinogen decarboxylase and ferrochelatase, two enzymes involved in heme 
biosynthesis. Protoporphyrinogen dehydrogenase 2 is not homologous to either 
protoporphyrinogen dehydrogenase 1 or protoporphyrinogen oxidase and is 
suggested to contain no cofactors implying that it may use molecular oxygen as a 
terminal electron acceptor. Protoporphyrinogen dehydrogenase 2 is found in the 
majority of eubacteria, where there is no confirmed protoporphyrinogen oxidase, as 
well as cyanobacteria and all proteobacterial groups except δ-proteobacteria (Boynton 
et al., 2011).  
 
The final step in the canonical pathway is the insertion of ferrous iron into 
protoporphyrin IX.  This is catalysed by the enzyme protoporphyrin ferrochelatase 
(PpFC). When protoporphyrin ferrochelatase binds protoporphyrin IX, the ring 
becomes distorted allowing insertion of iron. Ferrochelatases are one of the most 
studied enzymes in the heme biosynthetic pathway and they are discussed in detail in 
section 1.3 (figure 1.15) (Dailey and Dailey, 2003).  
 
1.2.4 Coproporphyrin-dependent heme biosynthetic pathway 
When compared to the siroheme-dependent pathway, the protoporphyrin-dependent 
and coproporphyrin-dependent pathways share one more common precursor, 
coproporphyrinogen III. This is formed by the sequential decarboxylation of the acetyl 
groups on each of the four pyrrole rings.  The decarboxylation of the side chains is 
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catalysed by the enzyme uroporphyrinogen III decarboxylase (Martins et al., 2001).  
After the formation of coproporphyrinogen these heme biosynthetic pathways diverge. 
 
Figure 1.16- Overall heme biosynthesis 
The green box highlights the current section of interest, the coproporphyrin-dependent 
pathway. Uro’gen is the last common precursor for tetrapyrrole biosynthesis and this pathway 
ends in the formation of heme. 
 
The coproporphyrin-dependent pathway is utilised by Gram positive bacteria, more 
specifically Firmicutes and Actinobacteria. This pathway was first discovered when 
searching for enzymes capable of converting coproporphyrinogen to 
protoporphyrinogen in Firmicutes and Actinobacteria. HemN or HemF, the previously 
discovered coproporphyrinogen III oxidases, are not encoded in these genomes 
(Dailey et al., 2015).  There are three enzymatic steps in this pathway that conclude 





Figure 1.17 – Coproporphyrin-dependent heme biosynthesis pathway 
Uroporphyrinogen is decarboxylated by UROD to produce coproporphyrinogen. 
Coproporphyrinogen is oxidised by CgoX to form coproporphyrin III and ferrous iron is inserted 
into the porphyrin ring by ferrochelatase (CpFC). ChdC decarboxylates coproheme (Fe-
coproporphyrin III) to produce protoheme. Abbreviations: URO’GEN (uroporphyrinogen III), 
UROD (uroporphyrinogen decarboxylase), COPRO’GEN (coproporphyrinogen III), COPRO 
(coproporphyrin III) CgOX (coproporphyrinogen oxidase) ChDC (coproheme decarboxylase), 
CpFC (coproporphyrin ferrochelatase). 
 
1.2.4.1 Discovery of HemY (CgOX) 
HemY was originally assigned as a protoporphyrinogen oxidase.  Genetic mapping of 
B. subtilis revealed two operons important in heme biosynthesis, the hemEHY operon 
and the hemAXCDBL operon. The hemEHY operon was required for heme 
biosynthesis between uroporphyrinogen and heme and the hemAXCDBL operon was 
implicated in heme biosynthesis from glutamate to uroporphyrinogen. Studies on the 
hemEHY operon showed that hemE (uroporphyrinogen decarboxylase) had sequence 
similarity to other uroporphyrinogen decarboxylases and hemH (ferrochelatase) had 
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activity similar to ferrochelatase when expressed in E. coli. The HemY protein 
(coproporphyrinogen oxidase) was assumed to be a coproporphyrinogen oxidase or 
a protoporphyrinogen oxidase (Hansson and Hederstedt, 1992, Hansson et al., 1991). 
 
B. subtilis HemY (coproporphyrinogen oxidase) has protoporphyrinogen oxidase 
activity (Dailey et al., 1994) and can oxidise protoporphyrinogen to protoporphyrin IX 
and mesoporphyrinogen IX to mesoporphyrin IX. However, when testing B. subtilis 
HemY for coproporphyrinogen oxidase activity the substrate coproporphyrinogen III 
was converted to coproporphyrin III instead of protoporphyrinogen. These results led 
to the conclusion that B. subtilis HemY lacked standard coproporphyrinogen oxidase 
activity but possessed normal protoporhyrinogen activity. Other protoporphyrinogen 
oxidases, however, are not able to use coproporphyrinogen as a substrate. Despite 
this irregularity B. subtilis HemY was assigned as a protoporphyrinogen oxidase at this 
point in time (Dailey et al., 1994).  
 
Homologues of HemY were found in the Gram positive bacteria Staphylococcus 
aureus (S. aureus) and Mycobacterium tuberculosis (M. tuberculosis). These enzymes 
were capable of oxidising coproporphyrinogen to coproporphyrin III as described for 
the B. subtilis HemY. Only HemY enzymes present in Gram positive bacteria could 
oxidise coproporphyrinogen to coproporphyrin III. The conversion of 
coproporphyrinogen to coproporphyrin was also faster than the oxidation of 
protoporphyrinogen to protoporphyrin IX. In addition, the Km values for coproporphyrin 
III were much lower than those for protoporphyrin IX (Dailey and Gerdes, 2015, Dailey 
et al., 2015, Lobo et al., 2015). These results, in conjunction with those described for 
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ferrochelatase below leads to the view that these enzymes are primarily 
coproporphyrinogen oxidases. 
 
1.2.4.2 Ferrochelatase (CpFC) Inserts Iron into Coproporphyrin III 
In the coproporphyrin-dependent pathway, insertion of ferrous iron into the porphyrin 
by ferrochelatase is the penultimate step in the heme biosynthesis, rather than the 
final step. Coproporphyrin ferrochelatases (CpFCs) have been identified in both 
Firmicutes and Actinobacteria; these are structurally similar to other identified 
ferrochelatases. The structure of ferrochelatase is discussed in section 1.3. The 
coproporphyrin ferrochelatases found in S. aureus, B. subtilis, and M. tuberculosis are 
able to insert ferrous iron into coproporphyrin III much faster than into protoporphyrin 
IX and Km for coproporphyrin III is lower than the Km for protoporphyrin IX. All tested 
protoporphyrin ferrochelatases present in Gram negative bacteria and eukaryotes 
failed to insert iron into coproporphyrin at a recordable rate (Dailey et al., 2015, Lobo 
et al., 2015).  
 
1.2.4.3 Coproheme decarboxylase (ChdC) decarboxylates 
coproheme to produce heme 
1.2.4.3.1 Discovery of coproheme decarboxylase (HemQ) 
Genomes of Gram positive bacteria lack the genes that code for the 
coproporphyrinogen oxidases that convert coproporphyrinogen to protoporphyrinogen: 
coproporphyrinogen decarboxylase (HemF) or coproporphyrinogen dehydrogenase 
(HemN) which are essential in heme biosynthesis. Complementation studies using E. 
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coli and Acinetobacter ADP1 heme auxotrophs were used to screen for the missing 
coproporphyrinogen oxidase in Gram positive bacteria. This process was used to 
identify protoporphyrinogen dehydrogenase 2 (HemJ) and protoporphyrinogen 
oxidase (HemY) but was unable to identify the missing coproporphyrinogen oxidase 
(Boynton et al., 2009, Boynton et al., 2011, Dailey and Gerdes, 2015).  
 
Further complementation studies were carried out in ΔhemG or ΔhemH E. coli, these 
are E. coli strains lack a hemG or hemH gene and show a reduced growth phenotype. 
When a plasmid containing Gram positive hemY (coproporphyrinogen oxidase) or 
hemH (coproporphyrin ferrochelatase) was introduced into ΔhemG or ΔhemH E. coli, 
these plasmids cannot complement the E .coli strains even when they were added 
together (Dailey et al., 2010), implying a component is missing.  
 
There are two major operons in heme-synthesising Actinobacteria that contain the 
heme biosynthetic genes. In one of these operons a gene encoding a hypothetical 
protein similar to chlorite dismutase was commonly found clustered with hemY and 
hemH. A BLAST search of this protein revealed it is frequently found in Gram positive 
bacteria and not in Gram negative bacteria, non-heme synthesising organisms or 
eukaryotes.  The group of chlorite dismutase-like proteins named COG3253 were split 
into three groups: those with chlorite dismutases, those with no known function but are 
no chlorite dismutase activity or those with no known function and only present in 
Actinobacteria. An Actinobacteria, Propionibacterium acnes (P. acnes) contains a 
coproporphyrin ferrochelatase fused to a chlorite dismutase-like protein suggesting 
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that this protein may be involved in heme biosynthesis (Dailey et al., 2010, Dailey and 
Gerdes, 2015). 
 
Complementation studies revealed that this protein, later named HemQ or ChDC 
(coproheme decarboxylase), was the missing component. Both Actinobacteria and 
Firmicute coproheme decarboxylase along with coproporphyrinogen oxidase and 
coproporphyrin ferrochelatase were able to return ΔhemG and ΔhemH E. coli growth 
to wildtype levels. Complementation did not occur when two out of the three enzymes 
were added to the mutated E. coli strains. Also, combinations of these three enzymes 
from different species of Gram positive bacteria (Firmicutes and Actinobacteria) were 







Figure 1.18 - Crystal structure of Listeria monocytogenes coproheme decarboxylase 
The first crystal structure of a coproheme decarboxylase (PDB: 5LOQ) with coproheme 
(magenta) bound in the active site.  The protein crystallised as a pentamer, the secondary 
structure is shown in teal and the protein surface in grey (adapted from (Hofbauer et al., 
2016c)). Abbreviations: ChDC (coproheme decarboxylase). 
 
1.2.4.3.2 Investigating the function and stability of HemQ 
UV-Visible spectroscopy and resonance Raman (RR) spectroscopy were used to 
investigate the mechanism of action of coproheme decarboxylase. The UV-Vis 
spectrum of coproheme decarboxylase in a complex with coproheme shows an 
asymmetric Soret band with a maximum at 394 nm. The asymmetry of this band is 
thought to the partial conversion of coproheme to the intermediate harderoheme (III 
or IV) even in the absence of an oxidant (Celis et al., 2015).  
 
RR spectroscopy showed propionyl bending modes in all four spectra (coproheme, 
harderoheme IV, harderoheme III and heme b) and vinyl bending modes in 
harderoheme and heme b. The addition of 10 molar equivalent of hydrogen peroxide 
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completely converts coproheme to heme. The reduction in propionyl bending bands 
and appearance of vinyl bending bands in RR spectroscopy are characteristic of an 
oxidative decarboxylation mechanism. Peracetic acid (PAA) was able to substitute for 
hydrogen peroxide, 2 molar equivalents resulted in 70% substrate turnover and 8 
molar equivalents resulted in complete substrate turnover with the formation of about 
85% heme (Celis et al., 2015). The catalytic efficiency for this oxidative 
decarboxylation is thought to be slow though biologically relevant (Hofbauer et al., 
2016c). The biological source of this hydrogen peroxide is thought to come from the 
conversion of coproporphyrinogen to coproporphyrin in a six electron oxidation 
producing three molecules of hydrogen peroxide (Dailey et al., 2017).  
 
Stopped flow spectroscopy was used to identify spectral intermediates in substrate 
and product binding. The high absorption coefficient for coproheme and fast binding 
made determining Kd difficult in stoichiometric excess so pseudo first order 
concentrations of coproheme were used. The binding of coproheme or hemin to apo-
coproheme decarboxylase is much faster than heme binding. There are spectral 
changes that occur upon binding of the substrate or product which indicates the 
formation of spectral intermediates in both reactions (Hofbauer et al., 2016a). 
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Figure 1.19 Cavity architecture of HemQ and chlorite dismutase 
Chlorite dismutases (top left, PDB ID: 2VXH) and coproheme decarboxylases (top right, PDB 
ID:5LOQ) have similar heme cavity architecture (Hofbauer et al. 2016c, de Geus et al.,2009). 
The porphyrin molecules heme (top left) and coproheme (top right) are coloured blue and the 
surface of the proteins are shown in a red mesh and light grey surface. The bottom figure 
shows the coordination of heme (yellow) and coproheme (cyan) in the chlorite dismutase (blue) 
and coproheme decarboxylase (red) when overlaid (PDB IDs 5LOQ AND 2VXH, respectively). 
 
Coproheme decarboxylase proteins have similar heme cavity architecture to chlorite 
dismutase (figure 1.19). However, coproheme decarboxylases lack a crucial arginine 
in the active site, which is important for chlorite degradation; HemQs do not have 
chlorite degrading activity. The catalytic arginine is generally replaced by serine, 
alanine, glutamine or leucine (Hofbauer et al., 2016b). 
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1.2.4.3.3 Structure of Coproheme Decarboxylase 
The first coproheme decarboxylase protein was crystallised with substrate in 2016 
(Hofbauer et al., 2016c) (figure 1.18). The L. monocytogenes coproheme 
decarboxylase structure was solved with coproheme bound, this crystal structure was 
able to confirm the coproheme binding site as well as identify the residues involved in 
binding of the metalated porphyrin. The substrate is anchored into the active site by a 
weakly bound proximal histidine (H174 in L. monocytogenes).  When hydrogen 
peroxide is at equimolar concentrations compared to coproheme-coproheme 
decarboxylase there is crosslinking between the protein and the heme group. 
(Hofbauer et al., 2016c). 
 
Molecular dynamics simulations predict that the residue Q187 interacts with the 
propionate at position 2 (p2) and Y147 and S225 interacts with propionate 4 (p4) of 
the coproheme. These interactions were confirmed in the crystal structure also Met149 
was another confirmed H-bond partner for p4 and G178 and V185 were additional 
interacting partners for p2 (Hofbauer et al., 2016a, Hofbauer et al., 2016c). 
 
1.2.4.4 Confirmation of the coproporphyrin-dependent heme 
biosynthesis pathway 
The function of each enzyme in the non-canonical heme biosynthesis pathway has 
been confirmed by enzyme assays (table 1.1). Enzyme assays had already been used 
to define a function from the coproporphyrinogen oxidase in Gram positive bacteria. 
This enzyme was capable of converting coproporphyrinogen III to coproporphyrin III, 
the first stage in the coproporphyrin-dependent pathway (Dailey et al., 1994). The 
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combination of enzymes coproporphyrinogen oxidase and ferrochelatase produced 
coproheme (Fe-coproporphyrin) when assayed with coproporphyrinogen and iron. 
This showed that coproporphyrinogen was converted to coproporphyrin using 
coproporphyrinogen oxidase and ferrous iron was inserted into coproporphyrin using 
ferrochelatase producing coproheme. These results indicated that the ferrochelatase 
was the second enzyme in the pathway. 
 
The third enzyme in the pathway is coproheme decarboxylase. This was confirmed 
when an assay was performed with all three enzymes, coproporphyrinogen and 
ferrous iron. The end product was heme, this indicated that coproheme decarboxylase 
was responsible for converting coproheme to heme (Dailey et al., 2015, Dailey et al., 
2010). Another coproheme decarboxylase (AhbD) is present in the siroheme-
dependent heme biosynthetic pathway and is frequently found encoded in the 
genomes of Gram positive bacteria. 30% of Gram positive bacteria contain both 
coproheme decarboxylase and AhbD, HemQ is thought to be an oxygen-dependent 
coproheme decarboxylase whilst AhbD could be an oxygen-independent coproheme 







Table 1.1 Results of enzyme assays 
SUBSTRATE(S) ENZYMES PRODUCT 
COPROPORPHYRINOGEN 
+ IRON 
CpOX and CpFC Fe-Coproporphyrin 
COPROPORPHYRINOGEN 
+ IRON 
CpOX, CpFC and ChDC Heme 
COPROPORPHYRIN + 
IRON 
CpFC and ChDC Heme 
FE-COPROPORPHYRIN ChDC Heme 
 
The currently accepted coproporphyrin-dependent pathway branches off from the 
protoporphyrin-dependent pathway at coproporphyrinogen. Coproporphyrinogen is 
oxidised by coproporphyrinogen oxidase to form coproporphyrin III, then ferrous iron 
is inserted into coproporphyrin III forming coproheme (Fe-coproporphyrin) through the 
action of coproporphyrin ferrochelatase. Two of the propionyl groups on coproheme 
are oxidatively decarboxylated by coproheme decarboxylase forming vinyl groups on 
rings A and B creating heme (Dailey et al., 2015, Dailey et al., 2010). 
 
These three enzymes are notably different to the three terminal heme biosynthesis 
enzymes in eukaryotes (i.e. the protoporphyrin-dependent pathway) and are potential 
therapeutic targets. The Gram positive enzymes have different substrate specificities 
to the eukaryotic enzymes, and this can be used as a basis for the development of 
antibiotics that specifically target Gram positive bacteria. Ferrochelatase is the most 
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studied enzyme of the three terminal enzymes and so studying and comparing 
ferrochelatases in the protoporphyrin and coproporphyrin-dependent heme 
biosynthetic pathways could lead to development of novel antibiotics (Sheldon and 
Heinrichs, 2015). An overview of the complete heme biosynthesis pathway is shown 
in figure 1.20. 
 
Figure 1.20 - The three heme biosynthetic routes: protoporphyrin, coproporphyrin and 
siroheme dependent pathways 
The red shows the conserved pathway that is taken by all known organisms. ALA, the first 
common intermediate is formed through two different routes. The siroheme-dependent 
pathway (orange) is present in archaea and sulfate-reducing bacteria. The protoporphyrin-
dependent pathway (blue) is mainly present in eukaryotes and the majority of Gram negative 
bacteria whereas the coproporphyrin-dependent (purple) is mainly observed in Gram positive 
bacteria. Abbreviations: ALA (δ-aminolevulinic acid), GSA (glutamate-1-semialdehyde), 
PBG (porphobilinogen), HMB (hydroxymethylbilane), URO’GEN (uroporphyrinogen III), 
COPRO’GEN (coproporphyrinogen III), COPRO (coproporphyrin III), PROTO’GEN 
(protoporphyrinogen IX), PROTO (protoporphyrin IX), SUMT (SAM (S-adenosyl methionine)-
dependent uroporphyrinogen methyltransferase), PC2 (precorrin-2), PCDH (precorrin-2 
dehydrogenase), SiHC (sirohydrochlorin), FC (ferrochelatase), SH (siroheme), 
Ahb(alternative heme biosynthesis), DDSH (12,18-didecarboxysiroheme), ALAS (δ-
aminolevulinic acid synthase), GluTR (Glutamyl-tRNA reductase), GSAM (glutamate-1-
semialdehyde aminomutase), PBGS (porphobilinogen synthase), PBGD (porphobilinogen 
deaminase), UROS (uroporphyrinogen synthase), UROD (uroporphyrinogen deaminase), 
CgOX (coproporphyrinogen oxidase), CpFC (coproporphyrin ferrochelatase), ChDC 
(coproheme decarboxylase), CgDC (coproporphyrinogen decarboxylase), CgDH 
(coproporphyrinogen dehydrogenase), PgDH1/2 (protoporphyrinogen dehydrogenase 1 and 
2), PgOX (protoporphyrinogen oxidase), PpFC (protoporphyrin ferrochelatase) . 
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1.3 Ferrochelatase (FC)  
1.3.1 Chelatases 
Chelatases catalyse the insertion of a metal ion into a tetrapyrrole ring; each 
tetrapyrrole biosynthetic pathway involves a chelatase that ensures the correct metal 
is inserted. Examples include ferrochelatase, which can catalyse the insertion of 
ferrous iron into protoporphyrin IX to form heme and magnesium chelatase that 
catalyses the insertion of magnesium into protoporphyrin IX in chlorophyll synthesis 
(Schubert et al., 2002). There are three categories of chelatase, class I are the ATP-
dependent heterotrimeric chelatases such as magnesium chelatase. Class II contains 
the ATP-independent chelatases such as ferrochelatase, they are found as monomers 
or homodimers.  Class III chelatases are ATP-independent multifunctional 
homodimeric chelatases, primarily involved in siroheme biosynthesis (e.g. siroheme 
synthase (CysG) (Brindley et al., 2003, Al-Karadaghi et al., 2006).  
 
1.3.2 Ferrochelatase Structure  
Ferrochelatases (FCs) have very low amino acid sequence conservation, with ~12% 
sequence identity across eukaryotes, Gram positive and Gram negative bacteria. 
Conserved residues are either involved in function or maintaining the overall protein 
fold. Despite this low sequence identity, the monomeric structures of these enzymes 
are relatively well conserved (figure 1.21). The ferrochelatases from B. subtilis and H. 
sapiens amongst other species have been crystallised and structural models inferred 
from X-ray diffraction data. The human FC (hFC) was resolved to 2 Å; it is homodimeric 
and is associated with the mitochondrial membrane, it synthesises heme using the 
protoporphyrin-dependent heme biosynthetic pathway (Wu et al., 2001). In contrast, 
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the B. subtilis FC (bFC) resolved at 1.9 Å is monomeric and soluble (Al-Karadaghi et 
al., 1997). B. subtilis is a Gram positive bacterium that synthesises heme through the 
coproporphyrin-dependent pathway. Comparing the structure of these enzymes may 
reveal differences that could explain the observed substrate specificity. 
 
The active site of FC is found between domains I and II. In H. sapiens ferrochelatase 
there is a 13-residue insert in domain I that is important in the shaping the active site; 
it is not present in B. subtilis ferrochelatase  (Al-Karadaghi et al., 1997, Wu et al., 2001). 
There are two faces of the active site above and below the plane of the porphyrin 
respectively (figure 1.25).  One face of the active site is the most conserved region 
and contains the amino acids H263 and E343; these are placed directly opposite the 
centre of the porphyrin and are essential in the catalytic mechanism of ferrochelatase 
(Dailey et al., 2007, Medlock et al., 2007a, Sellers et al., 2001, Hansson et al., 2007, 
Hunter et al., 2016). The second face of the active site is much less conserved and 
contains the residues M76, Y165 and R164 in human ferrochelatase. Two separate 
proposals describe binding of ferrous iron in the active site with amino acid residues 
in either the conserved face or non-conserved face binding iron before insertion into 
porphyrin. The other face not involved in iron binding is then thought to be involved in 
proton abstraction. There is evidence to support both hypotheses and the actual 
mechanism still remains controversial (Medlock et al., 2007a, Hansson et al., 2007).  
 
Before the discovery of the copro1-dependent pathway B. subtilis, a Firmicute, was 
thought to utilise the protoporphyrin-dependent heme biosynthetic pathway, a large 
quantity of published kinetic analysis of B. subtilis ferrochelatase has used 
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protoporphyrin IX or an analogue of protoporphyrin (e.g. deuteroporphyrin or 
mesoporphyrin) as a substrate rather than the correct substrate coproporphyrin III.  
The B. subtilis ferrochelatase has been structurally resolved with bound N-
methylmesoporphyrin (N-MeMP), a potent inhibitor of ferrochelatase. However, the 
binding of N-MeMP may not be an accurate representation of physiological substrate 
binding in B. subtilis ferrochelatase. The superposition of a monomer of H. sapiens 
ferrochelatase onto B. subtilis ferrochelatase is shown in figure 1.21. The structure is 
relatively well conserved apart from the α-helix covering the active site (N-terminal 
extension) and the C-terminal extension involved in binding the iron-sulphur cluster in 
H. sapiens ferrochelatase. 
 
Figure 1.21 – The structural relationship between H. sapiens and B. subtilis 
ferrochelatase  
A monomer of H. sapiens ferrochelatase (PDB ID: 2HRE) has been structurally aligned against 
B. subtilis ferrochelatase (PDB ID: 1C1H). H. sapiens ferrochelatase is shown in teal and B. 
subtilis ferrochelatase is shown in yellow. A zoomed image of the porphyrin binding in the 
ferrochelatase shows the difference in binding, N-methylmesoporphyrin is shown in cyan and 
protoporphyrin IX shown in green (Lecerof et al., 2000, Medlock et al., 2007a). The hash 
indicates the α helix in human ferrochelatase that sits over the active site (truncated N-terminal 
extension) and the asterisk highlights the helix turn helix structure involved in binding the iron-
sulphur cluster (C-terminal extension). The iron-sulphur cluster is highlighted in orange and 
the cysteine (C196, C403, C406,C411) residues involved in its coordination are in magenta. 
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1.3.2.1 Domain structure 
B. subtilis ferrochelatase has two domains (domain I and II), the active site is a 25 Å 
cleft is formed from the domains. The domains are similar and are suggested to result 
from a gene duplication event (Al-Karadaghi et al., 1997) (figure 1.23). They each 
resemble a α-β-α fold (four-stranded parallel β-sheet flanked by α-helices). The C-
terminal helices of each domain interact with the β-sheet in the other domain 
contributing to the formation of the active site cleft (Al-Karadaghi et al., 1997). 
 
The ferrochelatase domains contain a set of conserved glycines and prolines scattered 
throughout the protein, those in domain I corresponding to those in domain II. These 
conserved glycines and prolines are most likely involved in retaining the structure of 
ferrochelatase as they are commonly found in turns or the loop regions of the proteins 
and are involved in protein folding and compaction. Glycines and  -prolyl bonds have 
relatively fast loop formation dynamics whereas dynamics around trans-prolyl bonds 
are slow (Krieger et al., 2005)(figure 1.22). Two of the conserved prolines, P91 and 
P233 (one in each domain) are in the cis-conformation and the isomerisation from 
trans to a cis conformation can hinder or slow correct protein folding (Al-Karadaghi et 




Figure 1.22- Conserved prolines and glycines in B. subtilis HemH 
The conserved glycine and proline pairs (P16 and P186, P55 and P195, P91 and Pro 233, 
G52 and G193, G104 and G247) are shown on the ferrochelatase (PDB ID: 1AK1) in teal and 
the secondary structure is highlighted in grey. P91 and P233 are in the cis conformation.  
 
Other conserved residues are found in the functional loop between β-strand 2 in 
domain II and α-helix 4 in domain II (residues Q221, S222, W230 and L231) or lining 
or in close proximity to the active site cleft. These conserved residues are thought to 
be functionally important. There are three major differences between the domains of 
B. subtilis ferrochelatase. Firstly, the functional loop in domain II is not present in 
domain I. The secondary structure elements α3 and β2 are noticeably longer in domain 
I. Finally, α-helices 1-3 in the domain I contain 65 amino acids whereas the 




Figure 1.23 - B. subtilis ferrochelatase domain alignment 
Sequence alignment and secondary structure alignment performed using PRALINE alignment 
tool of the two domains in B. subtilis ferrochelatase (Pirovano and Heringa, 2010). The 
secondary structural elements are highlighted in blue (β-strands) and red (α-helices) and are 
taken from the crystal structure (Al-Karadaghi et al., 1997). 
 
The monomeric form of H. sapiens ferrochelatase is similar in structure to B. subtilis 
ferrochelatase, however it also contains N-terminal and C-terminal extensions. The N-
terminal extension contributes to the formation of the active site changing its 
architecture.  The C-terminal extension contains a helix-turn-helix motif that is 
important in binding an iron-sulphur cluster. Four cysteine residues (Cys196, Cys403, 
Cys406 and Cys411, H. sapiens ferrochelatase) coordinate the cluster, three are 
present in the C-terminal domain and one is in the N-terminal domain. The C-terminal 
extension stabilises the homodimer, of the 30 hydrogen bonds formed across the 
dimer interface, 18 form from residues in the C-terminal extension (Wu et al., 2001). 
 
1.3.3 Components important in deducing the mechanism of action 
The mechanism of action for ferrochelatase involves distortion of the porphyrin ring 
and exposure of the nitrogen lone pair orbitals of the pyrrole nitrogens to the incoming 
iron. A proposed mechanism includes the formation of the first coordinate bond 
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between the porphyrin and iron, followed by chelation and ring closure forming a 
sitting-a-top complex. Finally, deprotonation of the pyrrole nitrogens in the porphyrin 
completes metal insertion; the enzyme then releases the product (Sigfridsson and 
Ryde, 2003, Lecerof et al., 2003).  
 
1.3.3.1 Porphyrin distortion 
The ferrochelatase enzyme mechanism requires porphyrin distortion. Porphyrin 
distortion was proposed as part of the mechanism of action for ferrochelatase relatively 
early and several distinct approaches provide evidence to support it. The methods 
used include resonance Raman (RR) spectroscopy, theoretical calculations and 
inhibition studies. Resonance Raman spectroscopy can effectively probe the structural 
changes that occur in the mechanism of heme proteins, it was used to measure 
changes in the free-base porphyrin, mesoporphyrin IX (MPIX), in the presence of yeast 
ferrochelatase and the metal, Hg2+ (Blackwood et al., 1997). Theoretical calculations 
defined optimal geometrics for several porphyrins and determined whether porphyrin 
distortion was energetically feasible (Sigfridsson and Ryde, 2003). Inhibition studies 
of ferrochelatase show that distorted porphyrins bind exceptionally tightly suggesting 
that they can be considered as transition-state inhibitors. 
 
RR spectroscopy is capable of investigating potential porphyrin distortion as a free 
base or in the presence of ferrochelatase and metal. When Hg2+ was added to the 
ferrochelatase-MPIX complex, bands in the spectra associated with out-of-plane 
modes appeared. The appearance of these bands correlated to a reduction in 
symmetry in the porphyrin due to static out-of-plane distortion.(Blackwood et al., 1997, 
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Perng and Bocian, 1992). These out-of-plane modes were similar to those seen in the 
spectra of ferrocytochrome c (a heme protein) and Ni-OEP. Further investigation using 
RR spectroscopy showed out-of-plane modes characteristic of porphyrin saddling and 
mutation of specific amino acids (E280Q and H209N) in murine ferrochelatase result 
in increased porphyrin distortion and reduced binding to hemin, a planar molecule 
(Franco et al., 2011, Franco et al., 2000, Shi and Ferreira, 2004). 
 
Theoretical calculations of N-MeMP also support porphyrin distortion in the 
ferrochelatase active site. Tilting a neutral porphine by approximately 30° out of the 
porphyrin plane required less energy if metal free. A fully deprotonated metal-free 
porphyrin molecule containing a negative charge can easily be deformed requiring 
only less energy. It was suggested that a distorted porphyrin may be an intermediate 
in the insertion of ferrous ion into a porphyrin ring (Sigfridsson and Ryde, 2003). 
 
Inhibition studies indicated that a variety of porphyrins act as inhibitors of human 
ferrochelatase; IX isomers had Ki values of 13-70 μM, similar to the Km values for 
porphyrin substrates and N-alkylporphyrins had Ki values of <10 nM. N-alkylporphyrins 
are distorted approximately 30° compared to the planar IX isomers, the tight binding 
to ferrochelatase further supported the idea that a distorted porphyrin could be an 
intermediate in the metalation of protoporphyrin IX (Dailey et al., 2000).  
 
Various porphyrins and metalloporphyrins were assessed as inhibitors or substrates 
of murine ferrochelatase and Ki or Km values and Kd values were determined. The 
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metalloporphyrins assayed include Fe-protoporphyrin, Co-protoporphyrin, Zn-
protoporphyrin and Sn-protoporphyrin, the Ki values ranged from 2-13 µM. The zinc, 
cobalt and iron metalloporphyrins are the much more effective inhibitors than tin 
porphyrin. Alternative porphyrins tested were protoporphyrin, mesoporphyrin, 
hematoporphyrin and deuteroporphyrin. The Km values vary from 9-247 µM, 
deuteroporphyrin and mesoporphyrin have much higher Km values than 
protoporphyrin and hematoporphyrin. N-methylprotoporphyrin has a much lower Kd 
than the ones tested and a Ki in the nanomolar range (10 nM) (Dailey et al., 1989).  
 
These inhibition studies show that metallo-protoporphyrins are capable of inhibiting 
ferrochelatase with Ki values in the low micromolar range, these are planar molecules 
that cannot be easily distorted. Other related analogues of protoporphyrin such as 
mesoporphyrin, hematoporphyrin and deuteroporphyrin have varied Km values 
indicating that they can still act as substrates.  These molecules can be easily distorted 
by ferrochelatase and this may be why they are not inhibitory. Mesoporphyrin and 
deuteroporphyrin are frequently used as the porphyrin substrate in enzymatic assays 
and protein crystallisation as they are more soluble that protoporphyrin IX (Davidson 
et al., 2009, Dailey and Fleming, 1986, Medlock et al., 2009). A distorted porphyrin, 
N-methylprotoporphyrin, has a Ki value in the nanomolar range, significantly lower 
than the metallo-protoporphyrins. This suggests that a distorted porphyrin replicates 
the transition state however, the degree of distortion in the porphyrin molecule does 
not appear to be significant. These results are consistent with porphyrin distortion as 
part of the ferrochelatase enzymatic mechanism (Dailey et al., 1989). The crystal 
structure of the H. sapiens ferrochelatase and its substrate protoporphyrin IX reveal 
that the porphyrin is only moderately distorted, the actual degree of distortion shown 
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by the structure is approximately 12° rather than 30° seen with N-MeMP. However, 
the crystal structure shows the most stable enzyme-substrate complex and may not 
reflect a rarer conformation before catalysis (Medlock et al., 2007a, Al-Karadaghi et 
al., 1997).  
 
1.3.3.2 Substrate selectivity 
1.3.3.2.1 Metals 
It was suggested that the degree of porphyrin distortion indicates which metal is 
selected and inserted into the porphyrin ring. This prediction is based mainly on steady 
state kinetics and structural analysis (Al-Karadaghi et al., 2006). Further work including 
more structural analysis and transient kinetics has been completed and these results 
weaken the credibility of this proposed mechanism (Medlock et al., 2009). This work 
shows that ferrochelatase inhibition occurs after metal insertion and product release 
is prevented 
One plausible mechanism for the inhibition of ferrochelatase by Hg2+, Pb2+, Cd2+ and 
Mn2+ was that they bind but cannot be inserted into a porphyrin ring. This theory was 
tested using structural data. Crystal structures of H. sapiens ferrochelatase were 
produced using protoporphyrin or deuteroporphyrin in the presence of the metal 
inhibitors Hg2+, Cd2+ or Mn2+ which revealed that the bound porphyrin was metalated. 
This indicated that metal selectivity is not determined by the degree of distortion 
(Medlock et al., 2009).  These crystal structures proved that these inhibitory metals are 
inserted into the porphyrin and then the activity of ferrochelatase is inhibited by tight 
binding of the product (Medlock et al., 2009).   
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In activity assays of ferrochelatase different metals are frequently used. Zn2+ is used 
most often as it cannot be oxidised unlike the endogenous substrate Fe2+.  Other 
investigators have used Co2+, Cu2+ and Ni2+ and found that there was different 
preference of metals dependent on the species of ferrochelatase. Eukaryotic 
ferrochelatase such as H. sapiens and S. cerevisiae ferrochelatase will utilise Co2+ 
and not Cu2+ whereas a prokaryotic ferrochelatases such as B. subtilis ferrochelatase 
use Cu2+ over Co2+. Y13 in B. subtilis ferrochelatase is important in coordinating the 
iron in active site and directly binds to a nitrogen group on the Cu-mesoporphyrin. 
Sequence alignments reveal that this residue is not conserved across species and is 
a methionine in the H. sapiens and S. cerevisiae enzyme. Mutation of Y13 to a 
methionine results in metal specificity similar to the eukaryotic enzyme with a 
preference for Co2+ over Cu2+ (Hansson et al., 2011).  
 
1.3.3.2.2 Porphyrin selectivity 
The porphyrin selectivity of ferrochelatase was explained in the earliest studies on this 
enzyme. Ferrochelatase was harvested from mitochondria isolated from sheep liver. 
Assays were run using different porphyrins, with cobalt as the metal substrate. Firstly, 
the propionate groups present at positions 6 and 7 of the porphine ring were switched 
with the methyl groups at position 5 and 8, respectively. Switching the propionate at 
position 6 to position 5 resulted in decreased activity and substitution of both 




Figure 1.24 - Porphyrin structures 
The parent porphyrin compound porphine contains hydrogens at potential substitution 
positions 1-8 (red). Coproporphyrin III and protoporphyrin IX are examples of porphyrins where 
positions 1-8 have been substituted with methyl, vinyl and propionyl groups. 
 
Further studies were completed on IX porphyrin isomers. Deuteroporphyrin IX had the 
most activity followed by mesoporphyrin IX and then protoporphyrin IX. The different 
substitutions in each of the isomers are shown in table 1.2. There are hydrophobic 
substitutions at positions 1, 2, 3 and 4 in mesoporphyrin and protoporphyrin which 
unfavourably alter the Vmax but favourably change the Km, so these moieties maybe 
important in binding to a hydrophobic region in the enzyme active site. Furthermore, 
swapping the position 2 vinyl group in protoporphyrin IX to position 1 changes the 
molecule to protoporphyrin XIII and this does not alter the activity effectively. The 
porphyrin molecule that had the highest activity (porphyrin 1) has propionates at 
position 6 and 7, methyl groups at positions 5 and 8 and the other four sites were left 






Table 1.2- Substitutions of each porphyrin at each position 
PORPHYRIN POSITION 
1 2 3 4 5 6 7 8 
PORPHYRIN I H H H H Me P P Me 
DEUTEROPORPHYRIN IX Me H Me H Me P P Me 
MESOPORPHYRIN IX Me Et Me Et Me P P Me 
PROTOPORPHYRIN IX Me V Me V Me P P Me 
PROTOPORPHYRIN XIII V Me Me V Me P P Me 
H= Hydrogen, Me= Methyl, P= Propionate, Et= Ethyl, V= Vinyl 
1.3.4 Development of a catalytic model 
There have been many proposed mechanisms of for ferrochelatase. The literature 
reveals a controversy regarding the mechanism of iron insertion into the porphyrin and 
its route into the active site. One hypothesis is that the iron enters the porphyrin using 
the residues on the conserved face of the active site (H183 and E284 B. subtilis HemH) 
(Hunter et al., 2008, Hunter and Ferreira, 2010, Karlberg et al., 2002). The other 
hypothesis suggests the iron enters using the residues on the non-conserved face of 
the active site (K87 and H88 B. subtilis HemH) (Asuru and Busenlehner, 2011, Dailey 
et al., 2007, Sellers et al., 2001)(figure 1.25).   
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Figure 1.25 - The faces of H. sapiens ferrochelatase active site 
The two different faces of the active site are above and below the plane of the porphyrin. 
Residues in the conserved face of the active site (E343 and H263) are shown in cyan however, 
in this structure there is an E343K mutation. The residues in the non-conserved face of the 
active site (M76, R164 and Y165) are shown in pink. Protoporphyrin IX is coloured green. The 
protein structure used in this image has PDB ID: 2QD1 (Medlock et al., 2007b). 
 
1.3.4.1 Peripheral components of the active site 
1.3.4.1.1 Hydrogen-bonding network of H. sapiens ferrochelatase 
The hydrogen-bonding network present in the active site changes upon porphyrin 
binding, contributing to the closure of the active site mouth. There are several residues 
that have been implicated in the hydrogen bonding network, including H263, H341 and 
F337 (H. sapiens HemH numbering). To investigate the hydrogen-bonding network 
H263, H341 and F337 were mutated. The resulting mutants were structurally resolved 
using X-ray crystallography. H263C, H341C and F337A were structurally resolved with 
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no porphyrin bound and the active site architecture of each mutant was compared to 
R115L H. sapiens HemH. Analysis of the active site of each mutant showed residues 
that were differentially orientated.   The H263C and H341C mutant proteins had 
different side chain orientation when compared to the R115L mutant. The residues 
N75, M76, R164, H263, F337, H341, and E343 all showed different orientation. In the 
F337A mutant the side chain orientation remained similar to R115L HemH. This 
suggested that both H263 and H341 are important in the hydrogen-binding network. 
Figure 1.26 shows the difference in side chain orientation between R115L and H263C 
H. sapiens HemH (Dailey et al., 2007). 
 
Figure 1.26 - Overlay of H. sapiens R115L and H. sapiens H263C ferrochelatase 
The H. sapiens ferrochelatase variants are overlaid, the R115L variant (orange, PDB: 2HRC) 
and H263C variant (cyan, PDB ID: 2PO5). The R115L has similar structure and activity to 
wildtype whereas H263C has no measurable activity. The differences in these two structures 
are the residues highlighted. These residues are thought to be involved in the hydrogen-
bonding network as mutation of H263C disrupts the hydrogen-bonding network (Dailey et al., 
2007). Hydrogen bonding at rest is shown by black dashed lines and hydrogen bonding in an 
activated state is shown in magenta dashed line. The right image includes residues on the 
conserved side of the active site and the left image includes residues from the non-conserved 
side of the active site. 
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1.3.4.1.2 Solvent filled channels and the π-helix, two routes for iron entry into the 
active site 
Another peripheral element of the active site is the presence of solvent filled channels. 
In H. sapiens ferrochelatase there are solvent filled channels, these channels form 
from the outside of the protein and end at the active site. Two of the channels are 
named after the terminal residues they interact with H240 and Q139. The Q139 
channel is the shorter of the two channels and is present in H. sapiens, B. subtilis and 
S. cerevisiae ferrochelatase and H240 is only found in H. sapiens and S. cerevisiae. 
Both of these channels are capable of transporting water molecules and desolvated 
metal ions such as iron. The two channels converge at residue Phe337 (Medlock et 
al., 2012).  
 
The Phe337 residue was first studied when investigating the hydrogen-bonding 
network in the active site of H. sapiens HemH (section 1.3.4.1.1). These experiments 
showed that Phe337 was not involved in the hydrogen-bonding network. It is now 
posited to function as a gate for the solvent filled channels. In the 8 mutant the 
channels are permanently open, this is shown through comparisons of the solvent 
filled channels in the R115L mutant (like wildtype) the F337A mutant ferrochelatase 
(Medlock et al., 2012). In the F337A mutant and the activity of the enzyme is 
diminished. It is also diminished in F337R mutant, but this could be because arginine 
prevents the expulsion of water from the active site or the entry of iron (Medlock et al., 
2012, Dailey et al., 2007). In wildtype human ferrochelatase the Q139 channel is only 
open to the active site when porphyrin is bound and so could allow the transfer of iron 
into the active site. 
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The Phe337 residue is found in close proximity to another element of the 
ferrochelatase active site, the π-helix. π-helices are relatively rare compared to other 
helices and were originally thought to be fairly unstable due to their dihedral angles, 
large radius and the large entropic penalty required for them to form (Fodje and Al-
Karadaghi, 2002).  They are wider and flatter than α helices and the π-helix present in 
the active site of ferrochelatase (D340-C360 in H. sapiens) is dynamic and contains 
acidic residues (e.g. E343 and D340) along one edge, forming an acidic path into the 
active site (Medlock et al., 2007b).  
 
A mutant of H. sapiens HemH (F110A) was crystallised and structurally resolved with 
heme bound. This structure imitated the product bound state of ferrochelatase. When 
compared to the porphyrin bound state of H. sapiens ferrochelatase, the π-helix is 
unwound between residues 340-349, it is also rotated and extended (figure 1.27). The 
propionate at position 6 on protoporphyrin IX is bent backward towards the centre of 
the porphyrin, the H263 is positioned 5 Å away from the centre of the porphyrin rather 
than its normal 3 Å and the active site is open. In structures containing bound Pb-
protoporphyrin IX the active site architecture is similar to the heme bound 







Figure 1.27- Dynamics of the π helix 
An overlay of the two ferrochelatase variants R115L (teal PDB ID: 2HRC) and F110A 
(magenta PDB ID: 2QD2) shows the dynamics of the π helix. In R115L the π helix (orange) is 
fully formed and in the F110A the π helix (yellow) is unwound. F110A represents the product 
release conformation as the structure was crystallised with bound heme (green) and R115L 
variant represents the open conformation with no substrate bound. Zoomed versions of the π 
helices are also shown (Medlock et al., 2007a, Medlock et al., 2007b).  
 
The nature of the π-helix in this F110A mutant suggests that ferrochelatase undergoes 
structural reorganisation during its catalytic cycle. The unwinding and winding of the 
π-helix has been hypothesised to both allow iron to enter the active site and allow 
product release (Medlock et al., 2007b, Fodje and Al-Karadaghi, 2002). 
 
1.3.4.1.3 Secondary metal binding site 
The final component of the active site to consider is the secondary metal binding site. 
The secondary metal binding site was discovered in S. cerevisiae ferrochelatase. 
Significant inhibition was observed in the activity of yeast ferrochelatase in the 
 85 
presence of different divalent metal ions (Ni2+, Co2+, Zn2+, Cu2+). Inhibition was also 
observed in human ferrochelatase when it was assayed with Zn2+; no inhibition was 
observed with iron (Hunter et al., 2008, Davidson et al., 2009). The magnitude of 
inhibition was dependent on the metal ion, the most inhibitory metal ion was Ni2+ 
followed by Co2+, Zn2+ and then Cu2+, in S. cerevisiae ferrochelatase. The divalent 
metal ions were thought to bind to the secondary metal binding site and inhibit 
ferrochelatase when iron is not present thus preventing the formation of other 
metalloporphyrins that aren’t heme (Hunter et al., 2008). However, other studies show 
that the secondary metal binding site may serve to enhance the affinity for metal 
binding, it could be involved in substrate processing (Hunter and Ferreira, 2010) and 
is significant when ferrochelatase is bound to product (Davidson et al., 2009). 
 
Several potential metal binding sites have been observed in crystal structures of 
ferrochelatase (PDB ID: 1L8X, 2HK6, 1LD3 and 1N0I) these were used to confirm the 
important residues in the secondary binding site (Hunter et al., 2008, Karlberg et al., 
2002, Hansson et al., 2007, Lecerof et al., 2003).The most important residues in the 
secondary binding site were observed in murine ferrochelatase, these were H287 and 
F283.  Both of these residues are completely conserved in ferrochelatase. Despite 
complete conservation of the F283 residue it is not required for high levels of in vitro 
activity. It is present at the end of the π helix and is thought to help metal binding to 
H287. The mutants F283L and H278L caused partial and complete elimination of the 
observed inhibition, respectively (Hunter and Ferreira, 2010). Crystal structures from 
Cd2+ soaked murine ferrochelatase showed metal binding at both histidines (H207 and 
H287) thought to be involved in binding at the two different metal binding sites (Hunter 
and Ferreira, 2010). 
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This secondary metal binding site is present in the coproporphyrin ferrochelatases 
from B. subtilis and S. aureus. B. subtilis ferrochelatase can only be structurally 
resolved in the presence of Mg2+, this is thought to stabilise the π-helix and hold the 
ferrochelatase in the open conformation (Hunter et al., 2011, Medlock et al., 2012, 
Hansson and Al Karadaghi, 1995). The Mg2+ interacts with the residues E272, E268, 
R46 and E223; this is a secondary binding site proximal to the surface of the protein 
and approximately 7 Å away from the invariant H183 residue. Mutation of E272 
(E272S) resulted in elimination of any stimulatory effect caused by Mg2+ bound in the 
secondary metal binding site (Lecerof et al., 2003, Hansson et al., 2006). In S. aureus 
HemH, the presence of Mg2+ caused the inhibition exerted by iron to occur at lower 
concentrations compared to the iron inhibition occurring in the absence of Mg2+. 
Mutation of E271 in S. aureus (E272 in B. subtilis) to serine caused the elimination of 
the inhibition caused by iron (Hobbs et al., 2017). 
 
1.3.4.2 The role of the His-Glu pair as the final metal binding site 
before porphyrin metalation 
Amongst the ferrochelatases there is a His-Glu pair that is completely conserved 
despite their low sequence similarity (<20%). Mutation of the residues H263 and E343 
in H. sapiens ferrochelatase generally result in inactive ferrochelatase, however, there 
are some cases where minimal activity is retained. For example the conservative 
mutant E343D retains some activity (Hoggins et al., 2007). All mutations at H263 
results in an inactive enzyme. The addition of imidazole, a structurally similar 
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compound to histidine, cannot substitute the H263 residue and rescue activity (Sellers 
et al., 2001, Dailey et al., 2007, Medlock et al., 2007b).  
 
This His-Glu pair together has been postulated to act as a binding site for the iron in 
the active site prior to porphyrin insertion. This insertion would occur from the 
conserved side of the active site (figure 1.28) and a range of experiments support this 
hypothesis (Karlberg et al., 2002, Ferreira et al., 2002, Hansson et al., 2007). Binding 
assays with Zn2+ and the B. subtilis ferrochelatase mutant proteins, H183A and E264V 
showed an increase in Kd, compared to the wildtype ferrochelatase, paired with a large 
reduction in catalytic activity. When residues in the non-conserved face of the active 
site were mutated (K87A and H88A) the effects were less substantial. The H88A 
mutant had a Kd for Zn2+ similar to wildtype (2.8 ± 0.4 μM vs. 3.7 ± 0.4 μM) but low 
activity (5%) and the K87A mutant had a higher Kd value (13 ± 5 μM vs 3.7 ± 0.4 μM) 
but retained 92% activity compared to the wildtype (Hansson et al., 2007).  
 
The role of the His-Glu pair was investigated further using pH-dependent kinetics. The 
conserved face of the ferrochelatase active site contains residues that have ionisable 
groups (E343, H341, H263 H. sapiens numbering) whereas the non-conserved active 
site face mainly consists of residues unaffected by changes in pH. The research group 
reasoned that if the His-Glu pair was important in porphyrin metalation then the 
histidine and the glutamate would need to be deprotonated. When the pH is lower than 
the pKa of the two residues the activity of the ferrochelatase should be greatly 
diminished. Kinetic assays at different pH revealed that porphyrin metalation in the 
ferrochelatase reaction is dependent on pH suggesting that the His-Glu pair may be 
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important in metal binding and porphyrin metalation although several other residues 
are affected complicating the assignment (Hunter and Ferreira, 2010, Hunter et al., 
2016). 
 
To further support the role of the His-Glu pair as the final binding site prior to insertion, 
a crystal structure of B. subtilis ferrochelatase with iron bound and S. cerevisiae 
ferrochelatase with cobalt bound in the active site were structurally resolved using X-
ray crystallography (PDB ID: 2HK6 and 1L8X, respectively). They showed iron 
coordinated by the H183 and E264 in the B. subtilis structure and cobalt was bound 









Figure 1.28 - The faces of H. sapiens ferrochelatase active site 
The two different faces of the active site are above and below the plane of the porphyrin. 
Residues in the conserved face of the active site (E343 and H263) are shown in cyan however, 
in this structure there is an E343K mutation. The residues in the non-conserved face of the 
active site (M76, R164 and Y165) are shown in pink. Protoporphyrin IX is coloured green. The 
protein structure used in this image has PDB ID: 2QD1 (Medlock et al., 2007b). 
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1.3.4.3 An alternative porphyrin metalation model that utilises 
residues on the non-conserved side of the active site as the final metal 
binding site 
The other proposed function for the His-Glu pair is proton abstraction. In this model, 
H263 (H. sapiens) abstracts protons from the pyrroles on the porphyrin and they exit 
the active site using E343 and other residues in the π helix. It has been argued that if 
the His-Glu pair was the terminal metal binding site this would lead to the histidine 
becoming an axial ligand to the heme.  Histidine is frequently found as an axial ligand 
for heme in proteins containing heme as a cofactor and so the interaction between 
these would be strong and product release would not occur easily (Dailey et al., 2007, 
Medlock et al., 2009, Sellers et al., 2001). Kinetic assays have shown that the rate 
determining step in the ferrochelatase enzyme mechanism is likely to be product 
release (Hoggins et al., 2007).  
 
Site-directed mutagenesis of H. sapiens ferrochelatase active site residues showed 
the significance of residues potentially involved in iron binding and porphyrin 
metalation. Initially H263 was mutated to H263A/C/N all of which were inactive. Due 
to the inactivity of these mutants the definitive role of H263 could not be elucidated. 
However, if H263 were an iron ligand then some activity retention in H263C would be 
expected. What can be concluded from the lack of activity is that this invariant histidine 
is clearly essential in catalysis (Sellers et al., 2001, Dailey et al., 2007). Mutation of 
E343 mainly resulted in an inactive ferrochelatase, E343K/H/Q mutants were 
completely inactive but E343D had a Km for iron comparable to wildtype and a 
significantly lower Vmax value.  As these residues were hypothesised to act as proton 
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abstractors, mutation to a basic or an amine based residue would prevent proton 
abstraction and lead to the accumulation of substrate in the ferrochelatase active site. 
Most of these mutants were isolated with porphyrin bound in their active sites and no 
turnover was observed (Sellers et al., 2001). 
 
As the His-Glu pair is proposed to be involved in proton abstraction then the insertion 
of the iron into the porphyrin ring is thought to occur from the opposite side of the 
active site, the non-conserved face (figure 1.28). The residues thought to be the metal 
binding site immediately prior to insertion are R164 and Y165 (H. sapiens HemH) 
equivalent to K87 and H88 in B. subtilis HemH (Asuru and Busenlehner, 2011, 
Medlock et al., 2009, Dailey et al., 2007, Sellers et al., 2001).  
 
Site-directed mutagenesis revealed several residues that may have been involved in 
iron binding and/or porphyrin metalation due to the increase in their KmFe. The mutants 
R164L and Y165F resulted in a 2-fold increase in KmFe and the double mutant 
R164L/Y165F caused a 6 fold increase in KmFe compared to wildtype ferrochelatase 
thus supporting their role as the terminal metal binding site prior to porphyrin 
metalation. Mutation of other residues in ferrochelatase such as D383, H231 and Y191 
also resulted in higher KmFe values. D383 and H231 are thought to be an initial binding 
site for iron (Wu et al., 2001, Sellers et al., 2001) and conserved residues between the 
active site (W227, Y191, R164 and Y165) were thought to provide a pathway for iron 
to enter the active site (Sellers et al., 2001), This proposal however, predated the 
discovery of the solvent filled channels, another potential route for iron to enter the 
active site (Medlock et al., 2012).  
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Other techniques such as amide Hydrogen/Deuterium exchange mass spectrometry 
(HDX-MS) were utilised to probe the residues involved in forming the final metal 
binding site prior to insertion. HDX-MS studied the change in backbone dynamics in 
Apo H. sapiens ferrochelatase and Fe2+ bound H. sapiens ferrochelatase. There were 
notable differences in the peptides 89-91, 164-173 (containing R164 and Y165), 197-
203, 222-233 and 338-345 (contains the π helix) upon binding of iron. The dynamics 
in the region containing R164 and Y165 reduces when iron is bound, potentially 
indicating a role in iron binding. The peptide containing the H263, 260-269, does not 
alter in solvent accessibility or backbone dynamics in the presence of iron suggesting 
these residues do not have a role in iron binding. However, the peptide containing 
E343, 330-345, does show a decrease in dynamics when iron is present. Whilst this 
result supports E343 as a potential site for iron binding, the proton abstraction 
hypothesis claims that the protons would exit the active using this residue and other 
residues in the π helix and this could affect the dynamics of the π helix (Asuru and 
Busenlehner, 2011).  
 
1.3.4.4 Summary of catalytic model 
The face in which iron is inserted into the porphyrin still remains controversial, however 
what is clear is that the ferrochelatase undergoes significant structural reorganisation 
on substrate binding. Porphyrin binding leads to the reorganisation of several active 
site residues which ultimately causes closure of the active site mouth (Dailey et al., 
2007, Medlock et al., 2007a). One group had suggested that this closure is dependent 
on the protonation state of the invariant glutamate (E343) (Hunter et al., 2016). 
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Despite the controversy surrounding the role of the conserved His-Glu pair in catalytic 
mechanism, it is obvious that they are essential for the ferrochelatase function. 
Mutagenesis of these residues results in inactive enzymes which are still able to bind 
porphyrin substrate but unable to turnover (Sellers et al., 2001). They are also likely 
to take part in the hydrogen bonding network within the active site (Medlock et al., 
2009, Dailey et al., 2007).  
 
Crystallographic studies reveal that the π helix can unwind, extend and turn and this 
occurs once product has formed.  The unwinding of the helix is a potential mechanism 
for product release but presumably rewinding of the helix could provide a different 
function such as allowing either substrate entry into the active site (Medlock et al., 
2007b, Fodje and Al-Karadaghi, 2002). The roles of the other peripheral features of 
the ferrochelatase active site, the solvent filled channels and the secondary metal 
binding site, are yet to be fully understood (Medlock et al., 2012, Hobbs et al., 2017, 
Hunter et al., 2008, Hansson et al., 2006). 
 
An extensive amount of work has been completed to reveal the residues important in 
the enzymatic mechanism of ferrochelatase and further investigation using techniques 
such as stopped flow fluorescence/ absorbance spectroscopy can be used to build a 
detailed enzymatic mechanism (Dailey et al., 2007, Medlock et al., 2007a, Sellers et 
al., 2001, Hansson et al., 2007, Hunter and Ferreira, 2010, Hunter et al., 2016, Asuru 
and Busenlehner, 2011, Hoggins et al., 2007). 
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1.3.5 Kinetic characterisation of ferrochelatase 
1.3.5.1 Steady state kinetics 
Steady state kinetics have been utilised to define the activity of several different 
ferrochelatases (Sellers et al., 2001, Hoggins et al., 2007, Hobbs et al., 2017, Lobo et 
al., 2015, Hansson et al., 2007, Hunter et al., 2008). Most steady state kinetics were 
performed on a mutant of the H. sapiens ferrochelatase, R115L, as this ferrochelatase 
variant has comparable activity to the wildtype and was more stable. The steady state 
kinetic parameters for this ferrochelatase were deduced using UV-Vis spectroscopy:  
the Km for iron (Km Fe) and deuteroporphyrin IX  (KmDIX) were approximately 7.7 μM and 
5.5 μM, respectively and the Vmax was 1.21 μM min-1 (Hoggins et al., 2007). Several 
site-directed mutants of H. sapiens ferrochelatase have been produced targeting 
amino acid residues in the active site (H263, E343, R164, Y165, H341, F337, D340). 
These mutants were kinetically characterised using steady-state kinetics allowing 
comparison to the R115L mutant/ wildtype ferrochelatase (Sellers et al., 2001, Dailey 
et al., 2007). Combining the kinetic data of the mutants can give an indication of which 
residues are important in different aspects of the catalytic mechanism for an example 
some residues are important in iron binding, porphyrin binding or substrate turnover. 
 
Sellers et al. completed extensive work on the kinetically characterising H. sapiens 
ferrochelatase and its mutants. Mutation of the residues D340, E343 and E347 
resulted in negligible activity when mutated to alanine but when mutated 
conservatively these resulted in a decrease in Vmax. There was no change in the Km 
for either substrate suggesting that they are not important in substrate binding. 
Mutation of the aromatic residues Y165, W227 and T191 caused an increase in KmFe 
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and Y123 mutation affected the Vmax of ferrochelatase suggesting that the majority of 
the aromatic residues listed are important in binding iron or entry of iron into the active 
site.  The mutation R164L causes a 2-fold increase in KmFe and the double mutant 
R164L/Y165F (section 1.3.4.3) increases the KmFe 6-fold and decreases kcat 10-fold, 
this  could be have a role in iron binding and these residues are hypothesised to bind 
iron prior to porphyrin metalation, as previously discussed (Sellers et al., 2001). 
1.3.5.2 Transient kinetics 
When kinetically characterising proteins, steady state kinetics are not sufficient to 
completely characterise the enzymatic mechanism. Steady state kinetics look at the 
overall reaction mechanism, encompassing all steps in the reaction. When looking at 
the effect of amino acid residue mutation on the activity of the enzyme, steady state 
kinetics is able to give an insight to the importance of the residue in the enzyme 
mechanism but not much more. Transient kinetics is capable of teasing out the rates 
of each step in the mechanism using different experiments and comparison of the 
wildtype and the site directed mutants can give a better insight to the role of the residue 
in the catalytic mechanism. 
 
Limited transient kinetic investigation has been completed on ferrochelatase; these 
investigations have used human ferrochelatase or yeast ferrochelatase (Hunter et al., 
2016, Gillam et al., 2018, Hoggins et al., 2007). Transient kinetics performed by Hunter 
et al., and Gillam et al., mainly focus on the pH-dependence of the ferrochelatase 
reaction. Hoggins et al., looks at enzymatic mechanism of ferrochelatase and the 
active site residues involved. 
 
 95 
Hoggins et al. completed both steady state and transient kinetics on ferrochelatase to 
understand the role of a particular mutant (E343D) in the enzymatic mechanism.  The 
activity of the R115L mutant with wildtype activity was compared to the R115L/E343D 
double mutant.  From the steady-state kinetics of these two proteins the kinetic 
parameters kcat, KmFe and KmDIX, were obtained.  The KmFe values were 7.7 µM and 8.2 
µM for the R115L and R115L/E343D, respectively and the KmDIX values were 5.5 µM 
(R115L) and 5.8 µM (R115L/E343D) showing relative consistency between the two 
proteins. The kcat values were 1.21 µM min-1 (R115L) compared to 0.16 µM min-1 
(R115L/E343D) suggesting that the mutation doesn’t affect the binding of the 
substrates but is important in another aspect of the enzymatic mechanism (Hoggins 
et al., 2007). 
 
Transient kinetics can be obtained using stopped flow absorbance or fluorescence. 
The transient kinetics undertaken by Hoggins et al. suggests that the mutation E343D 
effects several different stages in the enzyme mechanism. The concentration of active 
enzyme was determined using an active site titration. The E343D mutant has a 
substantially lower kcat value and the metal chelation rates (kchel) (potentially metal 
chelation with an isomerisation) were much greater than kcat at 0.96 s-1 (R115L) and 
0.3 s-1 (R115L/E343D). The substantially greater kchel  compared to the kcat suggests 
that there is another much slower step involved in the enzymatic mechanism after 
metal insertion; this is most likely product release (Hoggins et al., 2007).  
 
These transient kinetic studies reveal that metal chelation is fast and is not the rate 
determining step. There is a slower, rate determining step after metal chelation which 
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is most likely product release. The E343D mutant is not important in substrate binding 
but is important in another part of the mechanism. Mutation of E343 to aspartate 
(E343D) results in a 7-fold decrease in kcat and a 3-fold decrease in kchel, suggesting 
that it is involved in the iron chelation but may be important in other enzymatic steps 
as well. Hoggins et al. shows how powerful transient kinetics can be in deducing the 
enzymatic mechanism of ferrochelatase (figure 1.29) and the importance of particular 
residues (Hoggins et al., 2007). 
 
Figure 1.29 - Schematic for the mechanism of iron insertion into deuteroporphyrin IX 
by human ferrochelatase (FC) 
This enzymatic scheme has been taken from Hoggins et al.; it shows how transient kinetics 
can be used to expand a simple enzymatic scheme to a more complex but more accurate 
scheme. Abbreviations: DIX (deuteroporphyrin), E (enzyme/ ferrochelatase), Fe (ferrous iron, 
Fe2+).   
 
1.3.5.3 General considerations for kinetics studies on FC 
In most kinetic studies particularly on the H. sapiens ferrochelatase, the endogenous 
substrates, protoporphyrin IX and ferrous iron have not been used. This due to the 
unstable nature of both substrates in solution. PPIX is very hydrophobic and as a result 
the molecules stack and produce insoluble aggregates. Ferrous iron can be easily 
oxidised to produce ferric iron, which is not a substrate for ferrochelatase. Generally, 
the alternative substrates used are deuteroporphyrin (DIX) and sometimes MPIX and 
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zinc. The porphyrins DIX and MPIX are more soluble than PPIX and zinc cannot be 
oxidised (Hunter et al., 2008, Davidson et al., 2009). 
 
In experiments completed by Davidson et al., the kinetic properties of H. sapiens 
ferrochelatase was explored. These assays used zinc as the metal ion and DIX as the 
porphyrin substrate. Despite the fact that these are not the physiological substrates 
information about the catalytic mechanism can still be obtained, however it is 
reasonable to assume that experiments undertaken may not relate to physiological 
behaviour of ferrochelatase. Deviation in the results could also occur as zinc can insert 
into porphyrin uncatalysed and non-physiological substrates could bind in the active 
site differently (Davidson et al., 2009). All the same, zinc binds to ferrochelatase in a 
very similar way to iron and is a more modest structural variation than site-directed 
mutagenesis of many amino acid side chains (Medlock et al., 2007a, Davidson et al., 
2009, Hunter et al., 2008).  
 
Zinc acts as a detergent-dependent uncompetitive substrate inhibitor as the kinetic 
behaviour alters in the presence of the detergent cholate. Zinc inhibition is dependent 
on the deuteroporphyrin concentration suggesting that zinc is the second substrate to 
bind. Also, a significant amount of the inhibited complex must accumulate for the 
inhibition to occur, implying that release of the metalloporphyrin may be rate limiting. 
Furthermore, as the addition of detergents like cholate alter the kinetic properties of 
the enzyme, this should be taken into consideration when undertaking kinetics studies 
on ferrochelatase (Davidson et al., 2009). 
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1.4 Thesis aims 
Heme biosynthesis is an essential pathway in bacteria, if an enzyme in the pathway, 
for example ferrochelatase is knocked out it is lethal to the bacteria. Gram positive 
bacteria synthesise heme using the coproporphyrin-dependent pathway, which was 
discovered in 2015. Since the discovery of the coproporphyrin-dependent pathway, 
little work has been completed on the coproporphyrin ferrochelatases. The 
protoporphyrin ferrochelatases in the protoporphyrin-dependent pathway are well 
characterised especially H. sapiens ferrochelatase. Investigating the enzymatic 
mechanism of the coproporphyrin ferrochelatases kinetically and structurally could 
lead to the design of new antibiotics specifically targeting Gram positive bacteria.  
 
The P. acnes (Gram positive bacterium) ferrochelatase is covalently linked (connected 
by a linker) to the subsequent enzyme in the coproporphyrin-dependent heme 
biosynthetic pathway, coproheme decarboxylase.  This linkage is only found in this 
species and not in other Gram positive bacteria, which utilise the same heme 
biosynthesis pathway. This suggests that there may be a potential interaction between 
the coproporphyrin ferrochelatase and coproheme decarboxylase protein or a 
mechanism whereby the porphyrin molecule gets transferred directly from one protein 
to the other. If the two enzymes do interact then drugs can be designed which target 
the protein-protein interactions. In the first results chapter, I describe my investigation 
of the protein-protein interactions between P. acnes HemH and HemQ and the 
substrate transfer between the two proteins. Protein-protein interactions between 
other HemH and HemQ proteins from different bacterial species were also tested. 
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The B. subtilis ferrochelatase (coproporphyrin ferrochelatase) expresses and purifies 
well. However, when assayed in previous work the porphyrin substrates used were 
analogues of protoporphyrin IX and not of coproporphyrin III. This resulted in a 
ferrochelatase that appeared largely inactive and did not reflect the true activity of the 
B. subtilis ferrochelatase (Hansson et al., 2007). Since discovery of the 
coproporphyrin-dependent pathway there is little kinetic characterisation of Gram 
positive bacteria ferrochelatases (CpFC) with their physiological porphyrin substrate, 
coproporphyrin III. The apoprotein structure and N-methyl mesoporphyrin bound 
structure of B. subtilis ferrochelatase were resolved using X-ray crystallography (Al-
Karadaghi et al., 1997). There are currently no existing structures of B. subtilis 
ferrochelatase bound to its porphyrin substrate coproporphyrin III.  
 
The second results chapter describes the kinetic characterisation of the wildtype B. 
subtilis and S. aureus ferrochelatase using the physiological porphyrin substrate, 
coproporphyrin III. This characterisation has used both steady state kinetics and 
transient kinetics and a combination of UV-visible and fluorescence spectroscopy.  
Crystal trials have been performed on B. subtilis ferrochelatase in the presence of 
coproporphyrin to structurally resolve the ferrochelatase bound to its endogenous 
substrate. To date, this has been unsuccessful. 
 
The role of active site residues in the H. sapiens ferrochelatase have been extensively 
explored by site-directed mutagenesis. This has not been completed for any 
ferrochelatase present in the coproporphyrin-dependent pathway in the presence of 
the physiological substrate. Using the same methods used to characterise the wildtype 
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ferrochelatases (B. subtilis and S. aureus), the active site mutants of B. subtilis 
ferrochelatase (K87A, H88A, H183A, E264A, E264Q) have also been characterised. 
This provides information on the role of the residues in the catalytic mechanism. The 
apoprotein structure of the B. subtilis ferrochelatase mutants H183A and K87A have 
already been resolved (Karlberg et al., 2008, Hansson et al., 2007). Crystal trials of 
K87A, H88A and E264A mutants in the presence of coproporphyrin III have been 
performed. The final results chapter aims to explore the role of individual amino acid 
side chains in the catalytic mechanism of B. subtilis ferrochelatase and investigate 














2. Materials and Methods 
2.1 Producing calcium competent cells 
E. coli cell strains BL21, BL21-DE3, Rosetta and JM109 cells were streaked out on LB 
agar plates and incubated at 37 °C overnight. A single colony was selected and grown 
in 10 mL of LB media overnight at 37 °C; this was used to inoculate a larger volume 
of LB media (500 mL). After inoculation, the cells were grown at 37 °C on a shaker 
until a suitable optical density (OD) was reached (0.6-0.8). The optical density was 
measured at 600 nm on a Cary 50 UV-Vis spectrometer. 
 
Once a suitable optical density was reached, the cells were incubated at 4 °C for 1 
hour. A small volume of the growth (50 mL) was pelleted (Eppendorf 5810R centrifuge) 
and the supernatant was discarded. The was pellet resuspended in 10 mL 0.1 M CaCl2, 
the suspension was incubated at 4 °C for 15 minutes before it was pelleted again. This 
was repeated using 5 mL 0.1 M CaCl2 for resuspension. The final resuspension was 
in 1.5 mL 0.1 M CaCl2 and 15% glycerol and the cells were snap frozen and stored at 
-80 °C. The centrifuge conditions were 1744 ×g, 10 minutes and 4 °C. All buffers and 






2.2 DNA sequencing and gene cloning of hemH and hemQ 
genes from different Gram positive bacterial species 
2.2.1 DNA sequencing of P. acnes hemH-Q, S. aureus hemH and S. 
aureus hemQ and B. subtilis hemH 
The P. acnes hemH-Q plasmid construct was sequenced (Core Genomic Facility, 
University of Sheffield) using primers HemHQ-For 193, HemHQ-For 949, HemHQ-
1262 and HemHQ-Rev 264 (table 2.1). The S. aureus hemH plasmid was sequenced 
(GATC Biotech) using the primers S. aureus HemH-For 179, HemH-For 671, HemH-
Rev 30 and HemH-Rev 574 (table 2.1). Sequencing for S. aureus hemQ was 
attempted using S. aureus HemQ-For 8, HemQ-For 600, HemQ-Rev 67 and HemQ-
Rev 685 and B. subtilis hemH sequencing was attempted using the primers N-term-
For and C-term-Rev (GATC Biotech). 
 
2.2.2 Production of P. acnes hemH-Q truncations 
Structural alignments were performed on HemH (P. acnes, S. aureus, B. subtilis, E. 
coli, H. sapiens and S. cerevisiae) and HemQ (P. acnes, S. aureus, B. subtilis, M. 
tuberculosis and A. meyeri).  The P. acnes HemH-Q fusion protein was included in 
both alignments. This used the alignment software PRALINE (Pirovano and Heringa, 
2010). The results from the PRALINE alignment were used define crude boundaries 
the HemH, HemQ and the linker regions in P. acnes HemH-Q (not shown). The 
primers for the P. acnes HemH-Q truncations were designed from the results of DNA 
sequencing and the PRALINE structural alignment.  The constructs designed were P. 
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acnes hemH (± linker or long/short) and hemQ (± linker or long/short); the plasmid 
containing the whole hemH-Q gene was used as the template DNA.   
 
The Q5 site directed mutagenesis kit was used to amplify the DNA using the standard 
protocol supplied by the manufacturer. All primers were from Sigma-Aldrich and 
diluted in Milli-Q water to produce a primer solution of 100 µM. Further dilution resulted 
in a stock solution of 10 µM, the primer sequences are listed in table 2.1. 
 
Four truncations of P. acnes hemH-Q were produced hemHS (hemH without the linker, 
hemH short), hemHL (hemH with the linker, hemH long), hemQS (hemQ without the 
linker, hemQ short) and hemQL (hemQ with the linker, hemQ long). The hemHS 
construct was cloned using the primers HemH-For and HemH Short-Rev whereas 
hemHL used the same forward primer (HemH-For) and a different reverse primer, 
HemH Long-Rev. They both used an annealing temperature of 58 °C and their 
extension times were 180 seconds and 300 seconds, respectively. The hemQS 
construct was amplified using the primers HemQ Short-For and HemQ-Rev (table 2.1); 
hemQL required a different forward primer, HemQ Long-For. Both the hemQ 
truncations were produced using the same conditions: an annealing temperature of 






Table 2.1 - PCR conditions for P. acnes hemH-Q and B. subtilis hemH mutants 
SPECIES GENE 
CONSTRUCT 
OLIGO NAME SEQUENCE (5'-3') 
B. subtilis K87A hemH K87A For GACTGGCGCATA 
K87A Rev ATAAACGGCTCGA 
H88A hemH H88A For GCGTATATCGGACT 
H88A Rev GCTCGATAGCCTTC 
H183A hemH H183A For TATCCGCAGCCAG 
H183A Rev GATTTTTTCGGCAGG 
E264A hemH E264A For TTGTCGCGGATC 
E264A Rev AGCACTGCTAAGT 
E264Q hemH E264Q For TCGCGGATCACT 
E264Q Rev AATCATAAAGCACTTGTA 
P. acnes  hemQ HemQ-Rev GCTAGCCATACCATGAT 
HemQ Long-For GCGGCTCGTGGTGAGGGT 
HemQ Short-For CCCGAGGAGGTCAACGCC 
hemH HemH-For AAGCTTGGCTGTTTTGGCGG 
HemH Long-Rev AATGACCGGGGTATCGCG 
HemH Short-Rev CGCGGCCTGGGACAAGATG 
hemH-Q HemHQ-For 193 CCGATTAACGATGCGA 
HemHQ-For 949 TTTATCGCTGATCTCGCCG 
HemHQ-For1262 CCATGTCTGATCATTCGAGT 
HemHQ-Rev 264 TCCAGTGCTGTTAGGGA 
S. aureus  hemH HemH-For 179 ATGACCAGGCTGATGC 
HemH-For 671 ATACAGGTACACCTTGG 
HemH-Rev 30 AGGTGTGCCATAAGCC 
HemH-Rev 574 TCTTGTGGATATGGATCATT 
hemQ HemQ-For 8 AAGCAGCCGAAACATTAG 
HemQ-For 600 AACATTGTTCTCAGATGACG 
HemQ-Rev 67 TGGAACTAGACGTAATGATGC 
HemQ-Rev 685 CCTACAAAGAAACTACCGAA 
All three 
species 




2.2.3 Production of B. subtilis hemH mutants by gene cloning 
The B. subtilis hemH gene was subjected to site directed mutagenesis causing single- 
or double-point mutations resulting in a single amino acid change.  The site-directed 
mutants produced were K87A, H88A, H183A, E264A and E264Q hemH. The primers 
for these mutants were designed using the NEBaseChanger. The plasmid containing 
the B. subtilis hemH gene (pTrcHisA-B. subtilis hemH) was used as the DNA template. 
Cloning of the four of the mutants (K87A, H88A, E264A and E264Q) required the 
extension time of 180 seconds and the H183A mutants had an extension time of 300 
seconds. The annealing temperatures for the mutations at residue E264 (E264A and 
E264Q) were 62 °C, for K87A, H88A and H183A they were 54 °C, 60 °C and 61 °C, 
respectively.  




TEMPERATURE / °C 
EXTENSION TIME / s 
P. acnes hemHS 58 180 
hemHL 58 300 
hemQS 58 165 
hemQL 58 165 
B. subtilis K87A 54 180 
H88A 60 180 
H183A 61 300 
E264Q 62 180 





2.3 Transformation of E. coli into a cloning strain and polymerase 
chain reaction (PCR) of gene 
The KLD (Kinase, Ligase & DpnI) reaction was used to re-circularise the linear 
plasmids gained from PCR and degrade the template DNA. This reaction was 
performed using the manufacturer’s instructions with a room temperature incubation 
of 30 minutes instead of 5 minutes. The circularised plasmid was introduced to DH5α 
E. coli and incubated on ice of 30 minutes. Heat shock at 42 °C for 45 seconds allowed 
entry of the plasmid into the E. coli. The E. coli cells were incubated on ice for a further 
15 minutes and then incubated in 950 µL of SOC media (New England Biolabs Inc.) 
for 90 minutes at 37 °C. A volume of 50 µL was plated onto agar plates containing 100 
µg mL-1 ampicillin and incubated overnight at 37 °C.  
 
To obtain DNA for sequencing after mutagenesis, a single colony from the agar plate 
was used to inoculate a small volume of LB media and grown at 37 °C overnight. 
Plasmid DNA was isolated using the QIAGEN Miniprep kit. In most cases the plasmid 
DNA was used as a template in a second PCR, this amplified the segment of the 
plasmid containing the gene. The primers used for this PCR were N-term For and C-
term Rev, (extension time of 60 seconds, an annealing temperature 58 °C). The DNA 
fragments were purified using the QIAGEN PCR clean up kit as per the manufacturer’s 
instructions.  The S. aureus hemH and hemQ plasmids were sequenced directly 
whereas all other constructs underwent the second PCR step and the fragment 
produced was sequenced. The sequencing primers used was N-term For and C-term 
Rev (table 2.1), the same primers used to amplify the fragment.  The DNA was 
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sequenced by GATC Biotech and analysis of sequencing data used MEGA X and 
BioEdit.  
2.4 Protein Expression 
2.4.1 Insertion of plasmids into expression E. coli strains 
All available plasmids were inserted into the E. coli strains BL21, BL21-DE3, Rosetta 
and JM109 as described in section 2.2.  Expression trials were performed if the protein 
yield was low. 
 
2.4.2 Expression trials  
Protein expression trials for S. aureus HemH and HemQ, P. acnes HemHL, HemHS 
and HemQL and B. subtilis H183A were completed in three different E. coli cell lines 
(BL21, BL21-DE3 and Rosetta) and using two different growth mediums (LB and 2YT). 
P. acnes HemHS expression trials were more extensive, it was also trialled in JM109 
E. coli in combination with CircleGrow media. Cell lines BL21, BL21-DE3 and Rosetta 
were also tested at different pre-induction temperatures in LB, 2YT media (37 °C, 
30 °C and 18 °C) and ZYM-5052 auto-induction media (30 °C and 37 °C). The 
expression trial combinations are shown in table 2.3.  
 
Expression trials were run in small volumes, 5 mL of media was inoculated with 50 µL 
of starter culture, most commonly incubated at 37 °C. In the LB and 2YT media the 
BL21, BL21-DE3 and Rosetta E. coli required induction by IPTG (isopropyl β-D-1-
thiogalactopyranoside). The growths were allowed to reach an optical density of 0.6-
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0.8 and 0.5 mM of IPTG was used for induction.  After the addition of IPTG the 
temperature was reduced to 18 °C and these were incubated for 18 hours, 1 mL of the 
growths was centrifuged at 6000 ×g for 10 minutes, the supernatant was discarded, 
and the pellet resuspended. A sample was taken from the resuspended pellet and 
used for SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis) 
analysis.  
 
The H183A B. subtilis mutant protein was found in inclusion bodies, additional trials 
were completed to solubilise the protein during expression. Pre and post induction 
temperatures were lowered (18 °C) and a one hour 4 °C incubation was completed 













Table 2.3 Protein expression conditions for S. aureus HemH and HemQ and the P. 
acnes truncations 
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Pre induction – 18 °C, 
30 °C and 37 °C 
Post induction – 18 °C 
30 °C and 37 °C 
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Pre induction – 18 °C, 
30 °C and 37 °C 
Post induction – 18 °C 








Pre induction – 18 °C, 
30 °C and 37 °C 
Post induction – 18 °C 
 
2.4.3 Full scale protein expression 
2.4.3.1 Standard expression protocol and expression cell lines 
P. acnes HemH-Q, P. acnes HemQS, P. acnes HemQL and B. subtilis HemH were 
expressed in Rosetta E. coli. The B. subtilis mutants (K87A, H88A, H183A, E264A 
and E264Q) were expressed in BL21-DE3 E. coli and P. acnes HemHL, P. acnes 
HemHS and S. aureus HemQ were expressed in BL21 E. coli. Finally, S. aureus HemH 
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was expressed in JM109 E. coli. All proteins except S. aureus HemH were expressed 
in LB media. S. aureus HemH required CircleGrow media.  
 
One colony of E. coli cells containing desired gene was grown in 20 mL of LB media 
at 37 °C for 18 hours. Half of the starter culture was used to inoculate 1 L of LB media 
and this was grown at 37 °C until the growth obtained an OD reading of 0.6-0.8. Protein 
expression was induced by the addition of 0.5 mM IPTG and the temperature was 
reduced to 18 °C, for 18 hours. Ampicillin (100 µg mL-1) was added to the growth 
media. The cells were harvested by centrifugation at 5488 ×g, for 20 minutes at 4 °C. 
The resulting pellets were stored at -80 °C. 
 
The expression of S. aureus HemH involves used a different expression protocol. The 
starter culture was produced in the same way and 10 mL was used to inoculate 1 L of 
CircleGrow media. The E. coli was grown at 30 °C for 24 hours and expression was 
not induced. The cells were harvested as above and ampicillin (100 µg mL-1) was 
present throughout.  
 
2.4.3.2 Different P. acnes HemHS expression conditions 
Different growth conditions were used to express P. acnes HemHS. Firstly, HemHS 
was expressed in LB media and induced using IPTG using the same method 
described in section 2.3.5 however; this was attempted in three of the E. coli cell lines 
(BL21, BL21-DE3 and Rosetta).  This protocol was also altered where the initial 
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incubation temperature before protein induction was changed from 37 °C to 30 °C and 
18 °C. 
2.5 Protein Purification 
2.5.1 Preparation of protein sample for immobilised metal affinity 
chromatography (IMAC) 
E. coli cell pellets stored at -80 °C, were defrosted and resuspended in binding buffer 
(50 mM Tris, 100 mM KCl, pH 8).  At this point protease inhibitors were added, most 
commonly Roche cOmplete mini EDTA (ethylenediaminetetraacetic acid) free (Sigma 
Aldrich) but sometimes SigmaFast protease inhibitor cocktail (EDTA free) (Sigma 
Aldrich) or Pefabloc SC (Sigma Aldrich).  Protease inhibitors were solubilised in MilliQ 
water before they were added to the cell pellet suspension. The resuspended cells 
were lysed using pulse sonication at 10 µm in ice, each pulse lasted for 30 seconds 
with 60 second rests in between, this was repeated six times. The lysate was 
centrifuged at 26902 ×g for 45 minutes at 4 °C separating the soluble and insoluble 
cell pellet fractions. 
 
2.5.2 Purification using IMAC 
All proteins (P. acnes HemH-Q, P. acnes HemHS, P. acnes HemHS, P. acnes HemQS, 
P. acnes HemQL, B. subtilis HemH, B. subtilis K87A HemH, B. subtilis H88A HemH, 
B. subtilis H183A HemH, B. subtilis E264A HemH, B. subtilis E264Q HemH, S. aureus 
HemH and S. aureus HemQ) used IMAC as their first purification step as all contain a 
N-terminal 6x histidine tag. The soluble fraction or supernatant after lysis and 
centrifugation was applied to a pre-equilibrated nickel/ cobalt column. P. acnes HemH-
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Q, P. acnes HemQS, P. acnes HemQL, B. subtilis HemH and S. aureus HemQ used 
columns containing nickel resin in the form of a 1 mL His GraviTrap or a 1 mL or 5 mL 
HisTrap (GE Healthcare Life Sciences).  P. acnes HemHL, B. subtilis mutants (K87A, 
H88A, H183A, E264Q and E264A) and S. aureus HemH use columns containing 
cobalt resin (TALON), these were in the form of 1 mL His GraviTrap TALON (GE 
Healthcare Life Sciences).  During the optimisation of P. acnes HemHS purification, 
both cobalt and nickel resin were used. 
 
After initial protein binding to the column the resin was washed with 20 CV (column 
volumes) of high salt buffer (50 mM Tris, 1 M KCl, pH 8). The resin was washed with 
10 CV of low imidazole buffer (50 mM Tris, 100 mM KCl, 10-30 mM imidazole, pH 8).  
The protein was eluted from the column in 5 CV of elution buffer (50 mM Tris, 100 mM 
KCl, 300 mM imidazole, pH 8).  The purification protocol of S. aureus HemH did not 
contain the high salt wash. In some experiments S. aureus HemH was purified using 
buffers that contained an addition of 1% sodium cholate and 50 mM MOPS (3-(N-
morpholino) propanesulfonic acid). These conditions were also used in an attempt to 
solubilise H183A B. subtilis HemH. 
 
Proteins that were successfully purified by IMAC (B. subtilis HemH mutants, P. acnes 
HemHL, P. acnes HemQS, S. aureus HemH) were desalted using a manually poured 
Sephadex G50 column into binding buffer to remove imidazole and stored at -80 °C. 
Those that required further purification (P. acnes HemH-Q, P. acnes HemQL, B. 
subtilis HemH and S. aureus HemQ) were also desalted in preparation for ion 
exchange chromatography (IEX).  
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2.5.3 Purification using ion exchange chromatography (IEX) 
P. acnes HemH-Q, P. acnes HemQL, B. subtilis HemH and S. aureus HemQ required 
further purification after IMAC and so they were purified further using IEX.  A Q 
Sepharose 5 mL HiTrap FF column (GE Healthcare Life Sciences) was used for IEX. 
The column was equilibrated in low salt buffer (50 mM Tris, pH 8) and a gradient of 
salt from 0 - 0.5 M was applied over 10 CV and 0.5-1 M over 5 CV. Proteins that 
successfully purified after IEX were stored at -80 °C. 
 
2.5.4 Optimisations for P. acnes HemH-Q purification 
2.5.4.1 Size exclusion chromatography (SEC) 
Steps to optimise the purification protocol for P. acnes HemH-Q included using SEC. 
The SEC column used was a HiLoad Superdex 26/600 200 PG column (GE 
Healthcare Life Sciences). The column was pre-equilibrated in binding buffer and the 
protein sample containing P. acnes HemH-Q was applied directly to the SEC column 
after elution off the IMAC. The column was run for 1 CV. This purification was also 
repeated in two different conditions these were high salt (1 M KCl) and 1 M urea.  
 
2.5.4.2 IMAC of P. acnes HemH-Q in denaturing conditions 
P. acnes HemH-Q was purified in the presence of 1 M urea and 8 M urea. This was 
performed in the same way as the standard IMAC procedure described earlier in 
section 2.5.2 however, the buffers used contained either 1 M urea or 8 M urea. The 1 
M urea preparation was then purified further by SEC also in the presence of 1 M urea. 
Due to the high viscosity of 8 M urea, SEC was not attempted under these conditions. 
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2.5.4.3 Treatment with EDTA to inhibit metalloproteases 
To improve the yield of P. acnes HemH-Q 5 mM EDTA was added to cell suspension 
along with protease inhibitor cocktail (SigmaFast) before sonication. EDTA was added 
to inhibit E. coli metalloproteases. The cells were lysed and centrifuged as described 
above in section 2.5.1. The soluble fraction was treated with ammonium sulphate (80% 
saturation) and incubated at 4 °C for 30 minutes to pellet P. acnes HemH-Q. The 
sample was centrifuged 10,000 ×g for 15 minutes at 4 °C and the resulting pellet was 
resuspended in binding buffer before application to a 1 mL His GraviTrap column. 
Ammonium sulphate precipitation removed the EDTA before IMAC. 
 
2.5.5 Optimisations for P. acnes HemHS purification 
2.5.5.1 Solubilising P. acnes HemHS using detergents and high salt 
The P. acnes HemHS cell pellet was resuspended in binding buffer containing either 
2 % Triton-X-100, 1 % sodium cholate, 15 mM CHAPS (3-[(3-cholamidopropyl) 
dimethylammonio]-1-propanesulfonate hydrate) or 500 mM KCl. Cell lysis occurred by 
sonication and the lysate was centrifuged as in section 2.5.1. The HemHS content in 
the lysate, insoluble and soluble fractions were analysed by SDS PAGE (section 2.6).  
 
2.5.5.2 Denaturing preparations of P. acnes HemHS 
The cell pellet was resuspended in binding buffer, lysed by sonication and centrifuged 
(section 5.2.1). The insoluble fraction (pellet) was resolubilised in binding buffer 
containing 8 M urea and centrifuged (26902 ×g, 20 mins, 4 °C). The supernatant was 
applied to a pre-equilibrated 1 mL His GraviTrap, the column was washed with 20 CV 
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of high salt buffer containing 8 M urea and then 10 CV of a low imidazole wash also in 
8 M urea.  When attempting on column refolding the urea concentration was lowered 
in 1 M steps until the urea concentration reached 1 M then there was a final wash of 
500 mM urea before the protein was eluted of the column in elution buffer containing 
no urea (5 CV).  Each of the low imidazole washes were 5 CV.  
 
2.6 Polyacrylamide gel electrophoresis (PAGE) 
2.6.1 SDS-PAGE 
The gels for SDS-PAGE were handmade, the resolving gel had an acrylamide 
concentration of 8-12 % and the stacking gel was 4-6 % acrylamide. The gel buffer 
solutions for each gel component was 1 M Tris, pH 8.8 (resolving) and 1 M Tris, pH 
6.8 (stacking). A combination of APS (ammonium persulphate) and TEMED (N, N, 
N′,N′-tetramethylethylene-diamine) were used to polymerise the acrylamide and SDS 
was used to denature proteins in the sample. After the Laemmli sample buffer 
containing fresh reducing agent (β-mercaptoethanol) was added to the protein, the 
samples were loaded into the SDS-PAGE gel. The running buffer used for SDS-PAGE 
was 1X Tris Glycine SDS running buffer bought as a 10X stock. Each gel was run at 
160-200V for 40-55 mins.  SDS-PAGE was used to analyse the presence and purity 
of desired proteins. 
 
2.6.2 Native PAGE 
Three different types of native PAGE gels were used in the native PAGE analysis of 
P. acnes HemH-Q: tris glycine, blue native (BN) and a hybrid of the two systems. Tris 
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glycine gels were made in the same way as the SDS gels described in section 2.6.1 
however SDS was excluded. The acrylamide concentration was varied between 6- 10 % 
and standard Laemmli sample buffer without SDS and reducing agent was used. BN-
PAGE gels were prepared similarly using an acrylamide concentration of 8%. The 
sample buffer for BN-PAGE contained Coomassie G250. The hybrid of the two 
systems used tris glycine gels and running buffer and the BN-PAGE Coomassie 
sample buffer. The gels were run at 4 °C for approximately 5 hours, depending on the 
mobility of the protein through the gel. 
  
2.7 Circular Dichroism (CD)  
2.7.1 Denaturing P. acnes HemH-Q 
P. acnes HemH-Q was exchanged in to phosphate buffered saline (PBS) and 
incubated with different concentrations of urea (0-4 M) or different concentrations of 
isopropanol (0-50 %) overnight. The secondary structure of HemH-Q after incubation 
was measured using circular dichroism.  The spectra were measured between 220 nm 
and 260 nm (Jasco J-810 Spectrometer), the quartz cuvette used has a path length of 
0.1 cm.  
 
2.7.2 Determining secondary structure and thermostability of B. 
subtilis HemH and its mutants 
Circular dichroism spectra of B. subtilis HemH and its mutants (K87A, H88A, E264A 
and E264Q) were taken at 200-260 nm (Jasco J-810 Spectrometer).  The 
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concentration of each protein was 4 µM and the spectra was measured between 200-
260 nm.  The thermostability was tested for the wildtype and the mutants, the ellipticity 
was molar residue ellipticity (θMR) was measured at 220 nm between 5-100 °C for 
unfolding and refolding. The rate of temperature change was 2 °C per minute. The 
unfolding and refolding data was fitted to the equation 1 allowing the calculation of the 
thermal melting temperature (Tm). In equation 1 AB is the θMR at the base of the 
sigmoid, ΔA is the change in θMR between the top and base of the sigmoid, V50 is the 
temperature with causes a 50% increase in θMR, this is the Tm and slope is the 
steepness of the curve. 





        Equation 1 
2.8 In-gel tryptic digestion and mass spectrometry (MS) 
2.8.1 Destaining and dehydration of gel pieces 
The protein band of interest was excised from a 10% SDS-PAGE gel. The excised 
band was treated with 1 mL destaining solution (50% acetonitrile (ACN) (Sigma 
Aldrich), 50 mM ammonium bicarbonate (ABC) (Sigma Aldrich)) and incubated on a 
shaker for 1 hour. The liquid was decanted off and the procedure was repeated twice 
more, ensuring that the gel pieces containing the protein band were thoroughly 
destained. The gel was dehydrated using 200 µL of ACN and incubated for 15 minutes, 
before the liquid was removed. Incubation steps occurred at room temperature and all 
following incubation steps were also at room temperature unless stated otherwise. 
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2.8.2 Reduction, alkylation and digestion of protein 
The resulting protein sample was reduced using 200 µL 50 mM TCEP (Tris(2-
carboxyethyl) phosphine hydrochloride (Sigma Aldrich) and incubated at 56 °C for 1 
hour. Alkylation required 200 µL 40 mM iodoacetamide (IAA) and an incubation of 30 
minutes in the dark. The supernatant was removed, and the protein sample was 
washed with 200 µL of 50 mM ABC twice, 15 minutes each time. A third wash used 
200 µL of the destaining solution. The gel was dehydrated again as previously stated. 
The supernatant was removed, and the gel pieces were left for 5 minutes to ensure all 
ACN had evaporated. Finally, 30 µL of trypsin solution (Sigma Aldrich) was added to 
the sample and digestion occurred overnight at 37 °C.   
 
2.8.3 Peptide extraction and mass spectrometry 
To stop digestion after overnight incubation 15 µL of ACN was added to the digested 
peptides and incubated for 15 minutes. A 30-minute incubation followed in 150 µL 0.5% 
formic acid (Sigma Aldrich) and extracted peptides were transferred to a new tube. 
The following steps were repeated three times: a 15-minute incubation with 100 µL 
formic acid, 15 minutes incubation with 50 µL ACN and transfer of extracted peptides 
into tube. The peptides were dried down in a speed-vac and stored at -20 °C. 
 
The dried peptides were resuspended in 40 µL 0.5% formic acid and the resuspended 
peptides were sonicated in a water bath for 5 minutes. After sonication, the peptides 
were centrifuged at 12,000 ×g for 5 minutes and transferred into a mass spectrometry 
vial. The peptide sample was run down a 50 cm C18 liquid chromatography (LC) 
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column; a gradient of acetonitrile (0-72%) was applied. As the peptides eluted off the 
column, they were analysed by mass spectrometry.  
 
2.9 Kinetic characterisation of B. subtilis HemH and S. 
aureus HemH 
2.9.1 Preparation and concentration determination of ferrochelatase 
and its substrates 
2.9.1.1 Concentration determination of ferrochelatase 
The concentration of B. subtilis HemH and its mutants (K87A, H88A, E264A and 
E264Q) were determined using an absorbance reading at 280 nm on a NanoDrop 
(ThermoFisher) with an extinction coefficient of 48820 M-1 cm-1.  S. aureus HemH had 
an extinction coefficient of 47790 M-1 cm-1(Hobb et al., 2017, Lobo et al., 2015). The 
enzyme concentrations were calculated using the Beer-Lambert law. 
 
2.9.1.2 Ferrous iron solution 
Approximately 40 mg of ferrous ammonium sulphate and 9 mg of L-ascorbic acid was 
solubilised in 20 mL of MilliQ water to form a ferrous iron solution.  A small amount of 
ferrozine was resuspended in 1 mL of MilliQ water. An iron sample was constructed in 
a 1 mL cuvette: 2 µL iron solution, 100 µL ferrozine and 900 µL Milli-Q water. The 
concentration of ferrous iron was determined using a Cary 50 UV-Vis spectrometer. 
Using the measured the absorbance at 563 nm and the extinction coefficient for the 
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iron ferrozine complex, 28000 M-1 cm-1 (Stookey, 1970) the concentration of iron can 
be determined using the  Beer-Lambert law. 
 
2.9.1.3 Coproporphyrin III (CPIII) solution 
A small amount of coproporphyrin III dihydrochloride was diluted in 1 mL assay buffer 
(0.1 M Tris, pH 8). Once completely resuspended the solution was diluted further in 
assay buffer until at a suitable working concentration. This solution was transferred 
into black centrifuge tubes and stored at -20 °C.  
 
To determine the concentration of CPIII, 2 µL CPIII solution was added to 1 mL 0.1 M 
HCl. A Cary 50 UV-Vis spectrometer measured the absorbance between 350-450 nm. 
The extinction coefficient for coproporphyrin III at 401 nm is 470000 M-1 cm-1 (Falk, 
1964) and the Beer-Lambert law was used to calculate the concentration of CPIII. 
 
2.9.2 Preliminary kinetics 
2.9.2.1 Scanning kinetics 
Two experiments were conducted using scanning kinetics to investigate the behaviour 
of B. subtilis HemH and its mutants. The first experiment used looked at absorbance 
peaks change in absorbance as the reaction progressed. The wildtype HemH was 
assayed with its substrates ferrous iron and coproporphyrin III in assay buffer (0.1 M 
Tris, pH8.0). The reaction was monitored between 350-600 nm and a spectrum was 
taken every 30 seconds for 30 minutes. In these assays the ferrous iron concentrations 
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were 0.8 µM, 8 µM or 80 µM and the CPIII concentrations were 2 µM and 10 µM. The 
ferrochelatase concentration for each of these assays was 50 nM. These spectra were 
monitored on a Cary 1 UV-Vis spectrometer at 25 °C.  
 
The second experiment looked at spectral shifts that occurred when CPIII was bound 
to enzyme. The spectral shifts were monitored between 350-450 nm, each scan was 
6 seconds for the first 10 minutes and every 30 s a spectrum of 2 uM CPIII was 
recorded. Firstly, in wildtype B. subtilis, to ensure the spectral shifts were a result of 
enzyme-substrate complex (2 µM CPIII and 2 µM HemH), the complex was denatured 
in ~30% ethanol. The samples were also spiked with 10 µM ZnCl2 to replicate zinc 
contamination. The wildtype S. aureus HemH and B. subtilis HemH and the B. subtilis 
HemH mutants’ spectral properties in the presence of porphyrin were also investigated.  
Initially, the spectra of 2 µM CPIII were recorded, then 2 µM of ferrochelatase was 
added. The spectral shift was monitored and when complete 20 µM ferrous iron was 
added and the further reaction was monitored. This was also performed for each of 
the B. subtilis HemH mutants (K87A, H88A, E264Q and E264A) and S. aureus HemH. 
These spectra were monitored on a Cary 1 UV-Vis spectrometer at 25 °C. 
 
2.9.2.2 B. subtilis and S. aureus HemH activity assays 
The progression of the reaction between B. subtilis HemH and S. aureus HemH and 
its substrates was monitored by a Cary 1 UV-Vis spectrometer at 25 °C at 393 nm. 
The absorbance was monitored continuously until the endpoint of the reaction was 
reached. The ferrous iron concentration was either 50 µM or 100 µM, the CPIII 
concentration was 4 or 10 µM and the ferrochelatase concentration remained constant 
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at 0.2 µM. The molar extinction coefficient for the reaction was calculated as 70410 M-
1 cm-1.  To compare the activity of the B. subtilis HemH mutants, endpoint assays were 
completed on them using 0.2 µM enzyme, 4 µM CPIII and 50 µM ferrous iron. 
 
2.9.3 Steady State Kinetics  
The steady-state kinetic parameters of B. subtilis HemH and S. aureus HemH were 
determined using the substrates ferrous iron and coproporphyrin III in a 
spectrophotometric assay on a Cary 1 UV-Vis spectrometer at 25 ˚C.  
 
In wildtype B. subtilis HemH, S. aureus HemH and B. subtilis H88A HemH the change 
in absorbance was monitored at 393 nm and the enzyme concentration remained 
constant at approximately 10 nM (when CPIII is varied) or 0.1 µM (when iron is varied). 
Whilst one substrate was held at saturating conditions the other was varied. The 
concentration of iron was varied between 0-200 µM and the CPIII concentration was 
held at approximately 0.5 µM, 1 µM, 1.7 µM (B. subtilis HemH only) and 2 µM in the 
wildtype proteins. In the H88A mutant the CPIII concentration was held at 2 µM and 
the different iron concentrations were repeated in triplicate. When the concentration of 
CPIII was varied (0-4 µM), iron was held at approximately 5 µM, 10 µM or 100 µM when 
assaying the wildtype proteins. In the H88A mutant the iron concentration was held at 
100 µM and the different CPIII concentrations were repeated in triplicate. Rates for 
each reaction were calculated from the instrument software and converted into µM s-
1 using the extinction coefficient for the reaction. The data were further processed by 
dividing the rate by the enzyme concentration to obtain values independent of enzyme 
concentration. These values were plotted against substrate concentration using Igor 
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Pro 8 (Wavemetrics). Equation 2A was fitted to the data in a multivariate fit (B. subtilis 
HemH and S. aureus HemH) where each of the two data sets for each enzyme was 
considered separately. This produced estimates for the kinetic parameters kcat and 
KmFe, KmCP and KCP.Fe. The B. subtilis H88A mutant data was fitted to the Michaelis-
Menten equation (equation 2B). This equation estimates the kinetic parameters kcat 














     Equation 2A            vi =
V[S]
𝐾m+[S]
    Equation 2B 
2.10 Static substrate binding assays 
Fluorescence quenching studies looking at binding between the substrates and 
enzymes were completed on a Fluoromax 3 (Horiba) at 25 ˚C. A 560 nm band pass 
filter was placed in front of the emission line to remove second-order scattered light 
when protein is excited at 280 nm. B. subtilis HemH, the mutants (K87A, H88A, H183A, 
E264A and E264Q) and S. aureus HemH were held at 50 nM and were excited at 280 
nm. The emission was recorded from 300-700 nm in the presence of different 
concentrations of CPIII (0-100 µM). The emission peak between 330-510 nm was 
integrated and the peak area was plotted against substrate concentration using Igor 
Pro 8 (Wavemetrics). The appropriate equations were fitted to the data (equation 3A 
or 3B). 




  Equation 3A 





  Equation 3B 
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2.11 Stopped flow fluorescence spectroscopy 
There are three different experiments used in stopped flow fluorescence that look at 
different parts of the ferrochelatase mechanism. The reactions are observed using an 
Applied Photophysics Pi-star spectrophotometer with a 2 mm light path in fluorescence 
mode. Coproporphyrin was excited at 393 nm detected at 90° through a 405 nm cut 
off filter (OG405). Ferrochelatase was excited at 280 nm detected at 90° through a 
blue cut off filter removing wavelengths before 300 nm and after 600 nm (table 2.4). 
The B. subtilis HemH and S. aureus HemH complex with CPIII was excited at 405 nm 
and the H88A mutant CPIII complex was excited at 396 nm, emission was detected at 
90° through a 515 nm cut off filter (OG515). Each reaction was recorded on a 0.5-10 
second time base and at least three reactions were run and averaged. An observed 
rate constant (kobs) was calculated by fitting equations (equation 4A or 4B) to the 
reactions using the Pi-Star fitting software (Pro-data 1.43). All experiments were 
performed at 25 ˚C and in 0.2M Tris, pH 8 assay buffer. 
Table 2.4- Band pass filters 
FILTER WAVELENGTH 
 RANGE 
SIGNAL USED STOPPED FLOW 
EXPERIMENT 
405 nm >410 nm CPIII – 393 nm 
CPIII-FC complex – 396 nm 
CP binding and Fe 
binding and 
metalation 
515 nm >520 nm CPIII-FC complex – 405 nm  Fe binding and 
metalation 
Blue 300-590 nm FC – 280 nm CP binding 
 
[P]t = Ae
−𝑘obst   Equation 4A 
[P]t = Ae
−𝑘obst + vit   Equation 4B 
[P]t = A1e
−𝑘1t + A2e
−𝑘2t + vit      Equation 4C 
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2.11.1 CPIII Binding 
The first experiment looks at CPIII binding, ferrochelatase and CPIII are prepared in 
separate syringes. The reaction is excited at 280 nm or 393 nm, at 280 nm when the 
CPIII concentration is varied (2-100 µM) and the enzyme concentration remained 
constant (0.1 or 0.2 µM). When the reaction is excited 393 nm the CPIII concentration 
is held at 50 nM and the enzyme concentration is varied 0.5 - 5 µM. To gain an 
observed rate constant these runs were fitted to equations 4A, the H88A mutant traces 
could be fit to equation 4C in some concentrations. The kobs value was plotted against 
substrate/enzyme concentration and the data were fit to equation 5. By fitting equation 
5 to the data the KCP and kiso values were estimated, the k-iso value was held at zero. 
This was completed for S. aureus HemH wildtype, B. subtilis HemH wildtype, K87A, 
H88A, E264Q and E264A. 





     Equation 5 
2.11.2 Iron binding and metalation of the porphyrin 
This experiment focuses on iron binding and metalation of CPIII. This experiment was 
not completed on S. aureus HemH. The reaction is excited at 405 nm (wildtype B. 
subtilis ferrochelatase) or 396 nm (H88A B. subtilis HemH). Ferrochelatase and CPIII 
are incubated in one syringe together at equimolar concentrations (1 µM). The 
ferrochelatase (1 µM) and the different concentrations of iron (0-400 µM) are also 
incubated in the other syringe. The final concentration of CPIII is 0.5 µM and 
ferrochelatase is 1 µM. To gain an observed rate constant the averaged data was fitted 
to equation 4B. The estimated kobs value was plotted against iron concentration. These 
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data were fitted to equation 6 to estimate KFe and kchel values whilst k-chel was held at 
zero.  





 Equation 6 
2.11.3 Burst kinetics 
The third setup looks at the collective rate constants for the enzymatic steps prior to 
the rate determining step. The ferrochelatase is in one syringe and both substrates 
are incubated in the second syringe. The porphyrin is excited at 393 nm, the 
ferrochelatase concentration is held at 0.2 µM and the CPIII concentration is 2 µM. The 
ferrous iron concentration is varied (1-200 µM).  The kobs value for S. aureus HemH 
was calculated by fitting the averaged reactions to equation 4B and these kobs values 
was plotted against ferrous iron concentration.  A line was fitted to the data using 
equation 7 allowing estimation of the kinetic parameter KFe and kburst. In B. subtilis 
HemH wildtype and its H88A mutant the rate constants gained from the previous two 
stopped flow experiments were plotted onto the averaged data using equation 4C. 





 Equation 7 
2.11.4 Rapid scanning kinetics 
Rapid scanning kinetics (OLIS DB 620 Spectrophotometer) were performed on the B. 
subtilis HemH mutants (K87A, H88A and E264A) and wildtype and the S. aureus 
HemH protein. The interaction between 1 µM enzyme and 0.64 µM CPIII was observed 
between 350 and 450 nm for 0.5-10 s. The scanning rate was 32 scans per second. 
To reduce the signal to noise ratio, scans were arrayed with 5 (K87A HemH) or 10 
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(wildtypes, K87A and E264A mutants) giving a time resolution of 0.15 seconds and 
0.3 seconds (32 scans per second), respectively. These spectra were processed and 
generated using Igor Pro 8 (Wavemetrics). 
2.12 Crystallisation trials 
Pre-crystallisation trials were performed on the B. subtilis HemH wildtype proteins and 
the K87A, H88A and E264A B. subtilis HemH mutants using the Hampton Research 
pre-crystallisation test protocol. Each of the proteins were screened in the presence 
of equimolar coproporphyrin III (well concentrations of approximately 100 µM for each). 
The screening process used the common crystallisation screens listed: Morpheus, 
JCSG+, PACT, pH Clear, Proplex, MPD and ammonium sulphate. The resulting 
crystal trays were produced using the Mosquito crystallisation robot. Crystal plates 










3. Expression and purification of HemH and HemQ 
from different species to determine interaction 
between two consecutive enzymes in the 
coproporphyrin-dependent heme biosynthetic 
pathway  
3.1 Introduction 
In the coproporphyrin-dependent heme biosynthetic pathway found in Gram positive 
bacteria, three enzymes differ from those in the protoporphyrin-dependent pathway 
found in eukaryotes (section 1.2.3 and 1.2.4). These three enzymes have homologous 
roles but are positioned differently in each of the pathways, giving rise to different 
substrate requirements. For example HemF (CgDC) and HemQ (ChDC) both 
decarboxylate the propionyl groups on rings A and B to form vinyl groups, however 
HemF is the first of the three enzymes in the protoporphyrin-dependent pathway and 
decarboxylates coproporphyrinogen to protoporphyrinogen whereas HemQ is the final 
enzyme in the coproporphyrin-dependent pathway and decarboxylates coproheme to 
heme (Dailey and Gerdes, 2015, Dailey et al., 2015).  
 
In the Gram-positive bacterial species Propionibacterium acnes (P. acnes) the HemH 
and HemQ proteins are fused into a single polypeptide. This observation led the 
hypotheses, firstly that the two enzymes interact and secondly that this interaction 
allows direct transfer of porphyrin from one active site to the other. The third, more 
general, hypothesis is that this interaction and substrate transfer between the HemH 
and HemQ proteins is a general property of the coproporphyrin-dependent pathway of 
heme biosynthesis.  
 129 
To test the interaction between P. acnes HemH and HemQ four truncations of the 
protein were produced using gene cloning, two for HemH (with and without the linker 
region) and two for HemQ (with and without the linker region). Four truncations were 
produced so that there was a greater chance of testing the interaction using 
truncations that make up the whole protein. HemH without linker (HemHS) was found 
in inclusion bodies upon expression and HemQ with linker (HemQL), when purified, 
gave poor yields. As a result, HemH with linker (HemHL) and HemQ without linker 
(HemQS) were used to test interaction between the two enzymes and so HemHS and 
HemQL were not needed. Size exclusion chromatography was used to identify 
whether the proteins were interacting with each other and results showed that HemHL 
and HemQS formed a complex. 
 
As the truncations showed that there was a complex forming between HemHL and 
HemQS, the purification of the full HemH-Q protein was attempted. The HemH-Q 
protein was required to test the substrate transfer mechanism between HemH and 
HemQ. Due to the fluorescent and absorbent nature of porphyrins this could be 
monitored using fluorescence and UV-vis spectroscopy. However, P. acnes HemH-Q 
proved difficult to purify due to its propensity to degrade.  Steps were taken to reduce 
or prevent this cleavage or stabilise the protein however these were unable to prevent 
HemH-Q breaking apart. 
 
Finally, testing the interaction between HemHs and HemQs from different species 
using SEC would indicate whether the interaction observed in P. acnes HemH-Q is 
specific to P. acnes or occurs in other species such as S. aureus where HemH and 
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HemQ are not covalently linked. In addition, interaction between HemHs and HemQs 
across species were also tested to investigate whether the interaction may be species 
specific. The results showed that there was no interaction between S. aureus HemH 
and HemQ or across the species.  The P. acnes truncations were the only set tested 
that were positive for interaction. 
 
Recently, the naming of these two genes (hemH and hemQ) and therefore their 
corresponding proteins have been changed to avoid confusion by distinguishing 
between the coproporphyrin and protoporphyrin-dependent ferrochelatases. The 
HemH protein is also called CpFC (coproporphyrin III ferrochelatase) and HemQ is 
called ChdC (coproheme decarboxylase) (Dailey et al., 2017). However, as this thesis 
focuses on the coproporphyrin ferrochelatases and coproheme decarboxylases, there 
is no ambiguity and HemH and HemQ will be used throughout. 
 
3.2 Investigating the interaction between HemH and HemQ 
using size exclusion chromatography 
The ferrochelatase in the species P. acnes is covalently linked to the subsequent 
enzyme in the coproporphyrin-dependent pathway, coproheme decarboxylase 
(HemQ), due to this linkage it was suggested that there may be an interaction between 
HemH and HemQ.  To investigate this interaction the four truncations of P. acnes of 
HemH-Q (HemHS, HemHL, HemQS and HemQL) were produced via gene cloning. 
The four truncations produced were HemH with and without the linker and HemQ with 
and without linker; HemHL, HemHS, HemQL and HemQS, respectively. The 
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truncations were expressed and purified and the interaction between them were tested 
using size exclusion chromatography. 
 
3.2.1 Gene cloning of P. acnes HemH-Q truncations 
The plasmid (pTrcHisA) containing the P. acnes hemH-Q gene was a gift from 
Professor H Dailey (University of Georgia) and was used to produce the HemH-Q 
truncations (appendix 7.2). To obtain approximate boundaries of each enzyme in the 
HemH-Q protein a structure based alignment was performed on the protein sequences 
of HemH and HemQ protein from different species using PRALINE (Pirovano and 
Heringa, 2010). The secondary structure from the B. subtilis ferrochelatase crystal 
structure (PDB: 1AK1)  was superimposed onto this alignment (for HemH) and crude 
boundaries for HemH and the HemQ and linker domain were deduced (Al-Karadaghi 
et al. 1997)(appendix 7.1)The TrcHisA vector containing the P. acnes gene was 
sequenced and primers were designed for the truncations (table 2.1) The four 
truncations that needed to be cloned were hemH, with and without linker, forming 
hemHL and hemHS, respectively and hemQ with and without the linker forming 
hemQL and hemQS (figure 3.1).  
 
 
The P. acnes hemH-Q truncated gene constructs were produced using the Q5 site-
directed mutagenesis method. The hemH and hemQ constructs were cloned with an 
annealing temperature of 58 °C and an extension time of 165 seconds (hemHS), 300 
s (hemHL) and 180 seconds (hemQS and hemQL). The vector was inserted into highly 
competent DH5α E. coli cells and the plasmids were isolated for sequencing. 
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Figure 3.1 – HemH-Q Truncations 
A simple diagram of each of the main parts of the protein HemH-Q and the truncations derived 
from this protein. 
 
3.2.2  Optimisation of protein expression of P. acnes HemH-Q 
truncations 
All truncations of the P. acnes hemH-Q gene were used to transform into several 
different strains of E. coli to evaluate them for protein expression. Expression trials 
were performed on the three of the four P. acnes HemH-Q truncations (HemHL, 
HemHS and HemQL, appendix 7.4) as optimising expression of HemQS was not 






Table 3.1 – Optimal expression conditions for the P. acnes truncations 
PROTEIN E. COLI STRAIN MEDIA 
HemHS BL21-DE3 LB 
HemHL BL21 LB 
HemQS Rosetta LB 
HemQL Rosetta LB 
Pre and post induction temperatures were 37 °C and 18 °C, respectively. 
3.2.3 Successful purification of P. acnes HemHL, HemQS and 
HemQL 
Three truncations (HemHL, HemQS and HemQL) were successfully purified. These 
three proteins contained a N-terminal histidine tag and so they could be purified using 
immobilised metal affinity chromatography (IMAC). In general, the metal resin used 
contained nickel but resin containing cobalt has previously proven to be effective in 
the purification of ferrochelatase proteins (Dailey and Dailey, 2002, Hobbs et al., 2017).  
Initially, all the truncation purifications were attempted using nickel resin (Ni-NTA), if 
this failed cobalt resin (Talon, GE Healthcare) was used. If the proteins were not fully 
purified than an additional anion exchange chromatography step was added. 
Purification of HemHL and HemQS required a single purification step by IMAC, 
HemHL used cobalt resin (Talon, GE Healthcare) and HemQS used nickel resin (Ni-
NTA), SDS PAGE analysis of the purification of these proteins are shown in figure 3.2. 
HemQL purification required an additional ion exchange chromatography step. Anion 
exchange chromatography (Q sepharose) was therefore used to further purify HemQL 
(appendix 7.5).  
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Figure 3.2- SDS PAGE of the purification of P. acnes HemHL and HemQS  
The SDS PAGE gel shows the progressive purification of HemHL and HemQS. L represents 
the lysed sample, S is the soluble fraction after centrifugation, F is the flow-through sample, 
the unbound protein. Washes 1 and 2 (W1, W2) are high salt (1 M KCl) and low imidazole 
wash (30 mM), respectively. E is the protein eluted off the column in high imidazole (300 mM) 
The arrows indicate the expected migration of each of the proteins. 
 
3.2.4 Purifying P. acnes HemHS 
As previously stated, protein expression of P. acnes HemHS showed that the majority 
of the protein was present in the insoluble fraction. However, purification of HemHS 
was attempted to see if any of HemHS was still soluble. Purification using IMAC (Ni-
NTA resin) and SDS PAGE analysis revealed that all of the protein was present in the 
insoluble fraction (figure 3.3). Other growth conditions using different E. coli cell lines 
(BL21-DE3 and Rosetta), media (LB, 2YT, ZYM-5052) and induction temperatures 
(18 °C, 30 °C and 37 °C) were used in an attempt to increase the over-expression of 
soluble protein (appendix 7.4.2). This proved unsuccessful. As a result, several 
methods were used to attempt to solubilise HemHS after expression.  
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Figure 3.3 - Purification of P. acnes HemHS 
The SDS PAGE gel of the purification of P. acnes HemHS by metal affinity chromatography, 
each of the lanes correspond to stages in the purification. L indicates the protein sample after 
lysis, P is the insoluble fraction after centrifugation and S is the soluble fraction. F is flow 
through, protein that doesn’t bind to the nickel resin and W refers to washes with high salt (1) 
and low imidazole (2), E is the eluted protein. The protein band corresponding to HemHS is 
highlighted (arrow) and the presence of HemHS in the pellet (insoluble) fraction is highlighted 
by the orange box. 
 
3.2.4.1 Solubilisation of the HemHS inclusion bodies with detergents and 
high salt concentrations. 
As HemHS is present in the insoluble fraction, detergents were utilised to attempt to 
bring HemHS into the soluble fraction. To solubilise HemHS three different detergents 
were used because of their different properties. Triton-X-100 is a very effective non-
ionic detergent, it is effective at solubilising protein from inclusion bodies (Kalipatnapu 
and Chattopadhyay, 2005), however its low critical micelle concentration (0.2-0.9 mM, 
~0.01 %) makes it difficult remove by dialysis. CHAPS was used as it has a high critical 
micelle concentration (8-10 mM, ~0.49 %) this means the detergent can easily be 
removed by dialysis. Sodium cholate (critical micelle concentration: 9-15 mM, ~0.41 %) 
has previously been used to solubilise H. sapiens ferrochelatase (Wu et al., 2001) and 
may be able to successfully solubilise the HemHS protein.  
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Each of the detergents (15 mM CHAPS, 1% sodium cholate, 2% triton-X-100) were 
added to the standard binding buffer and used to resuspend the pellet of E. coli cells 
after expression of HemH. The cells were lysed by sonication and the insoluble and 
soluble fractions were separated by centrifugation. The soluble and insoluble fractions 
were run on an SDS PAGE gel to determine the presence of HemHS in each of the 
fractions. These detergents failed to solubilise HemHS and HemHS remained in the 
insoluble fraction. As the detergents failed to solubilise HemHS, purification of HemHS 
was attempted in high salt conditions. 
 
The affinity purification of HemHS was repeated in high salt conditions (500 mM KCl). 
This increase in salt concentration could stabilise and solubilise HemHS, as seen with 
other proteins (Arakawa and Timasheff, 1982). Despite the increase in salt 
concentration HemHS remained insoluble and the stabilisation of HemHS was 
unsuccessful.  
 
3.2.4.2 Denaturation and refolding 
As it proved difficult to purify HemHS in native conditions, a denaturing purification 
strategy was attempted. In this case, the protein was completely denatured in 8 M 
urea and purified by IMAC chromatography. The resulting protein would then need to 
be refolded before biophysical or kinetic analysis. Refolding can either be attempted 
in solution, using stepwise dialysis to reduce the urea concentration, or with the protein 
immobilised and bound to the IMAC column (on column refolding). 
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3.2.4.2.1 Purification of HemHS in 8 M urea with on-column refolding 
In this preparation the cell pellet was resuspended and lysed as normal. The soluble 
and insoluble fractions are separated by centrifugation and the insoluble fraction was 
resuspended in a buffer containing 8 M urea. The high concentration of urea will 
solubilise protein aggregates and subsequent centrifugation removes heavy cellular 
structures leaving only solubilised protein. The resulting protein sample is bound to 
the nickel column and the urea concentration is slowly reduced allowing the protein to 
slowly refold. Once the concentration of urea has dropped to zero the protein is eluted 
in standard elution buffer (Veldkamp et al., 2007, Tsumoto et al., 2003). 
 
On column refolding allows quick and efficient refolding of a desired protein whilst 
simultaneously purifying it. There are potential problems with this method since 
reducing the urea concentration may lead to improper or non-native folding as well as 
an increased chance of precipitation occurring on the column. In addition, the 
immobilisation of the protein on the column may hinder correct folding. Purification of 
HemHS by on column refolding was not successful. Further purification of HemHS 
was halted in favour of using the more soluble HemHL protein. 
 
3.2.5 Interaction between P. acnes HemHL and HemQS using size 
exclusion chromatography 
Size exclusion chromatography is a quick efficient technique to determine if two 
proteins interact. SEC reveals strong interactions and not weak or transient 
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interactions so a negative result states that there are no strong interactions between 
the two proteins. The SEC column used was HiLoad Superdex 26/600 200 PG, 
calibrated before interaction studies.  
 
The P. acnes HemH-Q protein contains both HemH and HemQ linked together.  As P. 
acnes HemH and HemQ is naturally linked, running HemHL and HemQS down a SEC 
column is the most likely combination to interact. The truncations of P. acnes HemHL 
and HemQS make up the full protein; these were purified separately and run alone 
first for comparison. The A280 trace produced by P. acnes HemHL (48 kDa) shows a 
single peak at ~95 kDa this indicates the formation of a dimeric structure; 
ferrochelatases have been found as dimers (H. sapiens) and monomers (B. subtilis) 
so this is not unusual (Al-Karadaghi et al., 1997, Wu et al., 2001). The SEC 
chromatogram of HemQS (25 kDa) shows an elution peak at approximately ~79 kDa 
indicating the formation of a trimer.  HemHL and HemQS were then mixed together 
and this was injected onto the SEC column. The SEC trace indicates the presence of 
one peak ~86 kDa, this is close to the full HemH-Q protein (74 kDa) and the trimeric 
HemQS (~75 kDa). An SDS PAGE gel was used to confirm the presence of both 
HemHL and HemQS in the SEC peak (figure 3.4). 
 
These results show that there is non-covalent interaction between the two P. acnes 
truncations HemHL and HemQS. This interaction is strong enough to prevent the 
dimer/trimer interactions observed when HemHL and HemQS are run down the SEC 
column alone and the interaction between HemHL and HemQS appears to be 1:1.  
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Figure 3.4 –Analytical SEC filtration trace of P. acnes HemHL and HemQS 
The A280 traces produced by an ÄKTA pure during analytical SEC are shown.  The orange 
trace indicates the peak produced by HemHL (48 kDa) only, the blue trace indicates the peak 
produced by HemQS (25 kDa) only.  The black trace indicates the peak produced when 
HemHL and HemQS is run together. The SDS PAGE gel (inset) shows the proteins samples 
during the analytical SEC of the two proteins. QS is HemQS only, HL is HemHL only, HL+QS 
is both proteins mixed together, HL +QS –GF is the sample taken from the main peak after 
SEC and HL+QS- GF conc it the SEC protein sample after it has been concentrated. 
 
3.3 Investigating substrate transfer between HemH and 
HemQ in the P. acnes fusion protein 
The P. acnes fusion protein provides a unique opportunity to look at the substrate 
transfer mechanism of ferrochelatase to coproheme decarboxylase. As the enzymes 
are covalently linked substrate transfer assays can be developed to determine whether 
the coproporphyrin binds to ferrochelatase, is converted to coproheme and funnelled 
directly into the active site of coproheme decarboxylase or coproheme is released by 
ferrochelatase and then taken up by coproheme decarboxylase. To answer this 
question P. acnes HemH-Q must first be expressed and successfully purified. 
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However, purification of HemH-Q proved difficult and this was most likely due to 
spontaneous cleavage. 
 
3.3.1 P. acnes ferrochelatase fusion protein expression 
The plasmid containing the P. acnes hemH-Q (gift from Professor H Dailey) was 
inserted into Rosetta E. coli and grown in LB media. The HemH-Q protein was 
expressed using a standard IPTG protocol. The E. coli was incubated at 37 °C pre-
induction and 18 °C post induction. Due to the high yields of protein produced the 
protein expression was not further optimised. 
 
3.3.2 Purification of the P. acnes HemH-Q fusion protein 
The P. acnes HemH-Q protein contains a histidine tag, so it can be purified using metal 
affinity chromatography. The same protocol for the IMAC purification of the truncations 
(HemQS, HemHL and HemQL) was used to purify the HemH-Q. This resulted in an 
impure sample. In order to obtain higher purity, optimisation of the IMAC purification 
step was attempted, an imidazole gradient was used but this did not result in purer 
protein. The main problem was a persistent contaminant, a protein weighing 
approximately 27 kDa. In addition to optimising the IMAC purification step, additional 
purification steps such as ion exchange chromatography (IEX) and size exclusion 
chromatography (SEC) were added in an attempt to completely purify HemH-Q.   
The IEX of HemH-Q resulted in one main single peak at A280 at one salt concentration 
but SDS analysis revealed the protein sample contained more than one protein 
indicating incomplete purification (figure 3.5). The second purification step was 
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exchanged for SEC as this separates proteins based on their molecular weight rather 
than the surface charge of the protein. SEC of HemH-Q also produced a single peak 
at a single exclusion volume and while the sample showed fewer contaminating 
protein bands, one other protein was observed in the SDS PAGE gel (figure 3.5).  The 
persistent contaminant at approximately 27 kDa is present in the purified protein 
samples after IEX and SEC. This suggests that the contaminant has similar charge 
properties to HemH-Q which has a theoretical isoelectric point (pI) of 4.95 (Wilkins et 
al., 1999). SEC was used as the 27 kDa protein and HemH-Q differed greatly in 
molecular weight (27 kDa and 74 kDa). SEC should have been easily able to separate 
these two proteins using the HiLoad Superdex 26/600 200 PG column.  
 
Figure 3.5 - Purification of P. acnes HemH-Q by IEX and SEC 
Two A280 traces for IEX (A) and SEC (C) purification of the HemH-Q protein produced by the 
ÄKTA purifier. The filled in peak indicates the peak corresponding to the HemH-Q protein.  
The chromatograms show the absorbance at 280 nm in black and the salt gradient applied in 
IEX is shown in green. The SDS PAGE gels resulting from these purifications are shown 
adjacent to the graphs (B and D). The numbers on the lanes represent fractions within the 
shaded absorbance peak. 
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3.3.2.1 Reducing proteolysis 
From these purifications it was deduced that the one remaining band may be a 
proteolytic fragment. To reduce proteolysis the serine protease inhibitor Pefabloc was 
replaced by SigmaFast protease inhibitor cocktail (No EDTA) this inhibited aspartate, 
cysteine and serine proteases as well as aminopeptidases and thermolysin-like 
proteins.  The use of SigmaFast didn’t prevent the formation of the 27 kDa protein. 
SigmaFast doesn’t contain EDTA which inhibits metalloproteases, so the purification 
protocol was altered to include 5 mM EDTA.  
 
EDTA can inhibit metalloproteases but as it chelates metal ions it is not compatible 
with IMAC.  The EDTA was added before lysis of the cell pellet and an 80% saturation 
cut of ammonium sulphate and subsequent centrifugation was used to remove the 
EDTA. After the removal of EDTA the purification by IMAC proceeded. Attempts to 
reduce proteolysis failed to prevent the appearance of the 27 kDa protein band. 
 
3.3.3 Confirming interaction between HemH-Q and contaminating 
protein 
The SEC column used to purify P. acnes HemH-Q should be capable of separating a 
protein of ~27 kDa and P. acnes HemH-Q (74 kDa). As this separation is not observed, 
it is possible that the contaminating protein interacts with the HemH-Q protein this may 
also indicate why separation was not observed when using ion exchange 
chromatography as well.   
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3.3.3.1 Verifying the mass of HemH-Q by analytical SEC 
To test the hypothesis that the HemH-Q protein and the 27 kDa contaminating protein 
formed a complex, analytical SEC was used to determine the mass of the HemH-Q 
complex. A HiLoad Superdex 26/600 200 PG column was calibrated using the protein 
standards: blue dextran (1000 kDa), β-amylase (200 kDa), alcohol dehydrogenase 
(150 kDa), bovine serum albumin (66 kDa), carbonic anhydrase (29 kDa) and 
cytochrome C (12.4 kDa).  HemH-Q eluted at 131 mL, the calculated mass for HemH-
Q was 411 kDa, much higher than the predicted 74 kDa from the primary sequence 
(figure 3.6). This provides evidence for a multimeric structure however as the protein 
sample is not pure and contains the 27 kDa protein the number of HemH-Q molecules 
involved in this structure cannot be determined. To further support the formation of a 
multimeric structure native PAGE was utilised, the protein was so large it was barely 
able to penetrate the resolving gel despite several optimisations. Gel filtration and 
native PAGE of HemH-Q to determine the molecular weight shows the formation of a 
high order complex.  
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Figure 3.6 – Analytical gel filtration of HemH-Q 
A shows the A280 traces of each of the standards and the HemH-Q protein. B shows the 
calibration curve for molecular weight determination of the HemH-Q protein, the HemH-Q run 
is shown in red. The standards are: CC (cytochrome C), CA (carbonic anhydrase), BSA 
(bovine serum albumin), βA (β-amylase) and BD (blue dextran).  
 
3.3.4 Determining the interaction between HemH-Q and the 27 kDa 
protein 
To tackle the interaction occurring between the two proteins an approach was to 
prevent the binding of the 27 kDa protein to HemH-Q. This utilised IMAC, SEC and 
circular dichroism (CD). A range of different solution conditions were used to separate 
the two proteins, including high concentrations of salt, different concentrations of 
organic solvent (0-50% isopropanol), different concentrations of chemical denaturants 
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(0-4 M urea), detergents (cholate, Triton X-100, SDS), and varying the pH (±1 unit). 
None of these proved successful. Perhaps identifying the contaminating protein would 
lead to its removal. 
 
3.3.5 Identification of the 27 kDa protein by mass spectrometry (MS) 
The 27 kDa protein was isolated from a SDS-PAGE gel containing the partially purified 
HemH-Q protein. It was reduced, alkylated, digested with trypsin and loaded onto a 
C18 reverse phase chromatography column. A gradient of acetonitrile was applied to 
the column and peptides eluted dependent on their hydrophobicity. Analysis by mass 
spectrometry determined that the protein mainly consisted of a C-terminal fragment of 
HemH-Q (this work was completed by Dr Adelina Acosta-Martin). This fragment 
contained 246 amino acids starting from D437 and continued until it reached the end 
of the protein (figure 3.7).  
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Figure 3.7- In-gel tryptic digest and mass spectrometry 
The amino acid sequence of HemH-Q is shown; the red box indicates the part of the protein 
that is mainly found in the 27 kDa protein on the SDS gel. This sequence is consistent with a 
27 kDa protein 
 
3.3.5.1 Cleavage of HemH-Q may be due to labile bonds in the protein 
As mass spectrometry revealed that the contaminating protein is a fragment of the 
HemH-Q protein, potential mechanisms of protein hydrolysis needed to be 
reconsidered. Proteolysis by proteases present in the E. coli expression strain has 
been discussed above (section 3.3.2.1) and it is notable that use of protease inhibitors 
and E. coli strains with a reduced number of proteases was ineffective at removing the 
contaminating C-terminal fragment. One additional cleavage mechanism arises as 
aspartyl-prolyl bonds are heat labile and can be spontaneously broken during sample 
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preparation for SDS-PAGE gel electrophoresis (Kurien and Scofield, 2012). There are 
several of these bonds present in the HemH-Q amino acid sequence.  
 
Heat trials were performed to test for aspartyl-prolyl bond cleavage during SDS PAGE. 
SDS PAGE heat trials were completed to see if there was an increase in band intensity 
of contaminating protein in a SDS PAGE upon heating. The protein samples were 
heated to either 75 °C or 95 °C for 5, 20 or 60 minutes and run on a SDS PAGE gel. 
Analysis by SDS PAGE showed an increase in proteolytic fragments upon heating but 
no increase in band intensity of the 30 kDa proteolytic fragment. This shows that the 
whole HemH/Q protein is sensitive to heat and so is the proteolytic fragment and it is 
unlikely to be an SDS PAGE artefact.
3.4 Testing the interaction between non-covalently linked 
HemH and HemQ from different bacterial species and 
across species 
As P. acnes HemH and HemQ are shown to interact using size exclusion 
chromatography other HemH proteins (B. subtilis, S. aureus and P. acnes) HemQ 
proteins (S. aureus and P. acnes) were tested for interaction. S. aureus has a HemH 
and HemQ that are not covalently linked. Investigating the interaction between these 
proteins would show whether the interaction was specific to P. acnes or present in 
other Gram positive bacteria. Different combinations of HemH proteins and HemQ 
proteins from different species were also investigated to indicate whether the HemH 
and HemQ proteins must originate from the same species for interaction to occur. 
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Firstly, protein expression and purification of all the HemH and HemQ proteins were 
required. 
 
3.4.1 Expression of S. aureus HemH and HemQ and B. subtilis HemH 
Plasmids containing the genes for S. aureus HemH and S. aureus HemQ were a gift 
from Dr. M Shepherd (University of Kent), the S. aureus HemH was cloned into a 
TrcHisA plasmid and S. aureus HemQ was inserted into a pET14b plasmid. The 
plasmid containing B. subtilis HemH was a gift from Dr H Dailey (University of Georgia). 
The plasmid constructs were isolated and used to transform different E. coli strains 
(BL21, BL21-DE3, Rosetta and JM109). 
 
An expression protocol for S. aureus HemH was previously published (Hobbs, et al. 
2017), using CircleGrow media and JM109 E. coli cells. This expression protocol was 
originally developed for production of H. sapiens ferrochelatase as the high 
concentrations of human ferrochelatase produced in conventional IPTG induced 
systems are toxic and yields are low. In contrast, bacterial ferrochelatases such as 
those from B. subtilis and P. acnes express well when a standard IPTG induction 
protocol is used.  Expression trials on S. aureus HemH was completed to see if 
standard IPTG induction was a feasible route that could increase the protein yield. 
Optimal expression conditions for the S. aureus HemQ protein was also investigated. 
The conditions investigated (i.e. cell type, media, growth temperature) were the same 
as those previously described (section 3.2.2) when producing the P. acnes HemH-Q 




It appeared that the optimal conditions for S. aureus HemH expression were the use 
of JM109 E. coli and CircleGrow media as previously published (Hobbs et al., 2017). 
Both S. aureus HemQ and B. subtilis HemH require LB media and BL21 and Rosetta 
E. coli, respectively (table 3.2).  
 
Table 3.2 – Expression conditions for the S. aureus HemH and HemQ and B. subtilis 
HemH 
SPECIES PROTEIN E. COLI STRAIN MEDIA TEMPERATURE 
S. aureus 
 
HemH JM109 CircleGrow Incubation 30 °C 
No IPTG induction 
HemQ BL21 LB Pre induction - 37 °C  
Post induction - 18 °C 
B. subtilis HemH Rosetta LB Pre induction - 37 °C  
Post induction - 18 °C 
 
3.4.2 Purification of S. aureus HemH and HemQ and B. subtilis HemH 
All three proteins contain a N-terminal His tag and the first purification step is IMAC, 
S. aureus HemH was purified on a cobalt resin column (Talon) and B. subtilis HemH 
and S. aureus HemQ were purified on a nickel resin column (Ni-NTA). S. aureus HemH 
purification requires just the single purification step (Hobbs et al., 2017) whereas B. 
subtilis HemH and S. aureus HemQ need an extra IEX step for polishing. The IEX step 
uses the anion exchange media, Q Sepharose, this extra step successfully purifies 
both proteins in high yields (table 3.3). All three of these proteins have published 
purification protocols, these were used for the S. aureus proteins but not for B. subtilis 
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HemH. This B. subtilis HemH contained a histidine tag which was utilised in its 
purification; the published protocol used a construct of B. subtilis HemH which did not 
contain a histidine tag (Hobbs et al., 2016, Hobbs et al., 2017, Hansson and Al 
Karadaghi, 1995) 
Table 3.3- Purification conditions of S. aureus HemH and HemQ and B. subtilis HemH 






HemQ IMAC (Ni-NTA) 
IEX (Q Sepharose) 
Yes 
B. subtilis HemH IMAC (Ni-NTA) 
IEX (Q Sepharose) 
Yes 
 
3.4.3 Interaction between HemH and HemQ from different Gram-
positive bacterial species using size exclusion 
chromatography 
After the successful interaction of the HemHL and HemQS protein from P. acnes, 
HemH and HemQ proteins from different species were tested.  There were three 
HemH proteins (P. acnes, S. aureus, and B. subtilis) and two HemQ proteins (P. acnes, 
S. aureus) available making up four possible cross species tests, these were run in 




3.4.3.1 The P. acnes HemQS protein and S. aureus HemH or B. subtilis 
HemH do not interact 
The pure P. acnes HemQS (25 kDa) protein elutes off the SEC column as a molecular 
weight of ~79 kDa indicating the presence of a trimer. In these experiments, S. aureus 
HemH (35 kDa) did not express well and as a result it was difficult to obtain at a high 
concentration of pure protein without a larger scale up. S. aureus HemH elutes off of 
the SEC column at volume representative of a protein with molecular weight ~33 kDa 
near to the 35 kDa weight of S. aureus HemH (figure 3.9B).  
 
When the P. acnes HemQS and S. aureus HemH are run together the elution profile 
shows one peak ~79 kDa corresponding to the P. acnes HemQS trimer and a cluster 
of peaks at ~35 kDa indicating the presence of S. aureus HemH. Other peaks present 
are below the void volume or very close to the void volume indicating a high molecular 
protein or aggregate. These peaks suggest that there is no interaction between these 
two proteins; the absence of any strong peak at an elution volume indicating a protein 
of 60 kDa supports the lack of interaction (figure 3.8B). 
 
The B. subtilis HemH (~36 kDa) protein produces one peak in the SEC chromatogram. 
This peak corresponds to a protein ~32 kDa in weight. B. subtilis HemH is mixed 
together with P. acnes HemQS and the resulting elution profile shows two distinct 
peaks corresponding to B. subtilis HemH at ~32 kDa and P. acnes HemQS at ~79 kDa 
(figure 3.8A). The lack of any other peaks other than those matching the separate 
HemH and HemQ proteins indicates that there is no interaction between P. acnes 




Figure 3.8 –Analytical SEC chromatogram of P. acnes HemQS and S. aureus HemH or 
B. subtilis HemH 
A shows a SEC chromatogram of P. acnes HemQS and S. aureus HemH, B shows a SEC 
chromatogram of P. acnes HemQS and B. subtilis HemH. The traces represent the A280 traces 
produced by an ÄKTA pure during analytical SEC. The blue trace shows the chromatogram 
produced when P. acnes HemQS (25 kDa) is run alone. The orange trace indicates the peak 
produced by S. aureus HemH (35 kDa) only (A) or B. subtilis HemH (36 kDa) only (B). The 
black traces indicate the A280 trace produced when either S. aureus HemH and P. acnes 
HemQS (A) or B. subtilis HemH and P. acnes HemQS (B) are run together.
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3.4.3.2 S. aureus HemQ and P. acnes HemHL or B. subtilis HemH 
S. aureus HemQ forms a multimeric structure. S. aureus HemQ elutes off the column 
at a volume corresponding to the molecular weight of ~124 kDa, the monomeric weight 
of S. aureus HemQ is ~29 kDa (figure 3.9). This molecular weight suggests the HemQ 
forms a tetramer. P. acnes HemQS forms a trimer and the first crystallised structure 
of HemQ from L. monocytogenes was crystallised as a pentamer (Hofbauer et al., 
2016c)(figure 1.18). HemQs from different bacterial species appear to form different 
multimeric states. 
 
P. acnes HemHL forms a dimer when subjected to size exclusion chromatography, 
this gives the molecular weight of ~95 kDa which is not clearly resolvable on SEC from 
the S. aureus HemQ at 124 kDa. The two different proteins can be still be observed 
as P. acnes HemHL causes the appearance of a slight shoulder on the merged peak. 
As the peak is merged the peak spans a much larger elution volume encompassing 
both proteins, the appearance of this absorbance peak suggests that these two 
proteins do not interact (figure 3.9A).  
 
When B. subtilis HemH and S. aureus HemQ are injected onto the column together 
there are two distinct peaks on the SEC chromatogram corresponding to the 
absorbance peaks of each of the proteins suggesting no interaction (figure 3.9B). From 
these investigations, there is strong evidence to suggest that the cross-species 
combinations of HemH and HemQ do not interact when subjected to SEC. 
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Figure 3.9- Testing the interaction between S. aureus HemQ and P. acnes HemHL or 
B. subtilis HemH  
The SEC chromatograms show an absorbance (A280) trace produced by an ÄKTA pure. A 
shows the SEC chromatogram corresponding to S. aureus HemQ and P. acnes HemHL. B 
shows the SEC chromatogram corresponding to S. aureus HemQ and B. subtilis HemH. The 
blue line indicates the elution profile for S. aureus HemQ (29 kDa) alone.  The orange trace 
corresponds to P. acnes HemHL (A) alone (48 kDa) and B. subtilis HemH (B) alone (36 kDa). 
The black line for the chromatogram in A indicates a run of S. aureus HemQ and P. acnes 




3.4.4 Investigation into the interaction between S. aureus HemH and 
S. aureus HemQ 
Testing the interaction between HemH and HemQ from different species showed that 
there was no interaction when detected by SEC. The P. acnes HemHL and HemQS 
do interact and eluted off the SEC column together however, these proteins are 
naturally linked. S. aureus HemH and HemQ are not naturally linked but are derived 
from the same species so there may be an interaction that occurs between the two 
enzymes.  
 
These proteins S. aureus HemH and HemQ are run alone and the peaks produced 
are as expected from the parallel to molecular weights 32 kDa and 124 kDa, 
respectively. When these two proteins are run down the column the elution profile 
shows two peaks around the elution volumes of HemH and HemQ indicating no 





Figure 3.10- Analytical SEC of S. aureus HemH and HemQ 
The SEC chromatogram was produced by an ÄKTA pure which measured the absorbance at 
A280. The blue and orange trace reflects the elution profiles of S. aureus HemQ and HemH 
alone, respectively. The black line indicates the elution profile of S. aureus HemQ and HemH 
when they are run together.  
3.5 Chapter Summary  
Four truncations of P. acnes HemH-Q (HemHS, HemHL, HemQS and HemQL) were 
produced. The expression and purification of the truncations were optimised. HemHL, 
HemQS and were successfully purified whereas HemHS purification was 
unsuccessful. Several different methods were used to optimise the HemHS purification 
but the HemHS protein remained insoluble. As the truncation pair HemHL and HemQS 
were successfully purified these were used to analyse interactions between the two 
proteins, HemH and HemQ. The HemHS and HemQL truncations were no longer 
required as HemHL and HemQS could be used instead. Size exclusion 
chromatography revealed that these two proteins interact in a 1:1 ratio.  
 
The second part of the chapter investigated the substrate transfer mechanism using 
the full P. acnes HemH-Q protein. However, the HemH-Q protein could not be 
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successfully purified.  Due to the unstable nature of this multi-domain protein self-
cleavage was an issue. Steps were taken to attempt to reduce the proteolysis of 
HemH-Q however these failed. Cleavage occurred in the N-terminal part of the HemQ 
and the C-terminal cleavage product interacted with the remaining intact HemH-Q 
protein. The cleavage product would only disentangle from the full protein in the 
detergent SDS and was visible on a SDS PAGE. The identity of the cleavage product 
was confirmed using tryptic digestion and mass spectrometry.  
 
When subjected to SEC P. acnes HemH-Q eluted off the column at a much higher 
molecular weight indicating that not only was the C terminal cleavage product 
interacting with the intact HemH-Q protein, but the HemH-Q protein was also 
interacting with other intact HemH-Q proteins.  
 
In the final part of the chapter, the interaction between different HemH and HemQ 
proteins was tested using SEC. In this investigation the P. acnes truncations HemHL 
and HemQS were used as well as S. aureus and B. subtilis HemH and S. aureus 
HemQ. All cross-species combinations of the HemH and HemQ proteins were tested 
and all showed that there was no interaction between the two proteins. In addition to 
these experiments, the interaction between S. aureus HemH and HemQ was 
assessed. These two proteins were from the same species but were not covalently 
linked. The result of this experiment showed that there were no strong non-covalent 
interactions between the two proteins.  
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The lack of strong interaction between S. aureus HemH and HemQ suggests that a 
strong complex is not formed between these proteins. These results do not rule out 
the formation of any transient or weak complexes. No observed interaction between 
HemQ and HemH in S. aureus opposes a substrate funnelling mechanism where the 
coproheme in the ferrochelatase active site is funnelled direct into the active site of 
HemQ. However, these interaction studies were completed in the absence of substrate. 
Substrate binding and product release in B. subtilis and S. aureus ferrochelatase have 













4. Investigating the kinetic properties of B. 
subtilis and S. aureus HemH 
4.1. Chapter introduction 
The two bacterial species B. subtilis and S. aureus synthesise heme utilising the 
coproporphyrin-dependent pathway and belong to the same phylum, the Firmicutes. 
Typically, ferrochelatases are known to be structurally conserved but have low 
sequence similarity (~20%), these bacterial ferrochelatases have approximately 60% 
sequence identity (Needleman and Wunsch, 1970) and as a result are expected to 
behave similarly.  
 
In the past, investigation into B. subtilis HemH has been extensive. B. subtilis HemH 
was the first ferrochelatase structurally resolved (Al-Karadaghi et al., 1997) and a 
second structure was published with N-methyl mesoporphyrin bound (Lecerof et al., 
2000). In addition to structural analysis kinetic characterisation of B. subtilis HemH 
was attempted (Hansson et al., 2007); the enzyme appeared largely inactive when 
compared to H. sapiens HemH.  These kinetic studies on B. subtilis HemH were 
performed under the misconception that protoporphyrin IX was the endogenous 
porphyrin substrate. Recent work has revealed that the endogenous porphyrin 
substrate is coproporphyrin III (Dailey et al., 2015). The low activity observed with the 
B. subtilis ferrochelatase was due to the use of protoporphyrin IX and protoporphyrin 
analogues in the kinetic assays.  
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Since the discovery of the coproporphyrin-dependent heme biosynthetic pathway 
there has been little kinetic investigation of any coproporphyrin ferrochelatase (Hobbs 
et al., 2017, Dailey et al., 2015, Lobo et al., 2015) and in general, there has been little 
kinetic characterisation of any ferrochelatase using transient kinetics (Hoggins et al., 
2007, Hunter et al., 2016, Gillam et al., 2018).  
 
B. subtilis and S. aureus HemH have been successfully expressed and purified. 
Circular dichroism spectroscopy has shown that these proteins contain secondary 
structure elements, and thermo-melts have been performed to determine thermal 
melting temperatures. Fluorescent binding assays have been completed showing that 
CPIII can tightly bind to both ferrochelatases and steady state kinetics have allowed 
the determination of kcat, KmFe and KmCP values. Stopped flow fluorescence 
spectroscopy was used in three different experimental designs to reveal the rates 
constants for CPIII binding, Fe2+ binding and porphyrin metalation.  
 
4.2. Transformation and protein expression 
To produce the ferrochelatase proteins, the plasmids containing the genes for B. 
subtilis and S. aureus HemH was used to transform E. coli. The plasmid containing B. 
subtilis HemH was a gift from Professor H Dailey (University of Georgia) and the S. 
aureus HemH was a gift from Dr M Shepherd (University of Kent).  B. subtilis HemH 
was incorporated into Rosetta E. coli and grown in LB media, protein expression was 
induced using IPTG. Expression of B. subtilis HemH through IPTG induction resulted 
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in a large amount of protein. The large amount of protein expressed meant that further 
optimisation expression was not required. 
 
Previous publications (Hansson and Al Karadaghi, 1995) outline the method that they 
used to express HemH, the plasmid (pLUGT7-H) containing the B. subtilis hemH gene 
was used to transform BL21-DE3 E. coli and grown on tryptose blood agar plates 
containing  ampicillin (50 mg mL-1) and glucose (0.4% w/v). The E. coli was grown in 
LB media (with 100 mg mL-1 ampicillin) and protein expression was induced using 
IPTG (0.5 mM) at OD (0.4-0.5), the cells were harvested four hours after IPTG 
induction. The method used to express B. subtilis HemH was similar to the published 
method however the plasmid system used was different and so minor changes were 
made. 
 
The protein expression of S. aureus HemH was trialled using similar conditions those 
used in the protein expression of B. subtilis HemH using derivatives of BL21 E. coli 
and standard IPTG induction (table 2.2). Optimisation of protein expression using a 
standard IPTG induction system failed to produce high yields of S. aureus HemH. In 
a recent publication, the expression of S. aureus HemH was described using JM109 
E. coli and CircleGrow media (Hobbs et al., 2017). In this protocol protein expression 
was not induced by IPTG.  This method was also used in the expression of H. sapiens 
HemH and was able to produce high yields of S. aureus HemH (Burden et al., 1999, 
Hobbs et al., 2017)  
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4.3. Purification of B. subtilis HemH and S. aureus HemH 
The B. subtilis HemH protein contains an engineered histidine tag so it could be 
purified using metal affinity chromatography. A nickel column was used as the first 
purification step and an ion exchange column in the second step. The protein was 
eluted from the nickel column at 300 mM imidazole and desalted using a manually 
poured Sephadex G50 column removing the imidazole. Ion exchange chromatography 
completed purification and B. subtilis HemH eluted off the column at approximately 
400 mM salt; the purification of B. subtilis HemH is shown in figure 4.1A.  
 
The method used to purify B. subtilis HemH is different to the published protocol. The 
published protocol uses two rounds of ammonium sulphate precipitation (70% and 
90%), overnight dialysis and ion exchange chromatography (Al-Karadaghi et al., 1997, 
Hansson and Al Karadaghi, 1995). This protocol avoids using immobilised metal 
affinity chromatography (IMAC) as this could cause metal ion contamination.  Potential 
metal ion contamination can be an issue when assaying ferrochelatase as 
ferrochelatase is capable of inserting divalent metal ions such as Ni2+ into the 
porphyrin substrate (Hunter et al., 2008, Hansson and Hederstedt, 1994, Medlock et 
al., 2009, Davidson et al., 2009). However, the method using IMAC to purify B. subtilis 
HemH has been used to purify other ferrochelatases (Hobbs et al., 2017, Burden et 
al., 1999)  and is quicker, purifications can be completed in hours rather than days. 
Control experiments show minimal metal ion contamination and chelex 100 is used to 
remove and metal ions from the assay buffer prior to functional studies. 
 
S. aureus HemH was purified using a previously published protocol (Hobbs et al., 
2017), although it was also successfully purified without the addition of 50 mM MOPS 
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and 1% sodium cholate to the buffer (figure 4.1B). S. aureus HemH was purified using 
a single cobalt (Talon) column; it was washed with low imidazole (15 mM) and eluted 
in high imidazole (300 mM). The protein was then buffer exchanged into binding buffer 
to remove imidazole. The purification of S. aureus HemH is shown in figure 4.1B. 
 
Figure 4.1 Purification of B. subtilis HemH and S. aureus HemH 
A SDS PAGE gel of the purification of B. subtilis HemH (A) and S. aureus HemH (B), S 
represents the soluble fraction after lysis and centrifugation, F is the flow-through (unbound 
protein), W1 corresponds to a high salt washes whereas W and W2 correspond low imidazole 
washes 15 mM and 30 mM imidazole, respectively. E is the protein eluted off the IMAC column 
and IEX is the protein sample after IEX. 
 
 
4.4. Probing the secondary structure of B. subtilis and S. 
aureus HemH using circular dichroism 
4.4.1. Circular dichroism shows spectra consistent with the 
presences of secondary structure 
After successful purification of the HemH proteins, circular dichroism (CD) was used 
to confirm whether the proteins contained secondary structure. Unfolded and folded 
protein produce distinctive spectra when measuring the ellipticity across a mid UV 
range (200-260 nm).  
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CD of the two ferrochelatases reveal a broad trough in negative ellipticity range (figure 
4.2). The broad trough spans a large part of these spectra, this indicates the presence 
of both α helix and β sheet structures. Both ferrochelatases contain of two four-
stranded β sheets flanked by helices so the spectra are consistent with the expected 
protein fold (Al-Karadaghi et al., 1997, Hobbs et al., 2017).  Analysis of the B. subtilis 
HemH spectrum using the K2d method on Dichroweb (Andrade et al., 1993)  predicts 
that protein structure contains 37% α helix and 26% β sheet, the B. subtilis HemH 
crystal structure (PDB ID: 1AK1) states that the structure consists of 49% α helix and 
17% β sheet. This is reasonably consistent given the limited wavelength range 
(Andrade et al., 1993, Al-Karadaghi et al., 1997). The inconsistency in ellipticity 
between the two ferrochelatases is likely due to inaccurate protein determination. 
 
Figure 4.2- Circular dichroism spectra of B. subtilis and S. aureus HemH 
The CD spectra of B. subtilis HemH and S. aureus HemH each at approximately 4 μM, these 
spectra were normalised to protein concentration.  
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4.4.2. Testing the thermostability of B. subtilis and S. aureus 
ferrochelatase 
The thermostability of a protein can be determined by its melting temperature (Tm). 
The Tm of the HemH proteins can be measured using CD spectroscopy. The ellipticity 
at 222 nm is a strong signal for α helical structure, but 220 nm appeared a more 
appropriate wavelength to use. The temperature was increased from 5 °C to 100 °C 
and the ellipticity was monitored at 220 nm, after protein unfolding the temperature 
was slowly reduced to 5 °C allowing the protein to refold (figure 4.3). 
 
 The Tm of HemH unfolding and refolding was calculated using equation 1, the 
calculated Tm for HemH unfolding were 53 °C and 44 °C for B. subtilis HemH and S. 
aureus HemH, respectively. The difference in Tm for the unfolding of two proteins show 
that B. subtilis HemH is more thermally stable by approximately 10 °C (figure 4.3A and 
C). The Tm for refolding in B. subtilis and S. aureus HemH were calculated at 52 °C 
and 63 °C (figure 4.3B and D). Refolding of both proteins showed less negative 
ellipticities than the protein before unfolding, this could be because of degradation or 






Figure 4.3- Testing the thermostability of B. subtilis and S. aureus ferrochelatase 
The thermostability of the ferrochelatases were tested between 5-100 °C; the ellipticity was 
measured at 220 nm. During protein unfolding and refolding (A) the temperature was changed 
between 5-100 °C and the calculated melting temperature (Tm) was 53 ± 0.2 °C for unfolding 
(black) and 52 ± 0.3 °C (red) for B. subtilis HemH. (B) The temperature was changed between 
5-100 °C and the calculated melting temperature (Tm) was 44 ± 0.3 °C for unfolding (black) 
and 63 ± 1 °C (red) for S. aureus HemH. The errors given are ± one standard deviation.  
 
4.5. Kinetic characterisation of B. subtilis HemH and S. 
aureus HemH 
4.5.1. Preliminary kinetics of coproporphyrin ferrochelatase to define 
parameters of the experiment 
4.5.1.1. Scanning kinetics determines a suitable wavelength for 
steady-state kinetics 
Scanning kinetic assays were performed on the two ferrochelatases to identify a 
suitable wavelength to monitor the reaction. These assays were performed in the 
presence of the endogenous substrates coproporphyrin III and ferrous iron. The 
changes in absorbance were monitored in the wavelength range 350-600 nm and the 
spectra revealed peaks at 393 nm, 500 nm, 536 nm and 556 nm (figure 4.4). The 
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greatest change in absorbance was observed at 393 nm and this wavelength was 
selected to monitor the ferrochelatase reaction.  
 
Figure 4.4 – Scanning kinetics of B. subtilis ferrochelatase 
Change in absorbance as the ferrochelatase reaction proceeds across the wavelength range 
350-600 nm. The inset shows an expanded view of the wavelength range 450-600 nm. The 
ferrochelatase, coproporphyrin III and ferrous iron concentrations were 50 nM, 2 µM and 8 µM, 
respectively.  
 
4.5.1.2. Endpoint assay allows the determination of extinction 
coefficient of reaction 
After 393 nm was selected from the scanning kinetic assays, the extinction coefficient 
for the reaction must be obtained. This cannot be directly estimated from the extinction 
coefficient of the substrate as the product is highly absorbing. In the absence of pure 
product extinction coefficients for reactions can be determined by running the reaction 
to its endpoint, this is based on the assumption that the equilibrium constant is 
sufficiently large that essentially no substrate porphyrin remains. This is required to 
gain the absorbance change (ΔA) for the reaction; the ΔA can be divided by the 
concentration of the limiting substrate to gain the extinction coefficient for the reaction. 
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These assays were run at different substrate concentrations (Fe2+ 50 μM and 100 μM) 
to ensure the calculated extinction coefficient remained relatively consistent 
throughout and there are no issues with equilibrium (figure 4.5). The calculated 
extinction coefficient for this reaction using B. subtilis HemH and S. aureus HemH at 
393 nm is 70410 M-1 cm-1. 
 
Figure 4.5- Endpoint assay of B. subtilis HemH and S. aureus HemH to determine 
molar extinction coefficient for the ferrochelatase reaction. 
Graph shows the ferrochelatase reaction of B. subtilis and S. aureus HemH running to 
completion at different substrate concentrations. All assays contain 0.2 µM ferrochelatase. 
The black and grey traces contain B. subtilis HemH and the red and pink traces contain S. 
aureus HemH. The black and red traces substrate conditions are 4 µM coproporphyrin III and 
100 µM ferrous iron whereas the grey and pink traces contain 4 µM coproporphyrin III and 50 
µM ferrous iron. 
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4.5.2. Steady state kinetics of B. subtilis HemH and S. aureus HemH 
Steady state kinetics were performed on B. subtilis HemH and S. aureus HemH where 
one substrate was held under constant conditions whilst the other was varied. The 
reaction was monitored at 393 nm using a UV-Vis spectrometer and initial rates were 
obtained using the calculated extinction coefficient (70410 M-1 cm-1).  
 
The steady state data was analysed using a multivariate fit and the two-substrate 
equation (equation 2A), each of the four data sets shown in figure 4.6 were fitted in 
isolation to allow accurate calculation of steady-state parameters. When the two data 
sets for each ferrochelatase (figure 4.6A and B for B. subtilis HemH and figure 4.6C 
and D for S. aureus HemH) were analysed globally there were slight inconsistencies 
between the datasets most likely due to different amounts of active enzyme. When 
varying the concentration of coproporphyrin III (0-4 µM), ferrous iron was held at 
approximately 5, 10 and 100 µM. The enzyme concentrations were approximately 10 
nM, this low concentration was used to maintain steady-state conditions as low 
concentrations of CPIII were required to estimate the KmCP value. The estimated KmCP 
values were calculated as 0.14 and 0.15 µM (B. subtilis HemH) and 0.1 and 0.2 µM 
(S. aureus HemH), demonstrating that the KmCP   values in B. subtilis and S. aureus 
HemH are similar (figure 4.6A and C).  When investigating the second substrate, 
ferrous iron, the concentration of iron was varied (0-140 µM) and the concentrations 
of CPIII were 2, 1.7 (B. subtilis HemH only), 1 and 0.5 µM. The ferrochelatase 
concentration was 10-fold higher than those used in the previous assays at 0.1 µM as 
this gave more reliable rates. The calculated KmFe values were 1.8 and 3.8 µM and 
0.58 and 1.1 µM for B. subtilis HemH and S. aureus HemH, respectively. The slightly 
 170 
lower KmFe in S. aureus HemH indicates that it is more active than the B. subtilis 
enzyme at lower iron concentrations (figure 4.6B and D, table 4.7). 
 
The kcat value for the ferrochelatase reaction in each of the species was calculated. 
The kcat value for B. subtilis HemH was 0.32 and 0.35 s-1 and 0.36 and 0.44 s-1 for S. 
aureus HemH. The two enzymes have similar turnover numbers (kcat) however the S. 
aureus HemH protein is slightly faster showing that it there may be parts of its 
enzymatic mechanism that it does more effectively than the B. subtilis enzyme. In 
contrast to the KmCP, KmFe and kcat values, KCP.Fe was not calculated. The KCP.Fe value 
in this mechanism corresponds to the dissociation constant of the ternary complex, 
however, in general the definition of this term depends on the mechanism. In the 
analysis of the steady state curves the KCP.Fe value was constrained at either 0.1 or 
0.01 µM2 (figure 4.6A, B and D), as unconstrained curve fitting resulted in a physically 
unrealistic negative value.  The value of this coefficient is low when compared to the 
product of the two substrate concentrations. Changing the value from 0.1 to 0.01 or 
0.001 did not substantially change the best fit estimates of KmCP, KmFe and kcat. In the 
analysis shown in figure 4.6C this value was optimised as 0.023 µM2, however the 
large standard error suggests that the only reliable statement that can be made about 
this parameter is that it has a much lower value than the lowest product of substrate 




Figure 4.6- Steady-state kinetics of B. subtilis HemH and S. aureus HemH 
Steady-state kinetics of B. subtilis HemH (A and B) and S. aureus HemH (C and D). Part A 
shows when CPIII is varied (0-4 µM) and ferrous iron (Fe2+) is held at 107 µM (●), 12 µM (○) 
and 3 µM (■). B shows when Fe2+ is varied (0-100 µM) and CPIII is held at 2.2 µM (●), 1.7 µM 
(○), 1 µM (■) and 0.5 µM (□). These curves were produced using the two-substrate equation 
(equation 2) in a multivariate fit. The calculated kinetics parameters in A were kcat 0.32 ± 0.01 
s-1, KmFe 3.8 ± 0.4 µM, KmCP 0.14 ± 0.02 µM and was constrained KCP.Fe at 0.01 µM2. The 
calculated parameters for B were kcat 0.35 ± 0.01 s-1, KmFe 1.8 ± 0.3 µM, KmCP 0.15 ± 0.05 µM 
and KCP.Fe was held at 0.01 µM2. Graph C shows the activity of S. aureus HemH when the CPIII 
is varied (0-2 µM) and Fe2+ is held at 114 µM (●), 11 µM (○) and 4.5 µM (■). The traces in part 
D show when iron is varied between (0-140 µM) and CPIII is held at 2 µM (●), 1 µM (○) and 
0.6 µM (■). The calculated kinetics parameters in C were kcat 0.44 ± 0.02 s-1, KmFe 0.58 ±  0.05 
µM, KmCP 0.1 ± 0.03 µM and KCP.Fe 0.023 ± 0.2 µM2. The calculated parameters for D were kcat 
0.36 ± 0.02 s-1, KmFe 1.1 ± 0.2 µM, KmCP 0.21 ± 0.06 µM and KCP.Fe was constrained at 0.1 µM2. 
Calculated errors are ± one standard deviation. Each data point was a single reading taken 
from a single cuvette. 
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Table 4.7- Steady-state kinetics values of B. subtilis HemH and S. aureus HemH 
Experiment Parameters B. subtilis HemH S. aureus HemH 
STEADY STATE 
KINETICS 1 
KmCP / μM 0.14 ± 0.02 
0.15 ± 0.05 
0.1 ± 0.03 
0.21 ± 0.06 
KmFe / μM 3.8 ± 0.4 
1.8 ± 0.3 
0.58 ± 0.05 
1.1 ± 0.2 
kcat / s-1 0.32 ± 0.01 
0.35 ± 0.01 
0.44 ± 0.02 
0.36 ± 0.02 
KCP.Fe / μM2 0.01 ± 0 (held) 
0.01 ± 0 (held) 
0.023 ± 0.2 
0.1 ± 0 (held) 
 
Most previous steady state kinetics performed on B. subtilis and S. aureus HemH used 
protoporphyrin IX or porphyrin molecules related to protoporphyrin (deuteroporphyrin 
and mesoporphyrin). Also, the endogenous metal ion Fe2+ is frequently replaced by 
Zn2+ (Hansson and Hederstedt, 1994b, Hansson et al., 2006, Hansson et al., 2007, 
Olsson et al., 2002). The results of those kinetic investigations have shown that the B. 
subtilis enzyme is relatively inactive in those conditions compared to H. sapiens 
ferrochelatase. In this work, kinetic characterisation of B. subtilis HemH the 
endogenous substrates CPIII and Fe2+ have been used, providing a more natural 
insight to function of ferrochelatase.  
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CPIII is more soluble than stable protoporphyrin IX and deuteroporphyrin. As a result, 
detergents such as Tween 20 were not required to solubilise CPIII.  Oxidation of ferrous 
iron was a possible issue but exchanging Fe2+ for Zn2+ presented more problems. Zinc 
can insert into coproporphyrin III without the help of ferrochelatase in an uncatalysed 
reaction. This uncatalysed reaction is fast and high enzyme concentrations are 
required to outcompete the uncatalysed reaction (appendix 7.6.1). As a result, high 
concentrations of substrates are also required to maintain steady-state conditions. 
This prevents inaccurate estimation of kinetic parameters especially as Km values 
were low. An uncatalysed chelation was also observed when Co2+ was used although 
the reaction was slower (unpublished data). 
 
Recent steady-state characterisation has been completed on S. aureus HemH (Hobbs 
et al., 2017, Lobo et al., 2015) and B. subtilis HemH (Bali et al., 2011, Lobo et al., 2015) 
using both of the endogenous substrates (Lobo et al., 2015, Hobbs et al., 2017). In 
these papers there are small changes in the production, purification and 
characterisation of the ferrochelatase that could alter the activity of the enzymes.  
 
The kinetic characterisation of B. subtilis and S. aureus in both papers show that when 
iron is varied and CPIII is held at 1 µM or 10 µM there is significant substrate inhibition 
observed at low concentrations of iron (<12 µM). In this work, this inhibition was not 
observed when these enzymes were assayed where CPIII was held at 2 µM and iron 
was varied (0-200 µM), standard Michaelis-Menten kinetic behaviour was observed. 
In addition, the kcat values were different from those measured in this work (see table 
4.8) and were not consistent with each other. The KmFe values for S. aureus HemH are 
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consistent (0.60, 0.27 and 0.58 µM). The KmFe values for B. subtilis HemH inconsistent 
with at least 10-fold difference (1.8 and 3.8 vs 0.15 µM). In the experiments where 
CPIII was varied (this work and Hobbs et al.) the results are notably different from the 
each other with a 10-fold difference in KmCP values (0.1 and 0.21 vs 1.5 µM). 




kcat / s-1 KmFe / µM KmCP / µM KiFe / µM 
LOBO ET AL. B. subtilis 1.3 ± 0.2 0.15 ± 0.03 ND 2.8 ± 0.5 
S. aureus 2.8 ± 0.9 0.6 ± 0.1 ND 0.8 ± 0.2 
HOBBS ET AL. S. aureus 0.18 ± 0.007 0.27 ± 0.04 1.5 ± 0.2 - 
THIS WORK B. subtilis 0.32 ± 0.01 3.8 ± 0.4 0.14 ± 0.02 - 
0.35 ± 0.01 1.8 ± 0.3 0.15 ± 0.05 - 
S. aureus 0.44 ± 0.02 0.58 ± 0.5 0.1 ± 0.03 - 
0.36 ± 0.02 1.1 ± 0.2 0.21 ± 0.06 - 
 
The differences in the kinetic parameters calculated in all three research groups can 
possibly be explained by different protein constructs used as well as slightly different 
protein expression, purification and assay conditions. In the Lobo et al. paper, the 
plasmid construct is different (gene contained in pET23b rather than pTrcHisA) and 
protein expression of growth media is supplemented with iron. The purification of the 
ferrochelatase follows a standard IMAC and buffer exchange and purified protein is 
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stored in the assay buffer 0.1 M Tris, pH 8 (same assay buffer as in this work). In the 
activity assay the CPIII solubilised in water with a few drops of NH4OH, this consistent 
with the preparation of CPIII in Hobbs et al.  
 
In Hobbs et al., the plasmid construct and protein expression and purification protocols 
are the same as those used in these experiments, the major difference is the 
purification buffers. Hobbs et al. use MOPS and sodium cholate in their buffers, 
sodium cholate has been shown to affect enzymatic activity in H. sapiens 
ferrochelatase (Davidson et al., 2009) and the same is true for S. aureus HemH. In an 
endpoint assay the turnover of substrate by S. aureus HemH in the presence of 
detergent was much slower when compared to the assay in the absence of detergent 
(data incomplete, appendix 7.6.2).The assay buffer for the kinetic assays is also 
different, it contains 0.1 M Tris, 0.5% sodium cholate, 0.5% Tween 20 and 1 mM β-
mercaptoethanol, pH 8.1. It is reasonable to assume that these differences could lead 
to different enzyme activity. 
 
4.5.3. Investigating binding between B. subtilis and S. aureus 
ferrochelatase and their endogenous substrates 
Characterisation of B. subtilis and S. aureus HemH by steady-state kinetics looks at 
the whole of the reaction and not specific steps in the enzymatic mechanism. The kcat 
value determines the rate of the rate-determining step but not which part of the 
mechanism is rate determining. The kcat can be estimated using a standard UV-vis or 
fluorescence spectroscopy however faster steps in the mechanism require other 
techniques such as stopped flow spectroscopy. Stopped flow fluorescence 
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spectroscopy can be used to dissect the enzymatic mechanism of the two 
ferrochelatases and using different experimental designs the rate constants for each 
of the enzymatic step can be deduced.  
 
The first enzymatic step assessed was substrate binding, ferrochelatase binds its two 
substrates in an ordered mechanism, the CPIII binds first and the Fe2+ is second. 
Before using stopped flow fluorescence spectroscopy to deduce the rates of CPIII 
binding, binding equilibrium assays between ferrochelatase and CPIII were performed. 
This allowed the estimation of Kd values for CPIII binding in B. subtilis and S. aureus 
which aided experimental design for the CPIII binding kinetics. 
 
4.5.3.1. Static quenching of tryptophan fluorescence in ferrochelatase 
in the presence of CPIII 
In preparation for assessing the kinetics of substrate binding, static binding assays 
were completed. The ferrochelatases have strong intrinsic tryptophan fluorescence, 
when they are excited at 280 nm an emission peak is detected between 330-510 nm 
with a maximum at approximately 371 nm. This tryptophan fluorescence is quenched 
in the presence of both substrates CPIII.  Emission spectra of ferrochelatase in the 
presence of CPIII show that the peak representing tryptophan fluorescence between 
330-510 nm decreases as the concentration of CPIII increases. Excitation at 280 nm is 
also capable of exciting the porphyrin directly and energy transfer from the tryptophan 
residues to the porphyrin molecule occurs too. This direct excitation and energy 
transfer results in an increase in fluorescence intensity in the two emission peaks 
between 600 and 700 nm that correspond to coproporphyrin (figure 4.9A). The 
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tryptophan emission peak produced by excitation of B. subtilis and S. aureus HemH 
was integrated (330-510 nm) for each concentration of CPIII and the peak areas were 
plotted against CPIII concentration to produce a binding curve (figure 4.9B and C). The 
binding curves for both proteins show tight binding between the enzyme and 
coproporphyrin strongly indicating the formation of a complex between substrate and 
enzyme. The data was fitted to the tight binding equation (equation 3A) and the Kd for 
this interaction was calculated as 0.048 μM (48 nM) for B. subtilis HemH and 0.046 













Figure 4.9 – Static quenching of ferrochelatase tryptophan fluorescence by CPIII 
A shows a representative emission spectra of 50 nM B. subtilis ferrochelatase in the presence 
of increasing concentrations of CPIII (0-8 μM) when excited at 280 nm. The peak at 371 nm 
represents the tryptophan fluorescence and the two peaks between 600-700 nm represent 
emission produced by excitation of porphyrin. Coloured black is emission of FC in the absence 
of CPIII and coloured red is the emission of FC and the highest concentration of CPIII (8 μM). 
The peak representing tryptophan fluorescence of FC is integrated between 330-510 nm and 
plotted against CPIII concentration giving rise to the binding curves in B (B. subtilis) and C (S. 
aureus). Each data point is an average of three and the error bars are ± one standard deviation. 
The curve was fitted using equation 3A and the calculated Kd was 0.048 ± 0.02 μM and 0.046 
± 0.07 μM for B. subtilis and S. aureus HemH, respectively.  
 
 
Ferrous iron binding to ferrochelatase was also tested, ferrous iron is capable of 
quenching the tryptophan fluorescence of ferrochelatase. It can also quench CPIII 
fluorescence indicating that the quenching mechanism may be non-specific (dynamic) 
so Kd values for the interaction between iron and ferrochelatase cannot not be 
determined using this method.  
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4.5.3.2. Using stopped flow fluorescence spectroscopy to deduce the 
rates of CPIII binding to ferrochelatase 
Stopped flow fluorescence spectroscopy was required to deduce the individual rates 
of steps in the enzymatic mechanism of ferrochelatase. The binding equilibrium 
assays revealed that there is tight binding between CPIII and HemH. This data 
provided basic guidelines for investigating CPIII binding by stopped flow fluorescence 
spectroscopy.  
 
The experimental design for assessing CPIII binding involves preparing the enzyme 
and CPIII in two separate syringes, this prevented any interaction between them. The 
reaction was monitored at 280 nm or 393 nm depending on whether the 
coproporphyrin III or ferrochelatase was varied. When investigating the binding in B. 
subtilis HemH both wavelengths were used, and the 280 nm wavelength was used for 
S. aureus, this was because high concentrations of enzyme were unobtainable.  
 
Scheme 1- Two step substrate (CPIII) binding to enzyme (E)  
When monitoring the emission of CPIII the concentration of CPIII was held at 50 nM 
whilst the B. subtilis ferrochelatase concentration was varied between 0.5-5.5 μM. The 
average trace was fit to a single exponential (equation 4A) and the kobs value was 
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calculated.  The kobs value was plotted against ferrochelatase concentration and fitted 
to equation 5.  The curve was consistent with two step binding where the first stage 
was initial binding (KCP) and the second stage was likely a reversible isomerisation 
(kiso) as shown by scheme 1. The rate constant for the backward reaction in step 2 (k-
iso) was held at zero as the data show that k-iso is very small. The KCP was calculated 
as 5.5 μM and the forward reaction in step 2 (kiso) has a rate constant of 46.0 s-1 (figure 
4.10).  
 
Figure 4.10 - CPIII Binding in B. subtilis HemH when ferrochelatase is varied 
The kobs of the reaction for substrate binding when excited at 393 nm, the CPIII concentration 
was held at 50 nM, the ferrochelatase concentration was varied (0.5- 5.5 μM). A curve was 
fitted to the data using equation 5, the calculated KCP and kiso values were 5.5 ± 1 μM, 46 ± 5 
s-1, respectively and k-iso was constrained at zero. Error bars are ± one standard deviation.  
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When monitoring the tryptophan fluorescence of ferrochelatase, a blue cut off filter is 
used, this prevents excitation and emission at the same wavelength and prevents 
emission beyond 600 nm.  The peaks corresponding from direct porphyrin emission 
span 590-700 nm; this means that the filter removes the majority of the emission 
generated from direct excitation of porphyrin. Light in the wavelength range 590-600 
nm is not completely removed by the filter, however the fluorescence intensity here is 
very low (<5 %) compared to the fluorescence intensity at λmax (table 2.4). In addition, 
the transmittance of the filter at this wavelength is also very low. Even in high 
concentrations of porphyrin there is negligible excitation of free porphyrin detected. 
 
When observing tryptophan quenching, the ferrochelatase concentration can be held 
at 0.1 μM and the CPIII concentration is varied (1-70 μM). The traces are similar to 
those observed when exciting the porphyrin. The data was also fitted to a single 
exponential (equation 4A) and the calculated kobs values were plotted against CPIII 
concentration. Again, the data was fitted to equation 5, k-iso was held at zero and the 
curve fitting was distinctly two-step binding in both ferrochelatases (figure 4.11). The 
calculated KCP value was 5.6 μM in B. subtilis HemH and 7.6 μM in S. aureus HemH. 
These two KCP values are similar as their errors overlap. In addition, the two different 
binding kinetics approaches performed on B. subtilis HemH show that the KCP values 
are consistent (5.5 vs 5.6 μM). 
 
The forward rate for the isomerisation (kiso) were calculated as 25 and 70 s-1 in B. 
subtilis and S. aureus HemH, respectively. This shows that isomerisation is almost 
three-fold faster in S. aureus HemH compared to B. subtilis HemH.  The higher rate of 
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isomerisation in S. aureus HemH could explain the slightly higher kcat value observed 
in the steady-state kinetics (section 4.5.3). The two different experimental designs 
(when CPIII concentration is varied and when ferrochelatase concentration is varied) 
in CPIII binding kinetics for B. subtilis HemH are not consistent in their kiso values. 
When CPIII is held at 50 nM and HemH is varied the kiso value is approximately 2-fold 
higher at 46 s-1 compared to 25 s-1. Systematic errors such as inaccurate calculation 
of CPIII and HemH concentration could give rise to this observed discrepancy. A global 
fit was applied to both data sets to check for consistency (appendix 7.6.4); this showed 
that the two datasets were broadly consistent when errors in concentration were 






Figure 4.11 – CPIII binding to B. subtilis and S. aureus ferrochelatase 
A shows the kobs of the reaction for substrate binding in B. subtilis HemH when excited at 280 
nm, the enzyme concentration is held at 0.2 μM and the CPIII is varied (1-60 μM). B shows the 
kobs of the reaction for substrate binding in S. aureus HemH, the enzyme concentration is held 
at 0.2 μM and the CPIII is varied (1-70 μM). Equation 5 was used to fit a curve to the data, a 
representative example is shown in inset on A (black – raw data, red- fitted line). From this 
fitting the KCP, kiso and k-iso values were estimated. In B. subtilis HemH the calculated KCP and 
kiso values were 4.8  0.3 μM and 25  0.4 s-1, respectively and in S. aureus HemH the 
calculated KCP was 7.6  2 μM and the kiso was 70  7 s-1. The error bars are  one standard 
deviation 
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4.5.3.3. Scanning kinetics of the ferrochelatase-CPIII complex   
In conjunction with binding kinetics of CPIII and ferrochelatase, scanning kinetics were 
performed. Initially scanning kinetics were performed at 350-450 nm using the B. 
subtilis HemH. To start CPIII (2 μM) was scanned alone and then 2 μM of 
ferrochelatase was added. The scanning kinetics of this enzyme-substrate complex in 
equimolar concentrations showed a red shift in λmax of the Soret band from 393-405 
nm (figure 4.12). This spectral shift is not evident when steady-state conditions are 
used as there is only a low concentration of the bound complex compared to free 
porphyrin. To determine whether this spectral change was actually due to complex 
formation between B. subtilis ferrochelatase and CPIII a few tests were completed.  
 
A concern was that there may be zinc contamination and this would cause the shift in 
the peak. Zinc can be easily inserted in coproporphyrin III without the help of 
ferrochelatase forming Zn-coproporphyrin III however, when the reaction is spiked with 
10 μM Zn2+ a highly absorbing narrow peak with a λmax at 403 nm forms, indicating 
that the spectral shift does not occur as a result of zinc contamination (figure 4.12A). 
Furthermore, after the enzyme-substrate complex had formed it was treated with ~30% 
ethanol which denatured the ferrochelatase and the Soret band shifted back to 394 
nm, the same λmax as CPIII in the presence of ~30 % ethanol (figure 4.12B), 
demonstrating that the spectral shift is a result of complex formation between HemH 
and CPIII. The spectral shift that occurs in when CPIII binds B. subtilis HemH is also 
observed when CPIII binds to S. aureus HemH (figure 4.13B). 
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Figure 4.12- Determining whether spectral shift is a result of complex formation 
A shows the spectral shift when 2 μM CPIII shown by the (black) complexes with 2 μM B. 
subtilis HemH to give the spectrum coloured blue. The shift is shown by the arrow labelled 1 
and λmax changes from 393 nm to 405 nm. The spectrum given for Zn-coproporphyrin is shown 
in purple for comparison. B shows the spectral shift is due to complex formation between the 
CPIII and ferrochelatase. The spectrum of 2 μM CPIII in assay buffer (λmax 393 nm) and 30% 
ethanol + assay buffer (λmax 394 nm) is shown in black and red, respectively, these are controls. 
Addition of 2 μM ferrochelatase to CPIII in assay buffer causes a red shift in the Soret band 
(λmax 405 nm, blue). After complex formation the solution was added to an ethanol solution to 
form a solution containing the FC-CPIII complex in 30% ethanol which is shown by the orange 
trace (λmax 394 nm). The arrow numbered 1 indicates the initial shift that occurs when enzyme-
substrate complex is formed and the arrow numbered 2 shows a blue shift from 405 nm to 394 
nm which occurs in the presence of 30 % ethanol when the complex breaks apart. 
 
Rapid scanning kinetics were completed so that the spectral shift could be visualised 
on a millisecond time scale. The appearance of one isosbestic point indicated that 
there were two distinct species these an unbound porphyrin and a ferrochelatase 
bound porphyrin species (figure 4.13). Strangely, the rapid scanning kinetics in B. 
subtilis HemH showed the Soret band λmax move from 393 nm to 411 nm, the reason 
for this is unknown. All metal was removed with chelex 100 so metal contamination 
was not the issue, perhaps the batch of enzyme was older and losing activity and so 
different spectral properties were observed. As pseudo-first order conditions were not 
used rate constants for this could not be obtained. 
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Figure 4.13- Rapid scanning kinetics of ferrochelatase and CPIII complex formation 
The spectra show rapid scanning kinetics of B. subtilis (A) and S. aureus (B) complexion with 
CPIII. The spectral shift is measured over 5 s (B. subtilis) or 10 s (S. aureus). The 
concentrations of the ferrochelatases were 1 μM and the CPIII concentration was 0.64 μM. In 
A the λmax of CPIII shifts from 393 nm to 411 nm and in B the λmax of CPIII shifts from 393 nm 
to 405 nm. Each single trace is an average of 10 consecutive scans, this reduced noise. 
 
4.5.4. Investigating iron binding and porphyrin metalation 
The next step in the enzymatic mechanism investigated was iron binding to the 
complex ferrochelatase-CPIII complex and then metalation of the porphyrin. To assess 
these enzymatic steps a combination of stopped flow fluorescence and UV-visible 
spectroscopy was utilised. The experimental design involved preassembling HemH 
and CPIII in equimolar conditions and adding ferrous iron in greater than 10-fold excess, 
the enzymatic scheme that highlights the mechanistic steps that are being investigated 
is shown in scheme 2. 
 
Scheme 2- Iron binding and porphyrin metalation 
 187 
Scanning kinetics were performed to determine the spectra for product formation. 
Addition of 10-fold excess of ferrous iron to the ferrochelatase-CPIII complex shows 
rapid decrease in absorbance at 405 nm (figure 4.14). This shows that 405 nm can be 
used to determine rate constants for iron binding and porphyrin metalation.  
 
Figure 4.14 – Spectral shift upon complex formation in B. subtilis and S. aureus HemH 
The spectral shift upon complex formation of HemH and CPIII is shown with B. subtilis HemH 
(A) and S. aureus HemH (B). CPIII (2 μM) alone is shown by the black spectra, the spectra of 
equimolar CPIII and HemH is blue and the addition of 10-fold excess ferrous iron is red. The 
spectral shift in both proteins moves the λmax of the CPIII Soret band from 393 nm to 405 nm.  
 
4.5.4.1. Investigation of the rates of iron binding and porphyrin 
metalation using stopped flow fluorescence 
After investigating complex formation between CPIII and ferrochelatase using scanning 
kinetics, rates of metal binding and porphyrin metalation were assessed again using 
stopped flow fluorescence spectroscopy. In this experimental design, the reaction was 
excited at 405 nm, the λmax of the Soret band after complex formation between CPIII 
and ferrochelatase. The ferrochelatase and CPIII (1 μM) were incubated together in 
equimolar conditions. Incubation proceeded for a few minutes to ensure all CPIII was 
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bound to the enzyme and was then exposed to 10-fold excess of ferrous iron. Both 
syringes contained 1 μM ferrochelatase so that when they were mixed the 
concentration of ferrochelatase remained constant (1 μM). This design prevents an 
artefactual change in the porphyrin binding equilibrium. This experiment was only 
completed for B. subtilis HemH in with this design (figure 4.15). 
 
The raw traces for these experiments appeared to be single exponential with an 
additional linear phase, as a result they were fit to equation 4B and kobs values were 
estimated.  When the kobs values were plotted against Fe2+ concentration, the data 
was fit to equation 6 and indicated the presence of two steps; iron binding (KFe) and 
porphyrin metalation (kchel). The estimated binding (KFe) and rate constants (kchel) for 






Figure 4.15- Determining the rate of iron binding and porphyrin metalation in B. 
subtilis  
The rate constants for the iron binding and porphyrin metalation in B. subtilis HemH was 
determined using stopped flow fluorescence spectroscopy. The enzyme-CPIII complex was 
preassembled in equimolar conditions 1 μM. The syringe containing ferrous iron (Fe2+) also 
contained 1 μM enzyme. The final concentration of CPIII was 0.5 μM and HemH was 1 μM.  
The Fe2+ concentration was varied between 0-200 μM and the reaction was excited at 405 nm. 
A representative raw data trace is show in the inset in A (raw data – black, fitted curve- red). 
The KFe value were calculated as 90  20 μM for B. subtilis HemH and the kchel value for B. 
subtilis HemH were 16  1.6 s-1. The k-chel values were held at zero and error bars are  one 
standard deviation. 
 
4.5.5. Determining the rate constants in ferrochelatase mechanism 
from the beginning until the rate determining step 
The final experimental design used in the stopped flow spectroscopy looks at the rates 
of all the enzymatic steps in the ferrochelatase mechanism before the rate-determining 
step. The rate determining step occurs after porphyrin metalation and is most likely to 
be product release. The approximate rates for the rate determining step for each 
enzyme are the kcat values gained in the steady state kinetics (sections 4.5.3) 0.32 and 
0.35 s-1 and 0.36 and 0.44 s-1 for B. subtilis and S. aureus HemH, respectively. 
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The experimental design ensures that the ferrochelatase is separate from the 
substrates; the substrates are incubated together and are exposed to ferrochelatase 
at the same time.  The reaction was excited at 393 nm and the enzyme and CPIII 
concentrations were held at 0.2 μM and 2 μM, respectively. The ferrous iron 
concentration was varied between 2-200 μM. The raw traces were similar in 
appearance to those observed in the previous experiment (section 4.5.5.1), where 
there was an exponential phase followed by a linear phase. Using the B. subtilis HemH 
data from the previous two experiments the rate constant (kiso) for CPIII binding (at 2 
μM) and the rate constant for chelation (kchel) were at specific iron concentrations (2, 
3, 4, 5, 10, 20, 80 and 200 μM) were used to fit a double exponential equation 
(equation 4C) to the third stopped flow experiment (figure 4.16). This approach was 
used as the rate constants for kiso and kchel were too similar. As these values were too 
similar it was difficult to distinguish the two separate exponential phases. To 
distinguish between the two exponential phases there must be at a 10-fold difference 
in their rate constants. At lower concentrations of ferrous iron this was obtainable but 
not at ferrous iron concentrations higher than 4 μM. The data analysis of this 
experiment show that it is consistent with the binding kinetics and iron binding and 




Figure 4.16- Determining the rate of enzymatic steps in the B. subtilis HemH 
mechanism prior to the rate-determining step  
The rate of the enzymatic steps prior to the rate determining step in B. subtilis was determined 
using stopped flow fluorescence spectroscopy. The enzyme concentrations and CPIII 
concentration were held at 0.2 μM and 2 μM, respectively. The ferrous iron (Fe2+) 
concentration was varied (2 µM (A), 3 µM (B), 4 µM (C),5 µM (D), 10 µM (E), 20 µM (F), 80 
µM (G) and 200 µM (H)). The porphyrin was excited at 393 nm and progress curves measured 
the change in fluorescence (black). The progress curves were fitted to a double exponential 
equation (equation 4C). The rate of the first exponential phase was held at 7.35 s-1(the rate 
constant for the CPIII binding at 2 µM). The rate of the second exponential phase was held at 
rate constants for the porphyrin metalation at different iron concentrations (0.348 s-1 (A), 0.516 
s-1 (B), 0.681 s-1 (C), 0.842 s-1 (D), 1.60 s-1 (E), 2.91 s-1 (F), 7.51 s-1 (G) and 11.0 s-1 (H). The 
curve fitting for the double exponential equation is shown in red. 
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This stopped flow spectroscopy experiment was also completed in S. aureus HemH. 
However, as the iron binding and porphyrin metalation kinetics were not performed on 
S. aureus HemH the data analysis used on B. subtilis HemH cannot be used. The 
progress curves obtained in this experiment were fitted to a single exponential and a 
linear phase (equation 4B). Fitting to a double exponential equation resulted in a large 
range of values for the second exponential phase. After kobs values were obtained they 
were plotted against iron concentration and fit to equation 7. The estimated KFe value 
was 1.1 μM and the estimated kburst value was 30 s-1 (figure 4.17).  
 
Figure 4.17- Determining the rate of enzymatic steps in the S. aureus HemH 
mechanism prior to the rate-determining step 
The rate of the enzymatic steps prior to the rate determining step in S. aureus was 
determined using stopped flow fluorescence spectroscopy. The enzyme concentrations and 
CPIII concentration were held at 0.2 μM and 2 μM, respectively. The ferrous iron (Fe
2+) 
concentration was varied between 0-200 μM and the reaction was excited at 393 nm. The 
KFe value was estimated as 1.1± 0.2 μM for S. aureus HemH. The kburst value was 30 ± 0.8 s
-
1, respectively. The k-burst values were held at zero and error bars are ± one standard 
deviation.  
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The kburst value is a combined rate constant for kiso and kchel. As the CPIII concentration 
is not at saturating conditions with respect to the KCP values in the binding kinetics (but 
are with respect to KmCP and Kd values) the rate constant calculated is a combination 
of the ferrochelatase isomerisation and iron binding and porphyrin metalation rather 
than just iron binding and porphyrin metalation. The scheme for this reaction is shown 
in scheme 3.  
 
Scheme 3 – Enzymatic scheme of ferrochelatase reaction from start to rate determining 
step 
4.6. Chapter summary 
In this chapter, expression protocols and protein purification of B. subtilis and S. 
aureus HemH have been changed slightly compared to the published methods. B. 
subtilis HemH can be expressed using a standard IPTG induction method and 
purification involves normal IMAC and IEX chromatography. S. aureus HemH must be 
expressed in nutrient rich media with no IPTG protein induction (as stated in the 
literature) but can be purified in the absence of the detergent sodium cholate and 
MOPS following the same protocol previously published  (Hobbs et al., 2017). The 
presence of sodium cholate has shown that the activity of S. aureus HemH is severely 
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impaired (data incomplete, appendix 7.6.2) compared to its activity in the absence of 
detergent. In the absence of detergent, the activity of S. aureus HemH is comparable 
to B. subtilis HemH. Circular dichroism has shown that these two proteins have similar 
structural elements and B. subtilis HemH is more thermostable than S. aureus HemH.  
 
In kinetic characterisation using steady state kinetics the kinetic parameters for each 
of the ferrochelatases were similar, S. aureus HemH seems to have a slightly higher 
kcat value indicating that it is more efficient at releasing metalloporphyrin product. Also, 
its slightly lower Km value for iron (KmFe) means it can work more capably at lower iron 
concentrations compared to B. subtilis HemH. Binding assays and steady state data 
reveal that B. subtilis and S. aureus HemH have the same Km and Kd values for CPIII 











Table 4.16 Calculated kinetic parameters for steady state kinetics and binding assays 
Experiment Parameters B. subtilis HemH S. aureus HemH 
STEADY STATE 
KINETICS 1 
KmCP / μM 0.14 ± 0.02 
0.15 ± 0.05 
0.1 ± 0.03 
0.21 ± 0.06 
KmFe / μM 3.8 ± 0.4 
1.8 ± 0.3 
0.58 ± 0.5 
1.1 ± 0.2 
kcat / s-1 0.32 ± 0.01 
0.35 ± 0.01 
0.44 ± 0.02 
0.36 ± 0.02 
KCP.Fe / μM2 0.02 ± 0 (held) 
0.01 ± 0 (held) 
0.023 ± 0.2 
0.1 ± 0 (held) 
CPIII BINDING 
ASSAYS 
Kd / μM 
 
0.048 ± 0.02 0.046 ± 0.007 
1 Data re-represented for clarity. 
Stopped flow fluorescence spectroscopy was able to show upon binding CPIII the 
ferrochelatases both undergo an isomerisation. The rates for this isomerisation show 
that it occurs much quicker in S. aureus HemH however the KCP values appear lower 
in B. subtilis HemH. The backward reaction for the isomerisation (k-iso) was held at 
zero as this rate is very small. The rate of this can be calculated from the kinetic 
parameters gained in the binding assay and binding kinetics and is estimated as 0.25 
s-1 and 0.42 s-1 in B. subtilis and S. aureus HemH, respectively. The rates acquired in 
these experiments are summarised in table 4.17. 
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A combination of rapid scanning kinetics, standard scanning kinetics and stopped flow 
fluorescence spectroscopy was used to show that a spectral shift occurred when free 
porphyrin became bound to either ferrochelatase. Tests were undertaken to confirm 
that this spectral shift occurred due to complex formation between CPIII and B. subtilis 
ferrochelatase.  In the spectral shift the λmax for the Soret band shifts from 393 nm to 
405 nm, as a result transient kinetics were undertaken using the preassembled 
complex. The complex (in B. subtilis HemH) was excited at 405 nm and revealed that 
there is two step binding. These two steps have been attributed to iron binding and 
porphyrin metalation. The iron binding constant at 90 μM was relatively high and the 












Table 4.17 Calculated kinetic parameters for stopped flow fluorescence spectroscopy 
Stopped Flow  Parameters B. subtilis HemH S. aureus HemH 
CPIII BINDING KCP / μM 4.8 ± 0.3 7.6 ± 2 
kiso / s-1 25 ± 0.4 70 ± 7 
k-iso / s-1 0 ± 0 (held) 0 ± 0 (held) 
IRON BINDING AND 
PORPHYRIN 
METALATION 
KFe / μM 90 ± 20 ND 
kchel / s-1 16 ± 2 ND 
k-chel / s-1 0 ± 0 (held) ND 
ALL STEPS BEFORE 
RATE DETERMINING 
STEP 
KFe / μM - 1.1 ± 0.2 
kburst / s-1 - 30 ± 0.8 
k-burst / s-1 - 0 ± 0 (held) 
 
The final experimental design used in stopped flow looked at the rates of steps in the 
ferrochelatase mechanism prior to the rate determining step.  These were consistent 
with the rates gained in the CPIII binding experiment and the iron binding and porphyrin 
metalation setup (B. subtilis HemH only). These results show that whilst most 
calculated kinetic parameters for the two enzymes have been similar S. aureus is 
generally more capable of producing coproheme from coproporphyrin III. It is likely 
that the slight difference in sequence may be attributed to the difference observed 
between B. subtilis and S. aureus HemH. The enzymatic scheme for the overall 




















5. Defining the role of active site residues in the 
function of the B. subtilis HemH enzymatic 
mechanism 
5.1. Chapter introduction 
B. subtilis is a Gram positive bacterium that utilises the coproporphyrin-dependent 
heme biosynthetic pathway.  The B. subtilis HemH has been extensively studied 
before the discovery of the coproporphyrin-dependent pathway and as a result, our 
view of the structure-function relationship is distorted by the assumption that 
protoporphyrin IX was the substrate. The work presented here addresses the role of 
a set of B. subtilis HemH active site residues in the reaction with CPIII. 
 
Several structures of wildtype B. subtilis HemH and its mutants have been resolved 
using X-ray crystallography (Hansson et al., 2007, Hansson et al., 2011, Hansson et 
al., 2006, Karlberg et al., 2008, Lecerof et al., 2000, Lecerof et al., 2003, Shipovskov 
et al., 2005, Al-Karadaghi et al., 1997) and kinetic characterisation of the wildtype and 
mutant proteins has been performed (Hansson et al., 2007, Hansson et al., 2006, 
Hansson et al., 2011, Shipovskov et al., 2005). The main limitations of these kinetic 
experiments are that the porphyrin substrates used are not endogenous. In the kinetic 
assays performed, the protoporphyrin IX and related molecules such as 
deuteroporphyrin IX and mesoporphyrin IX have been used. As a result, the wildtype 
B. subtilis HemH has appeared relatively inactive compared to the H. sapiens HemH 
and mutation of the active site residues in B. subtilis HemH has reduced the activity of 
the ferrochelatase even more.  
 
 200 
The active site for the B. subtilis HemH is larger than the active site for the H. sapiens 
HemH and so the smaller more planar porphyrin molecules such as protoporphyrin 
can enter the active site of the ferrochelatase. These porphyrin molecules may bind in 
an orientation that is not correct and different to what is expected as shown in the 
crystal structure of B. subtilis HemH and N-methyl mesoporphyrin (Lecerof et al., 
2000). The N-methyl mesoporphyrin bound B. subtilis ferrochelatase structure (PDB 
ID: 1C1H) shows the porphyrin bound in a different orientation to the PPIX bound H. 
sapiens ferrochelatase (PDB: ID 2HRE) (Lecerof et al., 2000, Medlock et al., 2007a) 
shown in figure 1.18. As these smaller molecules can enter the active site of the B. 
subtilis HemH it may indicate why metalation of PPIX is still observed (Hansson et al., 
2007, Hansson et al., 2006). 
 
Additionally, other divalent metal ions have been used in ferrochelatase assays 
instead ferrous iron due to its propensity to oxidise to ferric iron and ferrochelatase 
cannot insert ferric iron into the porphyrin ring. Zn2+ is the most commonly used metal 
ion used in the assays as it does not oxidise however it has its own limitations. For an 
example zinc can insert itself into the porphyrin molecule without the help of 
ferrochelatase (unpublished data), this is much faster when using CPIII compared to 
PPIX. The combination of using the incorrect porphyrin molecule and other divalent 
metal ions in the ferrochelatase assays may not correctly report the actual activity of 
the B. subtilis HemH.  
 
The mutant proteins that have been previously investigated (K87A, H88A, H183A, 
E264Q and E264A) were selected for investigation (see figure 5.1 for location in active 
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site). These mutants were selected as they represent active site residues that are 
thought to be important in the enzymatic mechanism. There is an ongoing debate 
about which active site residues are involved in the key reaction steps; binding iron, 
metalating porphyrin and abstracting protons.  Two main arguments have been 
proposed. The first argument is that the conserved His-Glu pair bind iron and deliver 
it to the porphyrin ring, and the non-conserved face is responsible for proton 
abstraction. In contrast, the second argument proposes that the non-conserved face 
delivers the iron to the porphyrin ring and the pyrrole protons are abstracted by the 
conserved histidine residue(Hansson et al., 2007, Hunter et al., 2016, Sellers et al., 
2001, Dailey et al., 2007, Hoggins et al., 2007). Two of the mutants selected target the 
non-conserved face of the active site (K87A and H88A) and the other three mutants 
target the conserved face of the active site (H183A, E264Q and E264Q), a 
combination of kinetic experiments could give a deeper insight to the enzymatic 






Figure 5.1 – Structure of the B. subtilis HemH active site 
The secondary structure and surface of B. subtilis HemH (PDB:1AK1) are shown in dark grey 
and white, respectively. The non-conserved residues of the active site (K87 and 88) are 
highlighted in teal and labelled. The conserved residues of the active site (H183 and E264) 
are coloured yellow and labelled. The planar ring structure of the porphyrin would most likely 
fit in between these residues. 
 
The five mutants selected were successfully cloned and expressed. The H183A 
mutant was found in inclusion bodies and was not investigated any further. The other 
four mutants (K87A, H88A, E264Q and E264Q) were successfully purified, their 
secondary structures were similar and thermostability was comparable to wildtype. A 
combination of kinetic approaches were used to investigate the activity of each of the 
mutants, the extent of the investigation was dependent on the activity of the mutants. 




5.2. Gene cloning B. subtilis ferrochelatase HemH 
The five B. subtilis HemH mutant genes (K87A, H88A, H183A, E264A, and E264Q) 
were produced using the Q5 mutagenesis kit and the wildtype B. subtilis hemH 
plasmid was the DNA template. The primers were designed so that they were adjacent 
to each other and one primer contained the mutation (table 2.1). After mutagenesis 
the mutated gene was sequenced (GATC Biotech) confirming that only the desired 
change was present.  
 
5.3. Protein expression and purification of active site 
mutants 
Four of the five B. subtilis HemH mutants (K87A, H88A, E264A and E264Q) were 
expressed and purified successfully. The H183A HemH was not successfully purified 
and remained insoluble despite several attempts to solubilise it. Plasmids containing 
the mutated hemH genes were inserted in BL21-DE3 E. coli and grown on LB agar in 
the presence of ampicillin. The large-scale protein expression of each of these mutants 
followed a conventional IPTG induction protocol. The four mutants were purified using 
a 1 mL Talon GraviTrap column. Poor binding to Nickel-NTA HiTrap columns were 
observed. Imidazole was removed using a 20 mL Sephadex G50 column. The purified 
proteins were stored at -80 °C, SDS-PAGE analysis (figure 5.2) demonstrates the 
single step procedure provides pure (>95%) protein. 
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Figure 5.2 – Purification of B. subtilis HemH mutations 
SDS PAGE gel of the purified protein of K87A, H88A, E264A and E264Q compared to wildtype. 
 
5.4. Investigating protein secondary structure and 
thermostability of ferrochelatase active site mutations 
Circular dichroism spectroscopy shows that the B. subtilis HemH mutants contained 
similar structural elements to wildtype B. subtilis HemH (figure 5.3). The CD spectra 
of the HemH mutants was monitored between 200-260 nm.  
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Figure 5.3 – CD spectra of B. subtilis mutants 
The ellipticity of the ferrochelatase mutants was monitored between 200-260 nm. These were 
compared the wild-type (WT) protein shown in black. K87A (green), H88A (yellow), E264A 
(blue) and E264Q (purple) show folding similar to wildtype. All proteins were approximately 4 
µM. 
 
The thermostability of the each of the mutants was tested. The circular dichroism 
signal was monitored at 220 nm and the temperature was increased from 5-100 °C. 
The temperature increase lead to protein unfolding (figure 5.4A) and at 100 °C the 
temperature was slowly dropped to 5 °C to allow protein refolding (figure 5.4B). 
Sigmoidal curves were observed, and these were fit to the equation 1 and Tm values 
for unfolding and refolding in each mutant were estimated.  The Tm values for K87A, 
H88A, E264A and E264Q were 53 °C, 51 °C, 53 °C and 51 °C for unfolding and 49 °C, 
52 °C, 51 °C and 55 °C for refolding, respectively. The calculated Tm values for 
wildtype HemH was 53 °C for unfolding and 52 °C for refolding. This shows that the 
melting temperatures for the mutant proteins are relatively similar to the wildtype, 
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therefore mutation has not affected their thermostability.  More importantly, all of the 











Figure 5.4 –Thermostability of B. subtilis HemH mutants compared to wildtype 
Thermostability of the mutants were tested using circular dichroism, the ellipticity was 
monitored at 220 nm and the temperature was raised from 5 –100 °C, showing each of the 
mutants unfolding (black). The temperature was then dropped from 100 to 5 °C over the same 
timeframe allowing the proteins to refold (red). The thermal melting point (Tm) for unfolding 
and refolding was calculated using equation 1. The calculated Tm values for unfolding were 53 
± 0.2 °C (K87A), 51 ± 0.2 °C (H88A), 53 ± 0.3 °C (E264A) and 51 ± 0.2 °C (E264Q). The 
calculated Tm values for refolding were 49 ± 0.3 °C (K87A), 52 ± 0.4 °C (H88A), 51 ± 0.3 °C 
(E264A) and 55 ± 0.5 °C (E264Q). The unfolding and refolding for the wildtype (WT) protein 
are 53 ± 0.2 °C and 52 ± 0.3 °C, respectively. Each mutant is in one graph K87A (B), H88A 





5.5. Activity assays on the B. subtilis HemH mutants 
The activity of the B. subtilis HemH mutants were compared to the activity of the wild 
type protein in the presence of saturating substrate concentrations. The mutant 
proteins were assayed in the presence of 50 µM ferrous iron and 4 µM CPIII. The H88A 
mutant had activity comparable to wild type. E264Q was completely inactive whereas 
K87A and E264A retained a small fraction of activity. The activity assays are shown in 
figure 5.5. Due to the exceptionally low activity of E264Q, E264A and K87A steady-
state kinetics were not attempted on these mutants. 
 
Figure 5.5- Activity assays of B. subtilis HemH mutants 
Each of the mutants (K87A, H88A, E264A and E264Q) were assayed in the presence of 4 µM 
CPIII and 50 µM Fe2+, the reactions were monitored at 393 nm. The concentration of each of 
the mutants was approximately 0.2 µM. The mutant activity was compared to the wildtype 
(WT) protein.  K87A is shown in green, H88A is shown in yellow, E264A is shown in blue, 
E264Q is shown in purple and WT is shown in black. 
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5.6. Characterising the H88A B. subtilis HemH mutant 
In chapter 4 the wildtype proteins B. subtilis and S. aureus HemH were kinetically 
characterised used several different approaches and these approaches were used to 
characterise the B. subtilis mutants. Firstly, the overall activity of the mutant proteins 
were tested and those that were active enough (H88A HemH) were characterised 
using steady state kinetics. Steady state kinetics looked at the overall enzyme 
mechanism and deduced rate constant for the rate determining step (kcat).  
 
The substrate binding in ferrochelatase is ordered with CPIII binding first and Fe2+ 
binding second. As a result, CPIII binding in the mutants was the first step of the 
enzymatic mechanism isolated for investigation. CPIII static binding assays (monitoring 
intrinsic tryptophan fluorescence) and CPIII binding kinetics were performed to gain 
dissociation constants (Kd and KCP) and rate constants (kiso and k-iso) for CPIII binding. 
In addition, scanning kinetics were performed to observe CPIII binding across a 
wavelength range. Scanning kinetics performed in the presence of the wildtype 
ferrochelatases and CPIII show that the complex formation between the substrate and 
enzyme causes a change in the spectral properties of the CPIII, modelled structure of 




Figure 5.6 – Structure of H88A B. subtilis ferrochelatase 
Overlay of wildtype B. subtilis ferrochelatase (PDB ID: 1AK1, cyan) and a model (generated 
by Swiss-Model (Waterhouse et al., 2018) of the H88A mutant (template used PDB ID:1AK1, 
deep teal), the H88 (wildtype) and A88 (mutant) are shown in sticks and coloured yellow and 
magenta, respectively. The overlay was aligned to PPIX bound H. sapiens ferrochelatase 
(2HRE) to show porphyrin placement in the active site (dark blue) (Al-Karadaghi et al., 1997, 





Binding of the second substrate and resultant porphyrin metalation was assessed next. 
Scanning kinetics established whether the mutant HemH proteins were capable of 
binding iron or metalating porphyrin. Rate and dissociation constants for iron binding 
(KFe) and porphyrin metalation (kchel and k-chel) were determined for the mutant proteins 
that were capable of binding iron and metalating porphyrin (H88A HemH). 
 
Finally, burst kinetics were completed on mutants that were able to turnover substrate. 
Burst kinetics measured rate constants for all enzymatic steps prior to the rate 
determining step (kcat). These burst kinetics can be used to decide whether the results 
obtained in the CPIII binding and the Fe2+ binding experiments were consistent and 
whether additional steps should be added to the mechanism. 
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In these kinetic experiments different spectroscopic conditions were used dependent 
on the experiment completed. Steady state characterisation of the mutant proteins 
monitored the porphyrin absorbance at 393 nm. In the CPIII static binding assays the 
enzymes were excited at 280 nm and emission was recorded from 330 -700 nm. Three 
emission peaks were observed, the peak with a λmax of 371 nm is indicative of emission 
produced from excitation of tryptophan. This peak decreases in intensity as the CPIII 
concentration increases. The two additional peaks correspond to porphyrin 
fluorescence (600-700 nm) and increase in intensity as CPIII concentration increases. 
These peaks result from direct excitation of porphyrin as well as energy transfer from 
tryptophan to porphyrin. 
 
In the binding kinetics and burst kinetics the porphyrin is most commonly excited at 
393 nm and emission is recorded from 405 nm. In the K87A mutant binding kinetics 
the tryptophan residues are excited at 280 nm and emission is recorded from 330-600 
nm, the use of band pass filters removes the signal corresponding to direct excitation 
of porphyrin (table 2.4). In the iron binding and porphyrin metalation kinetics the 
ferrochelatase-CPIII complex was excited at 405 nm for the wildtype proteins whereas 
it is excited at 396 nm for the H88A HemH mutant. These wavelengths are used as 
the spectral properties of free CPIII are different from the ferrochelatase-CPIII in all of 
the mutants. 
 
The B. subtilis H88A HemH mutant is the most active mutant investigated in this 
chapter, as shown in the activity assays in section 5.5. The activity assays show that 
H88A has activity comparable to wildtype this means that a fuller kinetic 
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characterisation must be completed unlike the other mutants (K87A, E264A and 
E264Q) where activity has been significantly affected. In chapter 4, B. subtilis and S. 
aureus HemH were characterised using steady state kinetics and the H88A mutant 
can be characterised in the same way.  
 
5.6.1. Steady state characterisation of H88A HemH 
The previously described experimental design for the characterisation of the wildtype 
proteins provides a convenient starting point for the characterisation of the H88A 
mutant. As previously described, the consumption of the porphyrin substrate can be 
readily be monitored at 393 nm. To maintain the steady state conditions the substrate 
concentrations was at least 10-fold excess over enzyme. A simplified design was used 
where the concentration of one substrate was held at saturation while the other was 
varied. This approach provides good estimates for kcat and Km for both substrates, 
provided the concentration of the fixed substrate is sufficiently close to saturation. 
Initial rates were taken from the progress curves and changed from absorbance units 
into µM using the extinction coefficient for the reaction. 
 
The converted initial rates were converted into vi/[E]T values making them independent 
of enzyme concentration and they were plotted against the substrate concentration. 
Each individual data set was fit to the Michaelis-Menten equation (equation 2B). This 
enabled estimation of each of the kinetic parameters and optimised them for each data 
set (figure 5.7). When CPIII was varied (0-8 µM) the ferrous iron concentration was 
approximately 100 µM, the calculated kinetic parameters for this data were: kcat 0.37 
s-1 and KmFe 28 µM (figure 5.7A). When Fe2+ concentration was varied (0-200 µM) the 
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CPIII concentration was held at 2 µM, the calculated kinetics parameters for this data 
were: kcat 0.46 s-1, KmCP 0.2 µM (figure 5.7B).  
 
The results of steady-state kinetics on the H88A mutant reveal that it has a slightly 
higher kcat value (0.37 and 0.46 s-1) to the wildtype (0.32 and 0.35 s-1) and so the H88A 
mutant slightly faster at turning over substrate compared to wildtype B. subtilis HemH, 
however they appear broadly comparable. The KmCP value of H88A HemH (0.2 µM) is 
comparable to the wildtype protein (0.14 and 0.15 µM) indicating that the mutation 
does not affect the concentration of CPIII corresponding to 50% activity. The KmFe was 
estimated as 28 µM in the H88A mutant and the calculated KmFe value for the wildtype 
is 1.8 and 3.8 µM, which is substantially lower than the mutant thus showing that the 
mutant’s ability to handle the second substrate, ferrous iron, is affected.  
 
In the activity assays the H88A mutant appears to turnover substrate similarly to the 
wild-type, steady state characterisation has shown that whilst this is the case there are 
other factors involving the substrate iron that have been affected due to mutation at 
the His88 residue. To understand the functional implication of the mutation at position 
88, the enzymatic mechanism of the H88A mutant protein was investigated in greater 
detail. Other spectroscopic experiments such as stopped flow fluorescence 
spectroscopy, rapid scanning kinetics and scanning kinetics were performed to isolate 
and assess steps in the enzymatic mechanism.  
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Figure 5.7- Steady state kinetics of H88A B. subtilis HemH 
The traces show the rate of substrate consumption at 393 nm when one substrate is varied 
and the other is held. A shows when CPIII is varied (0-8 µM), ferrous iron (Fe2+) is held at 100 
µM and ferrochelatase concentration is 10 nM. B shows when Fe2+ is varied (0-200 µM); CPIII 
is held at 2 µM and the ferrochelatase concentration is 75 nM. These curves were produced 
using the Michaelis-Menten equation (equation 2B). The calculated kinetic parameters in A 
were kcat 0.46 ± 0.03 s-1 and KmCP 0.20 ± 0.07 µM. The calculated parameters for B were kcat 
0.37 ± 0.02 s-1 and KmFe 28 ± 4 µM. Calculated errors are ± one standard deviation.  
 
5.6.2. CPIII binding to H88A HemH 
In static binding assays, the H88A mutant protein was excited at 280 nm and emission 
was recorded from 310-700 nm in different in concentrations of CPIII (0-100 µM). As 
previously described, the emission spectra show three peaks similar to those observed 
in the wildtype (shown in figure 4.8) and the emission peak with λmax 371 nm was 
integrated. Quenching of tryptophan/tyrosine fluorescence by increased 
concentrations of CPIII show a weak binding relationship between the mutant 
ferrochelatase and CPIII. The weak binding equation (equation 3B) was fitted to the 
data and estimated a Kd value of 5.0 µM (figure 5.8). The wildtype B. subtilis HemH 
shows tight binding and estimates a Kd of 0.048, this shows that the H88A mutant 
binds CPIII approximately 100-fold weaker compared to wildtype. 
 215 
 
Figure 5.8- Static binding assays of H88A B. subtilis HemH 
The emission peak representing tryptophan fluorescence of the H88A mutant was integrated 
between 330-510 nm and plotted against CPIII concentration giving rise to the binding curve 
observed. The curve was fitted using equation 3B, the weak binding equation and the 
calculated Kd was 5.0  0.91 μM. Each data point is an average of three and the error bars 
are  one standard deviation.  
 
 
The results from the steady state characterisation and static binding assays indicate 
that the KmCP value is lower than the Kd value in the H88A mutant protein (0.2 vs 5 
μM). In contrast, the KmCP value is higher than the Kd value in the wildtype protein (0.1 
vs 0.048 μM) and the Km values are similar in both proteins. This shows that 
dissociation constant (KmCP) for the dissociation of CPIII from the ternary complex 
(E’CPIII...Fe) remains the same whereas the dissociation of CPIII from the enzyme-
substrate complex (E’CPIII) significantly increases when histidine is mutated at 
position 88 (Cornish-Bowden, 2012). 
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After static binding assays, binding kinetics were completed to determine the rate 
constants for each stage in the binding of CPIII. As high concentrations of CPIII were 
required to saturate the binding system, kinetics were performed where the intrinsic 
tryptophan fluorescence in ferrochelatase was excited at 280 nm (0.1 µM) and CPIII 
was varied (0-120 µM). The binding progress curves for wildtype B. subtilis HemH 
appeared single exponential and kobs values were estimated by fitting a single 
exponential to the data (equation 4A). In contrast, the H88A mutant shows traces that 
are biphasic and can be described as double exponential. This double exponential 
behaviour observed disappears as CPIII concentration increases (figure 5.9A) making 
it difficult to decipher what has led to this behaviour. When the binding progress curves 
were fitted to the double exponential (equation 4C), the second observed rate constant 
had errors that were comparable to the instrumental signal-to-noise ratio. As a result, 
no further analysis of this second phase was conducted. The existence of this second 
phase could indicate an additional step in the porphyrin binding reaction (porphyrin 
binding is weak so the step could be observed) or it could indicate a small amount of 




Figure 5.9- Stopped flow binding kinetics of H88A B. subtilis HemH 
A shows raw traces of CPIII binding in the H88A mutant. As the concentration of CPIII increases 
(black to light grey) the second phase of the double exponential decreases. B shows the 
estimated kobs values against CPIII concentration, the data is fitted to equation 5. The estimated 
kinetic parameters for the curve fitting are: 15  5.3 µM, 28  2.6 s-1 for KCP and kiso, 
respectively and k-iso was constrained at zero. The error bars are  one standard deviation 
 
The double exponential equation (equation 4C) was fitted to the progress curves 
displaying biphasic behaviour. The single exponential equation (equation 4A) was 
applied to those displaying monophasic behaviour and kobs values were estimated for 
the first exponential phase. The kobs data had similar characteristics to the kinetic 
binding data observed in the wildtype proteins B. subtilis and S. aureus HemH. They 
displayed two-step binding (scheme 1) indicative of initial porphyrin binding followed 
by enzyme/porphyrin isomerisation, this data was fit to equation 5. The estimated KCP 
and kiso values are 15 µM and 28 s-1, respectively and k-iso value was held at zero. The 
KCP value for the H88A mutant is almost three-fold higher than the wildtype protein 
suggesting that it is less able to bind CPIII, this is consistent with the static binding 
assays. The kiso values for the wildtype protein (25 s-1) and H88A mutants (28 s-1) 
 218 
remain similar indicating that the isomerisation after substrate binding is not affected 
by mutation at His88 (figure 5.9B).  
 
In these binding kinetics, the k-iso was held at zero. Binding kinetics on wildtype B. 
subtilis HemH show that the k-iso value is small (0.25 s-1) and therefore no 
distinguishable from zero in the experiment. Holding the k-iso value at zero may not be 
an accurate representation of the data as steady state kinetics and static binding 
assays suggest that CPIII binding overall is likely to be reversible. Estimation of k-iso 
from the binding assays and kinetics in the H88A mutant approximates the rate 
constant as 9.3 s-1. This is large enough to be observed. However, holding the k-iso 
value at 9.3 s-1 results in less optimal fitting, a five-fold higher KCP value (79 µM) and 
similar kiso value (29 s-1). If left unconstrained the k-iso is estimated as 4.6 s-1, the KCP 
value (33 µM) is higher and the kiso value (27 s-1) is similar. This suggests that the kiso 
is consistent despite any changes in k-iso value whereas the accuracy in estimating the 
KCP changes dependent on the value of the k-iso rate constant. 
 
Scheme 1- Two step substrate (CPIII) binding to enzyme (E)  
In addition to static binding assays and binding kinetics, rapid scanning kinetics 
(millisecond time base) were completed on the H88A mutant. In the wildtype protein 
complex formation between ferrochelatase and CPIII causes a spectral shift in the 
Soret band, the λmax shifts from 393 nm to 405 nm. Complex formation between H88A 
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ferrochelatase and CPIII shows that whilst a spectral shift occurs the λmax moves from 
393 nm to 399 nm (figure 5.10). This suggests that the porphyrin molecule is in a 
different environment when bound by the H88A mutant protein when compared to the 
wildtype protein. The H88A mutant or porphyrin molecule may adopt a different 
conformation when bound to each other compared to the wildtype protein. The spectra 
produced during rapid scanning kinetics shows that the shift occurs within 10 s 
(comparable to wildtype).  Accurate rates for this shift cannot be deduced as the 
concentration of CPIII (0.64 µM) and H88A ferrochelatase (1 µM) were not pseudo-first 
order with respect to one another, although the presence of one isosbestic point 
indicates the presence of two species. 
 
Scanning kinetics (second time base) were performed to determine whether any 
further shifting was observed at later time points. Scans were taken for free CPIII (2 
µM) and bound CPIII (2 µM of CPIII and ferrochelatase). This showed a spectral shift 
in the Soret band λmax from 393 nm to 396 nm. Monitoring this shift over a longer time 




Figure 5.10- Rapid scanning kinetics of the H88A mutant 
Rapid scanning kinetics was performed to monitor complex formation between H88A (1 µM) 
and CPIII (0.64 µM). The λmax of the Soret band shifts from 393 nm to 399 nm. Each trace 
shown is an average of 10 raw data traces. Black indicates the first spectrum and blue 
indicates the final spectrum, the red spectra are intermediary spectra (averages of 10 
consecutive scans). 
 
5.6.3. Iron binding and porphyrin metalation in H88A HemH  
The activity assays described in section 5.5 show that mutation of His88 to alanine 
does not significantly affect the function of ferrochelatase, the H88A mutant is capable 
of consuming substrate at rates comparable to the wildtype protein. The mutant is able 
to bind iron and metalate coproporphyrin and so the iron binding and porphyrin 
metalation studies completed on the wildtype protein can also be performed on B. 
subtilis H88A HemH.  
 
Scanning kinetics (second time base) were used determine whether the H88A mutant 
was capable of binding iron and metalating porphyrin similar to the wildtype protein. 
 221 
The enzyme porphyrin complex (2 µM) was scanned before 10-fold excess of ferrous 
iron was added (20 µM) and the absorbance peak at 396 nm drops rapidly, (figure 
5.11), thus showing conclusively that the mutant is capable of porphyrin metalation. 
 
Figure 5.11- Spectral change upon formation of enzyme-substrate complex in H88A 
HemH and subsequent porphyrin metalation after the addition of iron 
Scanning kinetics were performed to show the spectral properties of CPIII binding and 
porphyrin metalation across 350- 450 nm. The black spectrum indicates 2 µM CPIII only (λmax 
393 nm) and the blue spectrum show the spectral shift in the λmax when 2 µM of H88A 
ferrochelatase is added (λmax 396 nm). Upon completion of the shift at least 10-fold iron (20 
µM) was added and the red trace indicates the spectrum after the addition of iron. 
 
After confirming that the mutant is able to bind iron and metalate porphyrin the 
dissociation and rate constants for this part of the mechanism can be determined using 
stopped flow fluorescence spectroscopy. The scanning kinetics revealed that 396 nm 
was a suitable wavelength to use as the spectrum with λmax 396 nm showed stable 
formation of the ferrochelatase-CPIII complex over minutes. The experimental design 
for the transient kinetics were similar to those used for the wildtype in section 4.5.5.1. 
The CPIII and ferrochelatase were incubated in equimolar concentrations (1 µM), this 
ensured that they formed a complex, removing any rate or dissociation constants that 
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were associated with CPIII binding and ensuring that the spectral shift was complete.  
The iron (varied 5-200 µM) was also incubated with ferrochelatase (1 µM), this 
prevented dissociation of the complex upon mixing. When ferrochelatase was not 
incubated with iron the progress curves showed biphasic behaviour, the first phase 
was attributed to the equilibrium between bound and unbound porphyrin. In the 
experiment using the H88A mutant protein, the complex was excited at 396 nm 
whereas the wildtype-CPIII complex was excited at 405 nm. When mixed the final 
concentration of CPIII and H88A HemH were 0.5 µM and 1 µM, respectively. The 
reaction mechanism for this experiment is shown in scheme 2.  
 
Scheme 2- Iron binding and porphyrin metalation 
The raw traces were fitted to equation 4B and kobs values were estimated. The kobs 
values were plotted against ferrous iron concentration and showed data consistent 
with a two-step mechanism. The two steps in the mechanism are iron binding (KFe) 
and subsequent porphyrin metalation (kchel).  Fitting equation 6 to the data calculated 
KFe and kchel as 3.1 µM and 32 s-1, respectively whilst k-chel was constrained at zero 
(figure 5.12). In comparison to the wildtype protein, the H88A mutants has a 30-fold 
lower KFe value (3.1 µM compared to 90 µM) indicating can bind iron more efficiently 
and its kchel value is two-fold higher (32 s-1 vs 16 s-1) suggesting that it can metalate 
porphyrin faster. Previously literature has suggested that iron binding and porphyrin 
metalation may occur too quickly for accurate estimation of rates using stopped flow 
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fluorescence spectroscopy (Hoggins et al., 2007) however the data presented shows 
this is not the case in the B. subtilis ferrochelatase enzyme. 
 
Figure 5.12- Stopped flow fluorescence spectroscopy of iron binding and porphyrin 
metalation in H88A B. subtilis HemH 
The raw data was fitted to equation 4B (single exponential + linear phase) to estimate the kobs 
values. The graph shows the estimated kobs values against Fe2+ concentration fitted to 
equation 6 to give the kinetic parameters KFe and kchel and k-chel. The estimated KFe and kchel 
are 3.1  0.84 µM and 32  1.1 s-1, respectively and k-chel was held at zero. The error bars are 
 one standard deviation. 
 
5.6.4. Calculation of rates in the enzymatic mechanism of B. subtilis 
H88A HemH prior to the rate determining step 
The third and final stopped flow spectroscopy experiment investigates the kinetics of 
the H88A from the start of the enzymatic mechanism until the rate determining step 
(the step corresponding to kcat). Kinetic characterisation of H. sapiens wildtype HemH 
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and H. sapiens E343D HemH has been performed previously. The results of these 
experiments suggest that the rate determining step is product release (Hoggins et al., 
2007). If this is correct then the experiment measures the rate constants for CPIII 
binding, enzyme/porphyrin isomerisation, iron binding and porphyrin metalation 
collectively (see scheme 3 for enzymatic mechanism) as well as any other potential 
steps prior to product release. 
 
Scheme 3 – Enzymatic scheme of ferrochelatase reaction from start to rate determining 
step 
 
The substrates are incubated together and exposed to the H88A mutant at the same 
time. The enzyme concentration is held at 0.2 µM, the CPIII concentration is held at 2 
µM and the ferrous iron is varied from 0-200 µM. The porphyrin is excited at 393 nm 
and its consumption is measured against time. The raw traces represent bursts and 
they initially fit to the same equation 4B allowing the estimation of kobs values.  
 
Fitting of equation 4B (single exponential + linear phase) assumes that only one 
exponential phase was observed, and the raw data looks consistent with this curve 
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fitting. However, studies on CPIII binding (section 5.6.2) and iron binding and porphyrin 
metalation (section 5.6.3) have shown that an exponential phase is observed in each 
experiment and so two exponential phases should be observed in this experiment. 
Exponential phases can only be distinguished from one another easily when there is 
at least a 10-fold difference in their rate constants. In these experiments the two 
exponential phases are too close together and so the only way to determine the 
separate rate constants would be to average more progress curves (25-100) and 
reduce the signal-to-noise ratio significantly.  To overcome this issue rate constants 
were taken from the CPIII binding data and the iron binding and porphyrin metalation 
data and used to fit a double exponential equation (equation 4C) to each of the 
progress curves (figure 5.13). This showed that the results gained from the previous 




Figure 5.13- Stopped flow fluorescence spectroscopy of all enzymatic steps prior to 
the rate-determining step in the H88A mutant 
In this experiment, the substrates were exposed to the ferrochelatase at the same time, the 
enzyme concentration was 0.2 µM, the CPIII concentration was held at 2 µM and the ferrous 
iron was varied (2 µM (A), 4 µM (B), 8 µM (C),12 µM (D), 25 µM (E), 49 µM (F),  98 µM (G) 
and 196 µM (H)). The porphyrin was excited at 393 nm and progress curves measured the 
change in fluorescence (black). The progress curves were fitted to a double exponential 
equation (equation 4C). The rate of the first exponential phase was held at 3.25 s-1(the rate 
constant for the CPIII binding at 2 µM). The rate of the second exponential phase was held at 
rate constants for the porphyrin metalation at different iron concentrations (17.4 s-1 (A), 21.5 
s-1 (B), 24.3 s-1 (C), 25.4 s-1 (D), 26.7 s-1 (E), 27.3 s-1 (F), 27.6 s-1 (G) and 27.8 s-1 (H). The 
curve fitting for the double exponential equation is shown in red. 
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5.6.5. Summary of H88A mutant 
The B. subtilis H88A mutant was successfully expressed and purified and CD 
spectroscopy confirmed that protein folding and thermostability are similar to wildtype. 
Activity assays show that the H88A mutant had comparable activity to wildtype and so 
steady state kinetic characterisation was performed. Steady state kinetics show that 
the KmFe value is higher in the H88A mutant compared to the wildtype ferrochelatase 
indicating that wildtype B. subtilis HemH can work more efficiently at lower iron 
concentration compared to H88A HemH.  The KmCP and kcat values remain similar 
between the wildtype protein and the H88A mutant protein showing that these are not 
greatly affected by the mutation (see table 5.1).  
 
After steady-state characterisation of the H88A mutant, CPIII binding was investigated. 
Static binding assays and binding kinetics show that mutation of H88 to an alanine 
causes higher estimated Kd and KCP values compared to the wildtype protein and this 
is different from the KmCP calculated in the steady-state kinetics. These values are 
reporting on different steps in the enzymatic mechanism, the Kd is the dissociation 
constant for the interaction between ferrochelatase and CPIII, whereas the Km is the 
dissociation constant of the substrate from the ternary complex (when both substrates 
are bound). Whilst a difference is observed in the rate constants involving CPIII, the 
rate constant for the isomerisation of ferrochelatase is similar in the wildtype and 
mutant indicating the mutation has not altered the rate of isomerisation (table 5.1). 
Rapid scanning kinetics and scanning kinetics show that a spectral shift in the Soret 
band occurs when CPIII binds to H88A HemH this is similar to the wildtype, but the 
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shift is less extensive insinuating that the environment of the porphyrin is different 
when bound to the H88A mutant compared to wildtype. 
 
Iron binding and porphyrin metalation were assessed after CPIII binding, scanning 
kinetics showed that the mutant protein was capable of binding iron and metalating 
porphyrin. Transient kinetics were performed to gain rate constants for each of these 
steps. These kinetics showed that the H88A mutant had a lower KFe value and a higher 
kchel value compared to wildtype B. subtilis HemH thus indicating it is more capable of 
iron binding and porphyrin metalation compared to wildtype B. subtilis ferrochelatase. 
Finally, a third stopped flow fluorescence spectroscopy experiment assessed the 
combined rate constants for all of the steps prior to the rate determining steps. This 
showed that the three stopped flow fluorescence spectroscopy experiments were 
consistent (see scheme 4 for full mechanism). 
 
 
Scheme 4- Overall enzymatic mechanism of ferrochelatase 
As the activity of the H88A mutant was comparable to the wildtype, it was 
characterised to the same degree of the wildtype protein. Transient kinetic 
characterisation of the H88A mutant shows that the mutation at the H88 residue is 
detrimental to CPIII binding but is better at iron binding and porphyrin metalation 
compared to the wildtype protein.  
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Table 5.1- Summary table of the H88A mutant activity compared to wildtype 
EXPERIMENT PARAMETERS H88A HEMH WILDTYPE HEMH 1 
STEADY STATE 
KINETICS 
KmCP / µM 0.20 ± 0.07   
 
   
  
0.14 ± 0.02 
 
0.15 ± 0.05 
KmFe / µM 28 ± 4 
   
 
 
3.8 ± 0.4 
 
1.8 ± 0.3 
kcat / s-1 0.37 ± 0.02  
 
0.46 ± 0.03  
 
0.32 ± 0.01 
 
0.35 ± 0.01 
CPIII BINDING 
ASSAYS 
Kd / µM 5.0   0.9 0.048  0.02 
CPIII BINDING 
KINETICS 
KCP / µM 15  5  4.8  0.3 
kiso / s-1 28  3  25  0.4 





KFe / µM 3.1  0.9 90  20 
kchel / s-1 32  1  16  1 
k-chel / s-1 0  0 (held)   0  0 (held) 
1 Wildtype data re-represented for comparison 
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5.7. Characterising the K87A B. subtilis HemH mutant 
The second B. subtilis HemH mutant is K87A HemH, the activity assays (section 5.5) 
showed that this mutant protein has significantly reduced activity compared to the 
wildtype suggesting that it was unable complete part of its enzymatic mechanism. The 
characterisation of the K87A mutant began with assessing its CPIII binding capability. 
 
Figure 5.14 – Structural model of the K87A mutant B. subtilis ferrochelatase overlayed 
with wildtype ferrochelatase 
Overlay of wildtype B. subtilis ferrochelatase (PDB ID: 1AK1, cyan) and a crystal structure of 
the K87A mutant (PDB ID: 2H1V, deep teal), the K87 (wildtype) and A87 (mutant) are shown 
in sticks and coloured yellow and magenta, respectively. The overlay was aligned to PPIX 
bound H. sapiens ferrochelatase (2HRE) to show porphyrin placement in the active site (dark 
blue) (Al-Karadaghi et al., 1997, Medlock et al., 2007a). 
 
5.7.1. CPIII binding to K87A HemH 
Using fluorescence spectroscopy, static binding assays were performed on the K87A 
mutant to determine if it was able to bind its first substrate CPIII. Previous studies with 
the wildtype B. subtilis HemH protein (section 4.5.4) showed that CPIII could bind tightly 
to ferrochelatase. 
 
Analysis of the integrated tryptophan emission peak and the CPIII concentration 
demonstrates that the relationship between the K87A enzyme and substrate is tight 
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binding (figure 5.15). The tight binding equation (equation 3A) was fit to the data and 
a Kd value of 0.016 µM was determined. In comparison, the Kd for the wildtype protein 
was 0.048 µM. This shows that the K87A mutant has 3-fold tighter binding compared 
to the wildtype. The concentration of K87A assayed was 50 nM, higher than the 
calculated Kd value, under these conditions the estimated Kd value depends on the 
accuracy of the protein concentration. Despite this potential limitation it is clear that 
the Kd value is very low and there is tight binding between the K87A ferrochelatase 
and its substrate CPIII. 
 
Figure 5.15– Static quenching of K87A B. subtilis ferrochelatase tryptophan/tyrosine 
fluorescence by CPIII 
The graph shows the quenching of tryptophan/tyrosine fluorescence in the K87A mutant in 
increasing concentrations of CPIII. The enzyme concentration is held at approximately 50 nM 
and the CPIII concentration is varies (0-4 μM). Each point corresponds to the peak area of the 
tryptophan/tyrosine emission peak (330-510 nm) when it is excited at 280 nm. Each data point 
is an average of three measurements and the error bars are ± one standard deviation. The 




The static binding assay of the K87A mutant revealed that there was tighter binding 
with CPIII compared to the wildtype protein. As there is tight binding between the 
enzyme and its substrate the rate constants for this interaction can be determined 
using stopped flow fluorescence spectroscopy. There are two signals in this binding 
experiment that can be used to estimate rate constants: tryptophan/tyrosine 
fluorescence (280 nm) and porphyrin fluorescence (393 nm). Generally, the favoured 
signal is for this experiment is tryptophan/tyrosine fluorescence as this means the 
concentration of CPIII can be varied and a greater range of CPIII can be obtained. When 
the porphyrin signal is used the enzyme, concentration is varied instead. Both signals 
were used to delineate the rate constants for the binding reaction in the K87A mutant 
however, the CPIII signal was more successful. 
 
Scheme 1- Two step substrate (CPIII) binding to enzyme (E)  
To begin with, the tryptophan/tyrosine signal was measured and the K87A mutant 
concentration was held at 0.1 μM. The raw traces obtained at different CPIII 
concentrations (1-4 μM) were fitted to a single exponential equation (equation 4A) and 
the kobs values were estimated (figure 5.16) The kobs data is fitted to equation 5. The 
data shows behaviour consistent with two-step binding, the first step indicates initial 
CPIII binding (KCP) and the second step corresponds to an enzyme/porphyrin 
isomerisation (kiso) (see scheme 1).  
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The calculated KCP for this experiment was 0.48 μM however, the lowest concentration 
of CPIII is above KCP. This means that the estimated KCP is unreliable. The calculated 
kiso value was 43 s-1, which was between 1.5-2-fold faster than the wildtype protein 
whilst the k-iso was held at zero (appendix 7.6.5). However, these experiments were 
preliminary, and analysis of the raw data showed the reaction was fast and timeframe 
for each of the reactions were too long. When shorter timeframes were used there was 
high signal to noise and so more repeats were needed. In these binding kinetics it was 
challenging to measure the kinetics of a tight binding system under pseudo first order 
conditions. The difficulty arose as low concentrations of reagents were required and 
as a result signal changes are exceptionally low. This problem was circumvented by 
using porphyrin signal as it is more intense. In the binding kinetics using porphyrin 
signal, the CPIII concentration (10 nM) was held and the concentration of the K87A 
mutant (0-5 μM) was varied. This meant that the concentration of K87A HemH could 
go lower that the estimate KCP in the first binding experiment. The data was processed 
in the same way as the first binding kinetic experiment.  
 
In second binding kinetic experiment the KCP values were a little higher that those 
previously calculated (0.48 μM compared to 1.3 μM) but still consistently lower than 
the wildtype protein (KCP of 4.8 μM).  The kiso value is also much faster in the second 
setup at approximately 150 s-1 compared to 43 s-1, this shows that the kiso value is 6-
fold faster than the wildtype B. subtilis ferrochelatase.  
 
When equation 5 was fitted to the binding data, three rate constants were calculated, 
KCP, kiso and k-iso. Generally, the k-iso was held at zero this is because binding kinetics 
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on wildtype B. subtilis HemH show that the k-iso value is small (0.25 s-1) and therefore 
close to zero. The k-iso value can be estimated using the parameters calculated from 
the binding assays and binding kinetics, the estimated k-iso value is 1.8 s-1 (calculated 
from the second binding experiment). The calculated parameters for KCP and kiso did 
not change when the k-iso values was held at zero, 1.8 s-1 or left unconstrained. If left 
unconstrained the k-iso value was calculated at 1.7 s-1 and had an error that was 
approximately 10-fold higher. 
 
Figure 5.16 - CPIII binding kinetics of K87A B. subtilis HemH  
The data from the second binding kinetic experiment. The CPIII concentration was held at 10 
nM and the ferrochelatase concentration was varied (0.1-5 μM). Excitation occurred at 393 
nm and the raw traces were averaged and fitted to equation 4A to estimate kobs values. The 
kobs values were plotted against enzyme concentration and equation 5 was fitted to the data. 
The kinetic parameters were estimate and are as follows: KCP was 1.3 ± 0.5 μM and kiso was 
150 ± 20 s-1 and k-iso was held at zero. Error bars are ± one standard deviation. 
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The binding kinetics revealed rate constants for the forward and backward reaction of 
isomerisation (kiso and k-iso) are higher than the wildtype B. subtilis HemH whereas the 
dissociation constant (KCP) is lower in the K87A mutant protein compared to wildtype. 
This shows that the mutant protein can binding CPIII more tightly and isomerise quicker 
as a result it can it is ready to receive iron more quickly when compared to the wildtype 
protein.  
 
After confirming the K87A mutant is capable of binding substrate and deduction of the 
rate constants of the CPIII binding, the next step was to assess the spectral properties 
of the K87A-CPIII complex compared to the spectral properties of free CPIII. Spectral 
analysis of B. subtilis and S. aureus HemH revealed a spectral shift (393-405 nm) 
occurs when porphyrin complexes with the ferrochelatase. The progression of this shift 
indicates the presence of two spectrally distinct species (free porphyrin and bound 
porphyrin) (section 4.5.4.3). 
 
Rapid scanning kinetics (millisecond time base) were used to observe any spectral 
shifts that occur when CPIII binds to the K87A mutant. Monitoring the complex 
formation between the K87A HemH mutant and CPIII indicates that a spectral shift 
occurs, and this is similar to the wildtype HemH proteins (393- 405 nm). However, the 
binding occurs so fast that approximately half of the spectral shift occurs in the dead 
time of the machine, the first spectrum recorded has λmax 400 nm and the shift is 
complete in 0.5 seconds (figure 5.17). This spectral shift is much faster the wildtype B. 
subtilis HemH where the shift was completed by 5 seconds. Spectral analysis of the 
K87A mutant also reveals the presence of two spectrally distinct species. The static 
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binding assays and binding kinetics show that the K87A mutant binds tightly and 




Figure 5.17 – Rapid scanning kinetics of K87A HemH 
The spectra show the rapid scanning kinetics of 1 µM K87A ferrochelatase and 0.64 µM CPIII 
over 0.5 s, the black trace indicates the first spectral reading (λmax 400 nm) and the blue trace 
shows the final reading (λmax 405 nm). Each trace is an average of five consecutive scans. 
 
5.7.2. Iron binding and porphyrin metalation in K87A HemH 
The activity assay performed on the K87A mutant show that it is less active than the 
wildtype protein, this indicates that altering the side chain at position 87 reduces the 
activity of ferrochelatase. The static binding assays, binding kinetics and rapid 
scanning kinetics reveal that the K87A mutant is able to bind its coproporphyrin 
substrate more tightly and faster compared to the wildtype B. subtilis HemH. These 
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results show that the K87A mutation is capable of binding CPIII well and may affect the 
enzyme mechanism due to tighter binding. In order to investigate whether this was the 
reason for the inactivity of the K87A mutation, iron binding and porphyrin metalation 
were assessed. 
 
The next stages that need to be investigated in the enzymatic mechanism of the K87A 
mutant were iron binding and porphyrin metalation. In order to determine iron binding 
and porphyrin metalation in the K87A mutant scanning kinetics (second time base) 
were utilised. Scans in the wavelength range 350-450 nm were taken for free CPIII (2 
µM), the K87A-CPIII complex (2 µM) and when 10-fold excess (20 µM) of ferrous iron 
was added. The reaction was monitored across the wavelength range after the 
addition of the ferrous iron. Addition of 10-fold excess of ferrous iron shows a very 
slow decrease in the 405 nm peak (figure 5.18), suggesting that iron binding and 
porphyrin metalation is very slow.  
 
Scanning kinetics (second time base) can show the full shift from 393-405 nm but 
gives no data on rate of shift as the conditions are not pseudo first order (figure 5.18). 
They are also able to show whether the mutant protein is capable of iron 
binding/metalating porphyrin. Addition of an excess of ferrous iron shows a very slow 
decrease in the 405 nm peak (figure 5.18) and a blue shift back towards 393 nm 
forming a less distinguished broad peak. These spectral shifts suggest that iron 
binding, porphyrin metalation and/or product release is severely affected but still 
occurring. As product is formed slowly transient kinetics were not performed on the 
later stages of the enzymatic mechanism. 
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Figure 5.18 – Scanning kinetics of K87A HemH 
The spectral changes occurring across 350-450 wavelength range in the K87A HemH mutant. 
CPIII (2 µM) only is shown by the black trace, the blue trace shows the formation of the complex 
between K87A HemH (2 µM) and CPIII (2 µM) and an immediate red shift from 393 nm to 405 
nm in the λmax of the Soret band. The red trace shows the spectra immediately after the 
addition of 100 µM of ferrous iron, the purple trace shows the progression of the reaction after 
30 minutes.  
 
5.7.3. Summary of K87A mutant 
The K87A B. subtilis HemH mutant was successful purified and shown to have similar 
secondary structure and thermostability to the wildtype B. subtilis HemH. Activity 
assays show that the K87A mutation greatly reduces the ability for B. subtilis 
ferrochelatase to convert CPIII and ferrous iron into coproheme. Due to the inactivity 
of the K87A mutant, steady state kinetics were not completed. However, fluorescence 
spectroscopy, UV-visible spectroscopy and stopped flow fluorescence spectroscopy 
were used to identify the steps in the enzymatic mechanism that were affected by the 
mutation at Lys87 and those that are responsible for the lack of activity.  
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Static binding assays indicated that the K87A mutant had a lower Kd value for CPIII 
compared to the wildtype ferrochelatase, this was supported by the binding kinetics 
that showed that the KCP values was also lower in the K87A mutant. The isomerisation 
that occurs after CPIII binding was much faster in the K87A mutant indicating that it is 
prepared to receive iron much quicker than the wildtype, this suggests that if CPIII 
binding is responsible for the lack of activity then it will be because of tight binding. 
 
Scanning kinetics (second time base) and rapid scanning kinetics (millisecond time 
base) were performed using UV-visible spectroscopy, these showed that there is a 
spectral shift in the λmax of Soret band from 393 nm to 405 nm when there is complex 
formation between K87A ferrochelatase and CPIII. This observed spectral shift was 
completed in 0.5 seconds compared to the 5 seconds required for the wildtype protein, 
supporting the results of the binding kinetics. The spectra produced in the rapid 
scanning kinetics show that there are two spectrally distinct species corresponding to 
free porphyrin and enzyme bound porphyrin. Scanning kinetics showed that in the 
presence of an excess of ferrous iron the ferrochelatase-CPIII complex is unable to 
turnover substrate very quickly, thus showing that iron binding, porphyrin metalation 
and/or product release is limited in the K87A mutant. As these stages of the enzymatic 
mechanism significantly impaired by mutation at Lys87, the other two stopped flow 
experiments used on the wildtype ferrochelatase were not completed. A summary of 




Table 5.2 – Summary of the K87A B. subtilis HemH kinetics compared to wildtype 
EXPERIMENT PARAMETERS K87A HEMH WILDTYPE HEMH 1 
CPIII BINDING 
ASSAYS 
Kd / µM 
 
0.016  0.01 0.048  0.024 
CPIII BINDING 
KINETICS 
KCP / µM  1.3  0.52  4.8  0.28 
kiso / s-1  150  23 25  0.44 
k-iso / s-1 1.8 (calculated) 0.25 (calculated) 
1 Wildtype data re-represented for comparison 
5.8. Characterising the E264Q and E264A B. subtilis HemH 
mutants 
The E264 residue in B. subtilis HemH is completely conserved in all ferrochelatases 
and research has shown that it is important in the function of ferrochelatase (Hoggins 
et al., 2007, Hunter et al., 2016, Hansson et al., 2007, Sellers et al., 2001, Medlock et 
al., 2007a). Two different mutants were produced for the E264 residue, the first mutant 
E264Q is more conservative, conserving sidechain length and hydrogen bonding but 
removes the negative charge. The second mutant, E264A, completely removes the 
functionality of the glutamate. The activity assays reveal that both mutants are 
substantially less active than the wildtype protein. As a result, steady-state kinetic 
characterisation was not attempted. To discern which part of the enzymatic 
mechanism was affected by mutation at E264 a combination of fluorescence, UV-
visible and stopped flow fluorescence spectroscopy was utilised. 
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Figure 5.19 – Structural models of the E264Q (above) and the E264A (below) B. 
subtilis ferrochelatase mutants 
Above: Overlay of wildtype B. subtilis ferrochelatase (PDB ID: 1AK1, cyan) and a model 
(generated by Swiss-Model (Waterhouse et al., 2018) of the E264Q mutant (template used 
PDB ID:1AK1, deep teal, top), the E264 (wildtype) and Q264 (mutant) are shown in sticks and 
coloured yellow and magenta, respectively. The overlay was aligned to PPIX bound H. sapiens 
ferrochelatase (2HRE) to show porphyrin placement in the active site (dark blue) (Al-
Karadaghi et al., 1997, Medlock et al., 2007a). Below: Overlay of wildtype B. subtilis 
ferrochelatase (PDB ID: 1AK1, cyan) and a model (generated by Swiss-Model (Waterhouse 
et al., 2018) of the E264A mutant (template used PDB ID:1AK1, deep teal, ), the E264 
(wildtype) and Q264 (mutant) are shown in sticks and coloured yellow and magenta, 
respectively. The overlay was aligned to PPIX bound H. sapiens ferrochelatase (2HRE) to 
show porphyrin placement in the active site (dark blue) (Al-Karadaghi et al., 1997, Medlock et 
al., 2007a). 
 
5.8.1. CPIII binding to E264Q/A HemH 
The CPIII binding to the E264Q and E264A mutants was investigated. Static binding 
assays were performed using fluorescence spectroscopy, assessing the ability of CPIII 
to quench the intrinsic tryptophan/tyrosine fluorescence of the E264 mutants. In the 
wildtype protein CPIII binding quenched tryptophan/tyrosine fluorescence and the 
degree of quenching was dependent on the concentration of CPIII. The peak area of 
the tryptophan/tyrosine emission (330-510, λmax 371 nm) was plotted against CPIII 
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concentration, these data showed tight binding and consequently the tight binding 
equation (equation 3A) was fit to the data (figure 5.20). The estimated Kd for the E264Q 
mutant was 0.072 µM and 0.036 µM for the E264A mutant. The Kd value for the 
wildtype protein is 0.048 µM, so in all cases tight binding was observed. 
 
Figure 5.20- CPIII binding assays of the E264Q and E264A mutants 
Fluorescence spectroscopy was used to calculate binding constants (Kd) for the interaction 
between the E264Q/A mutant proteins and CPIII. The mutant ferrochelatase proteins (50 nM) 
were excited at 280 nm and emission was collected. The tryptophan/tyrosine emission peak 
was integrated (330-510 nm) and plotted against CPIII concentration, the resulting graph was 
fitted to equation 3A. A shows the E264Q HemH binding curve where the Kd was estimated 
as 0.056  0.08 µM. B shows the E264A HemH binding curve where the Kd was calculated as 
0.036  0.02 µM. The error bars are  one standard deviation.  
 
The static binding assays showed tight binding between CPIII and the mutant 
ferrochelatases establishing the conditions needed to proceed with investigating CPIII 
binding kinetics. The raw data for these binding kinetics were similar to those observed 
with the wildtype ferrochelatases (B. subtilis and S. aureus) (section 4.5.4.2) and as a 
result they were fit to a single exponential (equation 4A). From these fits kobs values 
were estimated and plotted against CPIII and subsequently fit to equation 5 allowing 
the definition of KCP and kiso (see scheme 1). The k-iso rate constant was assumed to 
indistinguishable from zero (figure 5.21). The calculated k-iso value from the binding 
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assay and kinetic parameters are 2.5 s-1 (E264Q) and 1.4 s-1 (E264A) which are not 
substantially different from each other. When the k-iso values are held at these 
calculated values instead of zero, the estimated for KCP and kiso appears essentially 
unchanged.  
 
Scheme 1- Two step substrate (CPIII) binding to enzyme (E)  
The calculated KCP parameter for the two mutants were similar, for the E264Q mutant 
it was 0.60 µM and 0.75 µM for E264A HemH. The KCP values in these mutants are 6-
8-fold lower than the estimated KCP value in the wildtype protein indicating that they 
bind CPIII more tightly. The kiso values were 21 s-1 and 30 s-1 for E264Q HemH and 
E264A HemH, respectively, these are slightly different and indicate the E264A mutant 
ferrochelatase can isomerise relatively quickly after initial CPIII binding. The kiso value 
for wildtype protein is 25 s-1, it is an intermediate value between the two mutants and 





Figure 5.21- CPIII binding kinetics of the E264Q and E264A mutants using stopped 
flow fluorescence spectroscopy  
The mutant ferrochelatases E264Q (A) and E264A (B) were held at 0.2 µM and excited at 280 
nm whilst the CPIII concentration was varied 0-35 µM. The raw traces averaged and fitted to 
equation 4A and kobs values were estimated. These were plotted against CPIII to give the 
graphs A and B. The calculated kinetic parameters for E264Q (A) were KCP 0.60  0.10 µM, 
kiso 21 0.44 s-1 and k-iso was constrained at zero. The calculated kinetic parameters for E264A 
(B) were KCP 0.75  0.26 µM, kiso 30  1.3 s-1 and k-iso was constrained at zero. The error bars 
are  one standard deviation (small and therefore not visible in A). 
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In addition to estimating the rate constants for the binding of CPIII to the E264 mutant 
proteins, a combination of scanning kinetics (second time base) and rapid scanning 
kinetics (millisecond time base) was used to investigate any spectral shift in the Soret 
band upon enzyme-substrate complex formation. This has been shown to occur in 
both wildtype ferrochelatases described in the previous chapter and the K87A and 
H88A mutant described above. Scanning kinetics instead of rapid scanning kinetics 
were used to assess spectral shift with the E264Q mutant. This was because the final 
stages of the spectral shift were slow (figure 5.22A). The λmax of the Soret band moved 
from 393 nm to 401 nm and this occurred over approximately 20 minutes, much longer 
than the wildtype (5 seconds). As the spectral shift was complete at 401 nm this 
indicates that the porphyrin molecule is in a different environment when bound to the 
E264Q mutant when compared to the wildtype protein. Rapid scanning kinetics were 
utilised to observe the spectral shift in the E264A mutant, the shift in the λmax of the 
Soret band was 393-402 nm and occurred within 10 seconds, a similar time frame to 
the wildtype protein (5 seconds) (figure 5.22B). The spectral changes observed in 
each of the E264 mutants show that they behave differently when compared to each 
other. The spectral shift corresponding to the E264Q mutant protein is very slow 
compared to the spectral shift that occurs when CPIII binds E264A this spectral change 





Figure 5.22- Rapid Scanning kinetics of E264Q and E264A B. subtilis HemH showing a 
spectral shift of CPIII upon binding to HemH 
Scanning kinetics (350-450 nm) of complex formation between CPIII (2 µM) and B. subtilis 
E264Q HemH (2 µM) (A). The black traces shows CPIII alone, the red traces show the shifting 
of the Soret band once 2 µM E264Q ferrochelatase has been added and the blue trace shows 
the final spectrum once the shift has finished, the peak shifts from 393-401 nm. B shows the 
spectral shift of the Soret band using rapid scanning kinetics, the black indicates the first 
averaged spectra, the blue indicates the final averaged spectra and the red indicates 
intermediate spectra, the λmax of the peak shifts from 393-402 nm. Each spectrum shown in 
the rapid scanning kinetics is an average of 10 consecutive traces. 
 
5.8.2. Iron binding and porphyrin metalation in E264Q and E264A 
HemH 
After the deducing the rate constants for CPIII binding and confirming that the spectral 
properties of the enzyme-substrate complex with the E264 mutants, iron binding and 
porphyrin metalation were assessed. Scanning kinetics were used to isolate the iron 
binding and porphyrin metalation steps and investigate whether the mutation affected 
these. Before addition of the enzyme the CPIII shows a characteristic Soret band with 
a λmax of 393 nm. The spectral shift from free CPIII to bound CPIII on adding the mutant 
ferrochelatase (E264Q) was slow (~20 mins) and the λmax of the complex was 401 nm. 
On addition of a 10-fold excess of ferrous the iron the absorbance at 401 nm increases 
slightly and remains stable at the higher absorbance. This indicates that the E264Q 
 247 
mutant is incapable of iron binding or porphyrin metalation and the slight increase in 
absorbance is most likely due to increased scattering caused by the addition of iron 
(figure 5.23A). When investigating the spectral properties of the complex between 
E264A ferrochelatase and CPIII, it appears similar to wildtype (shift from 393- 405 nm). 
The addition of ferrous iron (100 µM) causes a slow decrease in the peak at 405 nm 
(over 105 mins) thus suggesting that the mutant is capable of iron binding or porphyrin 
metalation, but it is severely affected by the mutation (figure 5.23B). The E264A 
mutant protein retains a fraction of activity whereas the E264Q mutant is completely 
inactive. Alanine has a smaller amino acid sidechain compared to glutamine, this leave 
spaces for a water molecule to substitute the mutated glutamate sidechain. The 
presence of the water molecule could lead to the activity observed in the E264A HemH 
protein. As the iron binding or porphyrin metalation in both mutations were reduced, 








Figure 5.23- Scanning kinetics of E264Q and E264A B. subtilis HemH showing a 
spectral shift of CPIII upon binding to HemH 
Standard scanning kinetics (350- 450 nm) show a shift in λmax of the Soret band upon complex 
formation between CPIII and either E264Q HemH (A) or E264A HemH (B). The black traces 
show the spectra of 2 µM of CPIII. The blue traces show the spectra where 2 µM of 
ferrochelatase has been added, in A the shift in λmax is 393-401 nm and in B the shift in λmax is 
393-405 nm. After the shift stabilised excess of ferrous iron was added (20 µM (A) and 100 
µM (B)), the red traces indicate the spectra produced after iron has been added. B shows a 
decrease in absorbance at 405 nm indicating iron binding and porphyrin metalation is 
occurring however this is very slow (105 mins). 
 
5.8.3. Summary of E264Q/A mutants 
Activity assays of the two E264 mutants show that they can either turnover substrate 
very slowly or cannot do this at all. Compared to the wildtype they look almost 
completely inactive and as a result, steady state kinetic characterisation was not 
performed on these mutants. CPIII binding assays show that they are both able to bind 
their substrate CPIII tightly and the estimated Kd values are comparable to wildtype. 
Binding kinetics were performed to deduce the rate constants for CPIII binding and 
these show that the KCP values are much lower that the wildtype and the rate of 
enzyme/porphyrin isomerisation (kiso) is similar compared to wildtype. The lower KCP 
values show that both mutants are better at initial binding than the wildtype protein. In 
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addition, to the binding kinetics a combination of scanning kinetics and rapid scanning 
kinetics were used to identify any shift in the Soret band when CPIII is bound by the 
mutant proteins. The E264Q mutant shows very slow shifting that reaches 401 nm 
rather than the 405 nm observed in the wildtype B. subtilis HemH. However, the 
shifting in the E264A mutant shows rate of shift and degree of shift equivalent to 
wildtype protein (393-405 nm, ~10 seconds).  
 
After determining the degree of spectral shift in the E264 mutant proteins’ ability for 
them to bind iron and metalate porphyrin was tested. Scanning kinetics show that the 
E264Q mutant is completely incapable of binding iron and metalating porphyrin as 
there is no decrease in the absorbance at 401 nm. The E264A mutant is capable of 
turning over substrate however this is very slow, too slow for stopped flow 
fluorescence spectroscopy. Due to the lack of iron binding and porphyrin metalation 
capability, kinetics investigating the rate of iron binding and porphyrin metalation were 
not completed. It is clear that mutation at E264 is detrimental to the function of 
ferrochelatase; it appears to mostly affect the ability of the enzyme during the iron 
binding and porphyrin metalation phase. However, slow product release could be 







Table 5.3- Summary of E264Q and E264A B. subtilis HemH mutants  








Kd / µM 
 
0.072  0.082  0.036  0.020 0.048  0.024 
CPIII BINDING 
KINETICS 
KCP / µM 0.60  0.10 0.75  0.26 4.8  0.28 
kiso / s-1 21  0.44 30  1.3 25  0.44 






1 Wildtype data re-represented for comparison 
5.9. Co-crystallisation of mutant HemH proteins with CPIII 
Currently, there are no resolved crystal structures of any coproporphyrin 
ferrochelatase where CPIII is bound in the active site. In combination with kinetic 
analysis crystallisation of the mutant proteins (K87A, H88A and E264A) in the 
presence of CPIII was attempted. Crystallisation of these and the wildtype protein in 
the presence or absence of CPIII could provide information about the orientation of the 
active site residues in the mutant proteins and when CPIII is bound. Analysing the 
orientation of the active site residues could provide data on the enzymatic mechanism 
and the importance of each residue in the mechanism. 
 
The three mutant proteins and wildtype were purified as usual and concentrated to 
approximately 10 mg mL-1. Pre-crystallisation trials were performed on each of the 
mutant proteins to determine whether they were concentrated to a suitable 
concentration, all mutants were sufficiently concentrated for crystallisation screens. 
Seven standard crystal screens (JSCG+, Morpheus, pH Clear, MPD, Ammonium 
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sulphate, PACT and Proplex) were used for the proteins in the presence of equimolar 
CPIII. Protein crystals did not form in any of these conditions. A custom screen of the 
wildtype protein in the presence of CPIII was attempted. This custom screen contained 
a buffer composition similar to the conditions used to crystallise the wildtype protein 
(PDB ID: 1AK1). This resulted in the crystals that diffracted at 1.8 Å however, the 
protein structure did not contain bound CPIII. The lack of crystal formation could be 
due to homogenous structures within the protein samples as the proteins did not 
undergo SEC prior to crystallisation. Also, when analysing the crystal trays CPIII 
frequently aggregated in the wells which is not surprised given the high concentration 
required. The apoprotein structure of K87A has previously been resolved (PDB: 2H1V). 
 
5.10. Chapter summary 
5.10.1. Overview of chapter results 
Four mutants of the five produced were successfully expressed and purified. CD 
spectroscopy confirmed that they contained secondary structure and their 
thermostability was similar to wildtype. Activity assays showed that K87A, E264Q and 
E264Q HemH had very little activity whereas the H88A mutant had activity comparable 
to the wildtype ferrochelatase.  
 
As the H88A mutant has activity comparable to wildtype, steady state characterisation 
was completed on the mutant, the results of these shown that the H88A mutant has a 
higher Km value for iron and a similar KmCP and kcat values when compared to the 
wildtype protein. This indicates that the H88A mutant is less efficient at low iron 
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concentrations compared to the wildtype. Steady state kinetic characterisation was not 
performed on K87A, E264Q and E264A due to lack of activity. 
 
To identify if the mutant ferrochelatases were still able to bind CPIII, fluorescent binding 
assays were performed. These binding assays show that all four mutants were still 
able to bind CPIII; the E264 mutants bound CPIII similarly to wildtype, the H88A mutant 
was worse at binding CPIII and the K87A was better at binding CPIII when compared 
to the wildtype protein.  Binding kinetics reveal that the most inactive mutants (K87A, 
E264A and E264Q) have lower KCP values than the wildtype whilst the H88A mutant 
has a higher KCP value, this consistent with the binding assays. The isomerisation in 
H88A, E264Q and E264A ferrochelatases are broadly similar to the wildtype and the 
K87A ferrochelatase is significantly faster. The rapid scanning kinetics also show that 
the K87A mutant is much faster at binding and isomerising compared to the other 
proteins.  
 
Investigation into the spectral shift that occurs when CPIII is bound shows that the λmax 
of the Soret band shifts from 393-405 nm in that K87A and E264A HemH (comparable 
to wildtype). The H88A mutant causes a λmax shift from 393-396 nm and E264Q λmax 
shift from 393 nm to 401 nm. The shift in E264Q is much slower than wildtype and 
takes minutes instead of seconds. Scanning kinetics also showed the change in 
spectral properties of the enzyme-substrate complex when 10-fold ferrous iron was 
added. The E264Q mutant remained unchanged indicating no product formation had 
occurred. The K87A and E264A mutant show that production of metalated porphyrin 
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was slow and H88A HemH produced metalated product almost immediately, this is 
similar to the wildtype HemH.  
 
Slow or no formation of metalated porphyrin in the E264A, K87A or E264Q mutants 
meant that transient kinetics were not performed to deduce rate constants for iron 
binding and porphyrin metalation. Transient kinetics were performed on the H88A 
mutant and these showed that the KFe value was lower than wildtype and kchel was 
faster in than wildtype indicating that the H88A mutant was better at iron binding and 
porphyrin metalation. Burst kinetics were completed on the H88A mutant and the rate 
constants from the two previous stopped flow experiments were fitted onto data from 
the third stopped flow spectroscopy experiment. This showed that all three stopped 
flow experiments were consistent. In addition to kinetic characterisation, crystallisation 
screens were attempted to resolve the apoprotein structure and CPIII bound structure 
of the wildtype and mutant proteins (K87A, H88A and E264A). However, protein 
crystals were not produced. 
 
Together these mutants give an insight into how the active site of B. subtilis HemH 
functions, it is clear that the K87A, E264A and E264Q mutations are not tolerated by 




5.10.2. Assessing the role of the residues in the non- conserved 
of the active site 
The K87 residue is part of the non-conserved face of the ferrochelatase active site and 
therefore there are different amino acids at corresponding positions in different species. 
In H. sapiens HemH the corresponding residue is R164 and steady state kinetics 
characterisation has been performed on this residue when it has been mutated 
conservatively to a leucine. Steady state kinetics of R164L reveal that upon mutation 
the Km for the porphyrin and the kcat was unchanged and the KmFe was 2-fold higher 
when compared to the R115L mutant (similar to wildtype) (Sellers et al., 2001). As 
discussed before the K87A mutant in this work retained very little activity and evidence 
indicated that the activity and CPIII binding is affected by mutation, no parameters were 
gained involving iron as turnover was very slow. 
 
Mutation from arginine to leucine shown in Sellers et al. is more conservative than 
lysine to alanine in this work and perhaps the long side chain in lysine, arginine and 
leucine is important for maintaining activity in both species of ferrochelatase. 
Additionally, at this site in both species the residue is a long chain positively charged 
amino acid so whilst they are not completely conserved, they are similar. From these 
experiments Sellers et al. hypothesise that R164 is part of the final metal binding site 
prior to metal insertion, the data displayed here support these hypotheses as iron 
binding and porphyrin metalation was severely affected in the K87A mutant. However, 
these results do not indicate whether metal insertion occurs from the conserved side 
or non-conserved side of the active site, K87 may have a role in proton abstraction 
instead and the same behaviour may still be observed (Sellers et al., 2001).  
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Activity assays have also been performed on the K87A mutant (B. subtilis) using the 
incorrect porphyrin molecule (protoporphyrin IX) and zinc as the metal ion.  These 
showed that the mutant was very active with 92% activity compared to the wildtype. 
The activity of the K87A mutant in the literature is grossly different to the activity of the 
K87A mutant observed here. Stopped flow fluorescence spectroscopy has revealed 
that the K87A mutant is capable of binding CPIII tightly and isomerising quickly 
compared to the wildtype protein. The tighter binding observed could indicate why the 
K87A mutant has limited activity when using its endogenous substrates, the CPIII may 
be bound so tightly it is not released easily whereas protoporphyrin may bind weakly 
and therefore turnover appears comparable to wildtype. However, there is no kinetic 
data to indicate how well protoporphyrin IX binds to B. subtilis K87A HemH (Hansson 
et al., 2007). 
 
 The H88 residue is the other residue on the non-conserved face of the active site that 
has been implicated in the ferrochelatase mechanism. In H. sapiens HemH the 
corresponding residues is Y165, whilst these residues are not identical, they are both 
aromatic and therefore similar. In Sellers et al., Y165 is mutated to phenylalanine 
which conserves the aromatic ring and removes the polar hydroxyl group, this is a 
conservative mutation compared to the conversion of histidine to alanine where there 
is no conservation of polarity or aromatic ring (Sellers et al., 2001). 
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Steady state kinetic characterisation of the Y165F showed a slightly higher KmFe and 
kcat and a slightly lower KmPPIX compared to the wildtype protein. In this work, the KmFe, 
value is higher and the KmCP and kcat values are similar wildtype protein, this is broadly 
consistent with the work completed with the Y165F mutant. The increases in the KmFe 
value observed in the H88A mutant is more drastic, this most likely due to the severity 
of the mutation. Sellers et al., suggests that the Y165 and R164 residues in the H. 
sapiens ferrochelatase make up the final metal binding site prior to porphyrin 
metalation as they have higher KmFe values compared to wildtype and relatively similar 
KmPPIX and kcat values and the data shown in this chapter supports this (Sellers et al., 
2001).  
 
Further investigation into the kinetics of the H88A mutant revealed that CPIII binding is 
actually affected by the mutation. The KCP and Kd values in the mutant are higher 
compared to wildtype and the rate constant for isomerisation subsequent to initial 
binding remains similar.  The spectral shift that occurs when CPIII is bound by H88A 
ferrochelatase is different to the wildtype ferrochelatase further support its ability to 
affect CPIII binding. The iron binding and porphyrin metalation kinetics of the H88A 
HemH show rate constants faster (kchel) and binding constants lower (KFe) than the 
wildtype protein indicating that they are better at iron binding and porphyrin metalation. 
Further assessment of the H88A mutant using transient kinetics and scanning kinetics 
reveal that CPIII binding is the main step affected by mutation.  
 
Kinetic characterisation of the B. subtilis H88A mutant has been attempted before 
however as stated above for the K87A mutant the wrong porphyrin molecule was used. 
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Using protoporphyrin IX instead of CPIII showed that the H88A mutant was only 5% 
active compared to wildtype extremely different from the activity of the H88A mutant 
when CPIII is used. The CPIII binding in the H88A is weak so the binding to 
protoporphyrin could be even weaker and therefore prevent turnover of substrate, 
however, there is no current published binding data for B. subtilis HemH and 
protoporphyrin IX so this cannot be determined. 
 
5.10.3. Assessing the role of the residues in the conserved of the 
active site 
The E264 residue in B. subtilis HemH is completely conserved in all ferrochelatases 
and is part of the conserved face of the active site. This residue is E343 in H. sapiens 
HemH, E289 in M. musculus and E314 in S. cerevisiae. Several kinetic experiments 
have been performed on this residue in all species mentioned above and mutagenesis 
appears to greatly reduce activity in most cases.  
 
Mutation of E314 (S. cerevisiae) to alanine showed that the Vmax and KmPPIX were 
significantly lower and the KmZn was comparable to the wildtype protein.  This is 
consistent with the findings in this work, steady state kinetic characterisation was not 
performed due to lack of activity in both E264Q and E264A. The KCP values in the 
binding kinetics were lower than wildtype but the Kd values in the static binding assay 
were similar. Any kinetic parameter involving iron or zinc was not gained as the mutant 
protein was not active enough (Gora et al., 1996). In the research undertaken by Gora 
et al., they hypothesise that the conserved glutamate residue is involved in proton 
abstraction and the conserved histidine it is paired with, is responsible for iron binding.  
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Activity assays performed on B. subtilis HemH mutants E264V and E264Q show that 
<1% and 21% activity is retained, respectively. However, these mutant proteins were 
assayed using protoporphyrin IX and may not reflect the true activity of the enzyme. 
In the work presented here both E264Q and E264A are very inactive so the results 
are slightly different dependent on the porphyrin molecule used (Hansson et al., 2007). 
 
Steady state kinetic characterisation has also been completed on the E343 mutants in 
H. sapiens HemH. The E343 residues has been mutated to aspartate (E343D), lysine 
(E343K), histidine (E343H) and glutamine (E343Q). The first mutant, E343D, was the 
only mutant that wasn’t inactive suggesting that the negative charge of glutamate is 
important in its role, this is supported by the work here where both mutants (E264Q 
and E264A) are both relatively inactive. Kinetics of the E343D mutant shows the Km 
values for iron and protoporphyrin IX are relatively similar to the wildtype HemH with 
the KmPPIX value being slightly higher in the mutant protein (Sellers et al., 2001).  
 
Transient kinetics has also been performed on this mutant using the third stopped flow 
experiment described in this work. It looks at the rate constants for all enzymatic steps 
prior to the rate-determining step. These show that the KFe and KDIX do not appear to 
change significantly upon mutation of E343D whereas the kburst values were 
approximately 3-fold different (Hoggins et al., 2007). The transient kinetics performed 
on E264Q and E264A show that the iron binding and porphyrin metalation is affected 
by the mutation. The mutants are able to bind CPIII easily but cannot turnover quickly 
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(E264A) or at all (E264Q) (Hoggins et al., 2007) and so kburst values for these mutants 
were not gained. Hoggins et al. suggested that mutation of the E343 residue in H. 



















CpFCs are a recent discovery and ferrochelatases belonging to this group of 
ferrochelatases were previously annotated PpFCs  (Dailey et al., 2015). Theses 
ferrochelatases were reallocated to the CpFC group after the discovery of the 
coproporphyrin-dependent pathway in 2015 (Dailey et al., 2015). As the endogenous 
substrate for CpFCs were assumed to be PPIX, when CpFCs such as B. subtilis 
ferrochelatase was assayed with PPIX or related porphyrin analogues they appeared 
largely inactive when compared to the activity of H. sapiens ferrochelatase (Sellers et 
al., 2001, Hansson and Hederstedt, 1994a, Hansson et al., 2010, Hansson et al., 2007, 
Hansson et al., 2006). The discovery of this new pathway meant that all previous 
kinetic analysis on CpFCs, particularly B. subtilis HemH, did not represent the actual 
capabilities of the ferrochelatase. Since 2015 new literature has been released where 
the correct substrate CPIII has been used in kinetic assays.  This shows that the CpFCs 
are much more active than first observed however, the literature is still very limited 
(Lobo et al., 2015, Hobbs et al., 2017, Dailey et al., 2015).  
 
In addition to kinetic analysis, several structures of B. subtilis HemH have been 
resolved using X-ray crystallography. The apoprotein structure of B. subtilis HemH 
was resolved in 1997 (Al-Karadaghi et al., 1997). When the apo-structure of B. subtilis 
HemH was compared to H. sapiens HemH there was structural conservation between 
the two ferrochelatase types with a few minor differences. The H. sapiens HemH has 
N-terminal and C-terminal extensions, the N-terminal binds to the membrane, the C-
terminal extension contains an iron-sulphur cluster. Both extensions form H-bonds at 
the dimer interface and contribute to dimer formation (Lecerof et al., 2000, Al-
Karadaghi et al., 1997, Wu et al., 2001). A second structure of B. subtilis HemH 
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containing a distorted porphyrin N-MeMP (inhibitor for PpFCs) was structurally 
resolved in 2000 (Lecerof et al., 2000). At the time, analysis of this structure showed 
a potential binding location and orientation within the active site. However, this binding 
location and orientation was different to what was observed in the PPIX bound structure 
of H. sapiens (Medlock et al., 2009). This suggested that N-MeMP binding in B. subtilis 
HemH may not represent the actual binding location and orientation for the porphyrin 
molecule. Despite this, the crystal structures are still useful for further investigation 
into CpFCs. To date, B. subtilis HemH is the most structurally investigated CpFC with 
16 deposited structures (Lecerof et al., 2000, Lecerof et al., 2003, Hansson et al., 2010, 
Karlberg et al., 2008, Hansson et al., 2007, Shipovskov et al., 2005). There is only one 
other CpFC structure deposited, this is the apoprotein structure of Bacillus anthracis 
HemH (PDB ID: 2C8J, paper not published).  
Table 6.1 Crystal structures of B. subtilis ferrochelatase 
PDB ID DESCRIPTION AUTHORS 
3M4Z Co2+ bound in the active site Hansson et al., 2010 
3GOQ Y13M mutant Karlberg et al., 2010 
2Q2O H183C mutant with deuteroporphyrin IX 
2,4-disulfonic acid dihydrochloride bound 
Karlberg et al., 2008 
2Q2N In a complex with deuteroporphyrin IX 2,4-
disulfonic acid dihydrochloride bound 
Karlberg et al., 2008 
2Q3J H183A mutant with N-Methyl 
mesoporphyrin 
Karlberg et al., 2008 
2H1V K87A mutant Hansson et al., 2007 
2H1W H183A mutant Hansson et al., 2007 
2HK6 Fe2+ bound in the active site Hansson et al., 2007 
2AC2 Y13F mutant with Zn2+ bound in the active 
site 
Shipovskov et al.,2005 
2AC4 H183C mutant Shipovskov et al.,2005 
1N0I Cd2+ bound in the active site Lecerof et al., 2003 
1LD3 Zn2+ bound at the active site Lecerof et al., 2003 
1C9E Cu2+ N-methyl mesoporphyrin bound Lecerof et al., 2003 
1C1H N-methyl mesoporphyrin bound Lecerof et al., 2003 
1DOZ Apoprotein structure Lecerof et al., 2000 
1AK1 Apoprotein structure Al-Karadaghi et al., 1997 
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The discovery of the coproporphyrin-dependent pathway also meant that HemQ 
(ChDC), the final enzyme in the pathway, was annotated as a decarboxylase instead 
of a chlorite dismutase. Prior to the discovery of the new pathway there was very little 
published information about HemQ. However, much more information is now available, 
most likely because of its high potential as a therapeutic target (Hofbauer et al., 2016a, 
Hofbauer et al., 2015, Hofbauer et al., 2016b, Hofbauer et al., 2016c, Celis et al., 2015, 
Streit et al., 2016, Dailey and Gerdes, 2015, Dailey et al., 2015, Dailey et al., 2010). 
One recent publication includes the first crystal structure of HemQ from L. 
monocytogenes (PDB ID: 5LOQ), bound to its substrate coproheme (Hofbauer et al., 
2016c). HemQ is of interest in conjunction with HemH as in P. acnes they are fused 
together, this could indicate that the proteins may interact and shuttle substrates from 
one active site directly to the other.  
6.1. Expression and purification of HemH and HemQ from 
different species to determine interaction between two 
consecutive enzymes in the coproporphyrin-dependent 
heme biosynthetic pathway  
In the first results chapter we explored three different hypotheses, the first was whether 
the HemH and HemQ from the species P. acnes form a complex. To test this 
hypothesis, truncations of the P. acnes HemH-Q fusion protein were produced. The 
SEC trace showed formation of a complex between HemHL and HemQS. This 
complex was 1:1. The formation of the complex showed a strong interaction between 
the two proteins.  
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The second hypothesis questioned the substrate transfer mechanism between the two 
proteins. To answer this question the full-length fusion protein was required. Attempts 
were made to purify the full-length protein however; the protein degraded when 
concentrated. Further optimisation of the expression and purification of HemHQ could 
be completed. 
 
To start the expression of the protein could be changed. The expression levels for 
HemH-Q were reasonable but use of a different expression system (e.g. insect cells) 
or expression conditions (temperature, media, cell line, addition of additives, presence 
of chaperones) may have stabilised the protein during expression and prevent the 
cleavage observed. The cell lysis procedure could be optimised, the power level of the 
sonicator could be reduced thereby reducing the chance of protein cleavage. The cell 
lysis method could be altered to lysozyme, a gentle method of lysis. 
 
During the purification of the addition of different stabilising chemicals or proteins could 
reduce protein degradation. The purification buffers could be altered so that they 
promote stability of the protein. This could involve an addition of detergent or glycerol, 
change of pH, increased salt concentration or using a different buffer base (e.g. MOPS 
or HEPES). However, changing the buffer composition could alter the kinetic 
behaviour of the enzyme and as a result any potential substrate transfer assays. 
Additionally, pull down studies could be completed to identify a binding partner that is 
required for stabilisation.  Tryptic digest and mass spectrometry of the degradation 
product has identified the area where cleavage occurs in the full-length fusion protein, 
this could be mutated to prevent degradation however, this could result in misfolding 
protein and the exact site of cleavage is unknown. There is limited literature on the 
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purification of the full-length P. acnes HemH-Q protein. One publication mentions a 
purification but notes that cleavage products were observed when analysed by SDS-
PAGE (Dailey et al., 2010).  
 
The final part of the chapter investigates complex formation between S. aureus HemH 
and HemQ. These two enzymes are not covalently linked unlike the P. acnes HemH-
Q fusion protein. Protein-protein interactions were also tested across species of Gram-
positive bacteria (S. aureus, P. acnes and B. subtilis) using SEC. SEC of S. aureus 
HemH and HemQ showed no interaction occurring between the two proteins and no 
interaction was observed when cross species combinations of HemH and HemQ 
species were used.  
 
SEC relies on strong protein-protein interactions between the two proteins. If the 
interactions are weak or transient, then SEC would show that the proteins do not 
interact. As only one method was used to determine protein-protein interactions 
between the HemH and HemQ other methods could probe protein-protein interactions. 
We have shown that any protein-protein interactions occurring between S. aureus 
HemH and HemQ and cross species HemH and HemQ are not strong enough to be 
observed using SEC.  
 
Coimmunoprecipitation or pulldown assays can also determine whether proteins 
interact with each other, these require an antibody specific to one protein or an affinity 
tag on one protein. As all HemH and HemQ proteins contained his-tags, a nickel resin 
could be used for pulldown assays, but the his-tag would need to be cleaved or 
engineered out of one of the protein constructs. Other techniques that probe protein-
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protein interactions include surface plasmon resonance, analytical ultracentrifugation, 
atomic force microscopy, microscale thermophoresis and co-crystallisation. Surface 
plasmon resonance is frequently used in industry to determine association and 
dissociation constants of the protein-protein interaction.  These techniques may be 
able to differentiate between weak interactions and no interaction. But as the 
hypothesis was that HemH and HemQ form a tight long-lived complex with obligatory 
substrate transfer, SEC is more than adequate to demonstrate that this doesn’t take 
place. 
6.2. Investigating the kinetic properties of B. subtilis and S. 
aureus HemH 
The second results chapter demonstrates the kinetic behaviour of two CpFCs, B. 
subtilis and S. aureus HemH when assayed with their endogenous substrate. Both 
ferrochelatases have not been fully characterised kinetically with the correct substrate 
CPIII. As stated before very little available literature has described the kinetics of either 
ferrochelatase. In this chapter we have demonstrated the CpFCs are more active than 
previously described.  
 
Steps within the mechanism were isolated and examined separately using stopped 
flow fluorescence spectroscopy and scanning kinetics. Rates of CPIII binding were 
calculated using stopped flow fluorescence spectroscopy. This technique revealed 
that CPIII binding was a two-step mechanism, initial binding followed by an 
isomerisation. The initial binding constants and rates of isomerisation are different in 
both proteins. B. subtilis HemH exhibits a tighter initial binding and a slower 
isomerisation rate compared to the S. aureus HemH.  
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The metal binding constant and iron chelation rate constant for the ferrochelatase 
reaction was isolated and investigated using stopped flow fluorescence spectroscopy. 
CPIII binds tightly to ferrochelatase and CPIII in an enzyme-substrate complex has 
different spectral properties when compared to unbound CPIII. This meant that the 
enzyme-substrate complex could be assembled before exposure to iron and 
enzymatic steps subsequent to CPIII binding could be assessed.  This experiment was 
completed using B. subtilis HemH and not in S. aureus HemH. The results of these 
experiment showed two observable kinetic steps that have been attributed to iron 
binding and metal chelation. The rates of iron chelation were previously assumed to 
be very fast (Hoggins et al., 2007) and so could not be accurately determined using 
stopped flow fluorescence spectroscopy. The experiments shown in this chapter show 
that iron chelation is not as fast as predicted and can be estimated using stopped flow 
fluorescence. In fact, the estimate kchel values are actually slower than the estimated 
kiso constants for the ferrochelatase reactions.  
 
Finally, the third stopped flow fluorescence experimental design considered all steps 
prior to the rate determining step in the mechanism of ferrochelatase. The substrates 
were exposed to the ferrochelatase simultaneously. The rate determining step is 
thought to be product release and the work here shows that this is likely to be the case. 
We have shown that the CPIII binding, enzyme/porphyrin isomerisation, iron binding 
and metal chelation stages are not rate determining. This experimental design ensured 
that the previous two experiments (CPIII binding and iron binding and porphyrin 
metalation) were consistent with each other. As the iron binding and porphyrin 
metalation experiment was not completed using S. aureus HemH equation 4B (single 
 267 
exponential + linear phase) was fitted to the raw data of the third experiment.  A double 
exponential equation (equation 4C) was not fitted to this data as accurate estimates 
of the second rate constant could not be obtained without data from the second 
experiment. Completing the iron binding and porphyrin metalation experiment on S. 
aureus would provide the information needed to check for consistency. The main 
caveat for this experiment is producing enough pure protein and protein yields were 
low and large scale up during protein expression would be required. The kburst constant 
for S. aureus HemH was estimated at 30 s-1 this is the combined rate constant of kiso 
and kchel indicating that kchel could be much slower.  
 
Using stopped flow fluorescence spectroscopy, we have shown that there are four 
observable steps in the ferrochelatase mechanism. The three experiments isolate 
particular steps and are consistent with each other. We can confirm that product 
release is most likely to be rate determining and metal chelation is slow enough to be 
observed by stopped flow fluorescence spectroscopy. This information would not have 
been gained using simple steady-state kinetics and can be used to compare the 
potency of inhibitors in rational drug design. Co-crystallisation of the different CpFCs 
with their endogenous porphyrin substrate CPIII could reveal interactions between CPIII 
and ferrochelatase that could also aid drug design.  
6.3. Defining the role of active site residues in the function 
of the B. subtilis HemH enzymatic mechanism 
The final results chapter assesses the activity of mutants of the B. subtilis 
ferrochelatase.  These proteins contain mutations in important active site residues. 
Two of the mutants contain changes to residues in the non-conserved face of the 
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active site whereas the other three mutants have mutations in the conserved face of 
the active site.  In B. subtilis HemH the important residues in the conserved active site 
face are completely conserved in all ferrochelatases, H183 and E264 (B. subtilis 
numbering). The two mutants from the non-conserved active site face were K87A and 
H88A (in B. subtilis HemH). These residues are an arginine and tyrosine in the H. 
sapiens HemH but remain the same in S. aureus HemH. There has been a large 
debate as to which residues are involved in iron binding and porphyrin metalation. All 
the residues mutated (K87, H88, H183 and E264) have been implicated in iron binding 
and porphyrin metalation. 
 
The mutant proteins were kinetically characterised using the same experiments used 
to characterise the wildtype ferrochelatase proteins. Fluorescence spectroscopy 
showed that despite the lack of activity observed in three of the mutants, all four 
mutants were capable of binding CPIII.   
 
Using stopped flow fluorescence spectroscopy, we have shown that the rates and 
binding constants for CPIII binding in the mutants vary when compared to wildtype. We 
have shown that even though all of the mutants are all capable of binding their 
porphyrin substrate, they interact with CPIII differently and as a result this can alter the 
environment of the bound porphyrin and the spectral properties of the CPIII.  
 
When the iron binding and porphyrin metalation ability was tested in each of the mutant 
proteins, we have shown that the H88A mutant was the only one able to bind iron and 
metalate on a time scale observable by stopped flow spectroscopy. The K87A and 
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E264A mutants were only able to bind iron and metalate CPIII very slowly whereas the 
E264Q mutant was completely inactive after CPIII binding.  
 
Finally, the H88A mutant protein was assessed using the third and final stopped flow 
fluorescence experiment. This estimated the rate constants for the step in the 
ferrochelatase mechanism prior to the rate determining step. We have shown that in 
the H88A mutant it is likely that product release remains the rate determining step as 
CPIII binding, enzyme/porphyrin isomerisation, iron binding and porphyrin metalation 
are all faster than the estimated kcat value gained in the steady-state kinetics. The rate 
constants gained from the previous two stopped flow fluorescence experiments using 
the H88A mutant protein were fitted to the raw data gained from the third experiment 
using a double exponential curve (equation 4C). This showed that all three 
experiments are consistent with each other. 
 
Investigation into the B. subtilis ferrochelatase active site mutant proteins originating 
from the conserved and non-conserved face of the ferrochelatase active site cannot 
provide evidence that specifically supports one of the hypotheses for iron binding and 
porphyrin metalation. What has been shown is that all mutants bind their first substrate. 
K87A, E264A and E264Q bind their substrate tightly and H88A binds CPIII weakly. 
Three of the mutants are capable of iron binding and porphyrin metalation. The H88A 
mutant can bind iron and metalate porphyrin more effectively compared to wildtype 
whereas iron binding and porphyrin metalation in the mutant proteins K87A and E264A 
has been severely affected by mutation. The E264Q protein is incapable of binding 
iron and metalating porphyrin and this is the major difference observed between the 
E264A and E264Q mutants. In the K87A and E264A mutants iron binding and 
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porphyrin metalation may have become rate determining however this is difficult to 
determine with the data provided.  
 
Using several different techniques, we have shown how steady-state kinetics are not 
substantial enough for kinetic characterisation of an enzyme. Steady-state kinetics do 
not provide a complete picture of the enzyme mechanism and the steps that are 
affected by mutation. If activity assays and steady-state kinetic were performed to 
characterise the H88A mutant, then it would seem as though the enzyme mechanism 
was not affected by mutation at His88. Stopped flow fluorescence and rapid scanning 
kinetics has shown that the mutation of H88 to an alanine has changed the 
ferrochelatase mechanism substantially and several steps have been affected.  
 
Investigating specific the role of specific active site residues could indicate important 
reaction surfaces that could aid drug design in the absence of crystal structures.  Co-
crystallisation of the mutants with CPIII and apoprotein structures could provide more 
visual information on the interactions occurring in the active site and changes that 
occur when porphyrin is bound. Attempts were made to produce these structures but 
this beared no fruit, there are currently structures of apo-K87A (PDB ID: 2H1V) and 
apo-H183A (PDB ID: 2H1W) deposited in the PDB (Hansson et al., 2007). 
6.4. Future work 
We have demonstrated that there are interactions between P. acnes HemH and HemQ 
truncations and these interactions should be investigated further. The HemH-Q 
complex and the interaction interface between the two proteins could be investigated 
structurally using techniques such as X-ray crystallography, SAXS (small-angle X-ray 
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scattering), SEC-MALS (size exclusion multiple angle light scattering) and AUC 
(analytical ultracentrifugation). MST (microscale thermophoresis), AFM (atomic force 
microscopy) and SPR (surface plasmon resonance) could also deduce binding 
constants for this interaction. Substrate transfer assays could be developed to assess 
the movement of the substrate from one protein to the next and in the P. acnes and S. 
aureus species.  Further attempts could be made to purify the full-length P. acnes 
HemH-Q protein so that it could be used in the substrate transfer assays instead. 
However, the protein may need fluorescent tagging if coproheme is not 
spectroscopically distinct. 
 
With regard to the determining protein-protein interactions between S. aureus HemH 
and HemQ and the cross-species combinations, we have shown that they do not 
interact when tested using SEC.  Other techniques probing protein-protein interactions 
are required. These techniques could be used to check consistency with the SEC 
results and perhaps determine whether weaker interactions occur between HemH and 
HemQ. Probing protein-protein interactions between HemH and HemQ in the 
presence of CPIII would be worth investigating as HemH is known to undergo an 
isomerisation when binding CPIII, this could reveal an interaction surface for HemQ. 
 
In the second results chapter we have kinetically characterised two CpFCs (B. subtilis 
and S. aureus) using several different techniques and experimental designs. Iron 
binding and porphyrin metalation kinetics were not completed in S. aureus HemH. 
These kinetics are required to compare both ferrochelatases completely. After 
complete characterisation using the endogenous substrates the metal and porphyrin 
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substrates can be altered. The metal ions such as Zn2+, Co2+, Ni2+ or Cu2+ could be 
tested to determine differences in the behaviour of the enzyme. A combination of 
different porphyrin molecules could also be assayed. This collection of porphyrins 
could include analogues related to protoporphyrin IX and coproporphyrin III and the 
techniques described in this thesis could help the production of inhibitors specific to 
CpFCs. pH-dependent kinetics and isotopic kinetics could be used in combination with 
the different metals to gain more mechanistic information about metal entry (into the 
active site), metal binding and porphyrin metalation. 
 
In the third results chapter, we have shown that both sides of the B. subtilis 
ferrochelatase active site are important in the function of the enzyme. We targeted 
residues from each of the active site faces and investigated their role in the enzymatic 
mechanism. All of the residues were mutated to alanine (K87A, H88A, H183A and 
E264A) and E264 was also mutated to a glutamine. As K87A, E264A and E264Q were 
very inactive these residues could be mutated to other amino acids that are more 
conservative, for an example E264 could be mutated to aspartate and K87 could be 
mutated to an arginine instead. These mutations could result in substantially higher 
ferrochelatase activity allowing more information to be gained from them. H88A was 
the most active mutant and more experiments could be used to determine the role of 
H88 in the enzymatic mechanism. Other residues in the active site could also be 
mutated to define their importance in ferrochelatase. 
 
To investigate the roles of the H88A mutant further, pH-dependent kinetics or isotopic 
kinetics could be performed alongside the wildtype ferrochelatase. Each of the active 
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site residues have different pKa values this means that changing the active site pH can 
change the protonation state of each of the residues independently. The protonation 
state of some residues will not change (pH independent) but others will be pH-
dependent. Proton abstraction of the porphyrin pyrrole groups and iron entry and 
binding is essential in the ferrochelatase mechanism. If particular residues are 
protonated/deprotonated this could give an insight to residues important in these parts 
of the mechanism. Fine tuning the pH could lead to different protonation/deprotonation 
patterns and therefore different enzymatic activity. This could identify residues 
specifically involved in iron entry and binding and proton abstraction. Equally isotopic 
kinetics could identify residues that readily exchange their protons, this could also help 
identify pathways for metal entry and proton abstraction. Whilst the iron binding and 
porphyrin metalation transient kinetics has shown that there is a difference between 
the wildtype protein and the H88A mutant with regard to iron binding and porphyrin 
metalation, we cannot say conclusively that this is because iron utilises the non-
conserved face of the active site to enter the active site and H88 makes up part of the 
final iron binding site prior to insertion. pH-dependent kinetics may be able to 
determine whether the H88A mutant is important in iron binding prior to insertion or 
proton abstraction. 
 
In this thesis, we have shown a deep kinetic investigation into two CpFCs (B. subtilis 
and S. aureus) and several active site mutants of the B. subtilis ferrochelatase. This 
type of kinetic investigation has not been completed on any ferrochelatase before and 
provides substantial mechanistic information on the ferrochelatase reaction. In 
addition to this kinetic investigation, co-crystallisation of B. subtilis ferrochelatase 
(wildtype and mutants) with CPIII has been attempted to supplement this kinetic data. 
 274 
Finally, protein-protein interactions between HemH and HemQ have been investigated 
in Gram positive bacteria (P. acnes, B. subtilis and S. aureus) to explore a potential 
substrate transfer mechanism. Gaining more data about the CpFCs and their 
interaction partners will aid the development of novel antibiotics targeting the 
coproporphyrin-dependent heme biosynthesis pathway found with Gram positive 

















7.1. Structural alignments to determine domain boundaries 
of P. acnes HemHQ 
7.1.1. P. acnes HemH PRALINE output 
Red indicates alpha helical structure, blue indicates beta sheet structure 
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7.1.2. P. acnes HemQ PRALINE output 
Red indicates alpha helical structure, blue indicates beta sheet structure. P. acnes  
HemQ was start at residue 326. 
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7.2. Plasmid and sequence information for constructs 
7.2.1. P. acnes HemHQ constructs 
7.2.1.1. P. acnes HemHQ truncations 
P. acnes HemHL (2-459) 











Analysis Entire protein 
Length 470 aa 




Isoelectric point 4.99 







































P. acnes HemQS (478-683) 






Analysis Entire protein 
Length 239 aa 




Isoelectric point 6.12 





































P. acnes HemHS (2-330) 








Analysis Entire protein 
Length 343 aa 




Isoelectric point 5.83 






































P. acnes HemQL 








Analysis Entire protein 
Length 366 aa 




Isoelectric point 4.91 








































7.2.1.2. P. acnes HemHQ full length 














Analysis Entire protein 
Length 695 aa 




Isoelectric point 5.14 


















































7.2.2. B. subtilis HemH construct 







Analysis Entire protein 
Length 324 aa 




Isoelectric point 5.06 




































7.2.3. S. aureus HemH and HemQ constructs 
S. aureus HemH 







Analysis Entire protein 
Length 320 aa 




Isoelectric point 5.15 

























S. aureus HemQ 







Analysis Entire protein 
Length 263 aa 




Isoelectric point 5.62 





















7.3. Derivation of kinetics equations 
































































































This can be tidied by multiply all terms by 𝐾𝑖𝐴𝐾𝑚𝐵 
𝑣 =
𝑉+𝑎𝑏
𝐾𝑖𝐴𝐾𝑚𝐵 + 𝐾𝑚𝐵𝑎 + 𝐾𝑚𝐴𝑏 + 𝑎𝑏 
 

































7.3.2. Derivation of equation 3A 
 
Kinetic equation is derived from the scheme above but does not resort to the free 








=  −𝑘𝑜𝑛[𝐸][𝑆] + (𝑘𝑜𝑓𝑓 + 𝑘𝑐𝑎𝑡)[𝐸𝑆] 
𝑑[𝑃]
𝑑𝑡
=  𝑘𝑐𝑎𝑡[𝐸𝑆] 
𝑑[𝐸𝑆]
𝑑𝑡
=  𝑘𝑜𝑛[𝐸][𝑆] − (𝑘𝑜𝑓𝑓 + 𝑘𝑐𝑎𝑡)[𝐸𝑆] 
 
Assume [ES] reaches steady-state 
𝑑[𝐸𝑆]
𝑑𝑡
= 0  𝑘𝑜𝑛[𝐸][𝑆] = (𝑘𝑜𝑓𝑓 + 𝑘𝑐𝑎𝑡)[𝐸𝑆] 
Free Enzyme concentration, [E], is equal to total enzyme concentration, [ET], minus 
[ES]. [S] equals [ET]. 
𝑘𝑜𝑛([𝐸𝑇] − [𝐸𝑆])([𝑆T] − [𝐸𝑆]) = (𝑘𝑜𝑓𝑓 + 𝑘𝑐𝑎𝑡)[𝐸𝑆] 
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Rearrangement gives: 
𝑘𝑜𝑛([𝐸𝑇] − [𝐸𝑆])([𝑆T] − [𝐸𝑆]) = (
𝑘𝑜𝑓𝑓 + 𝑘𝑐𝑎𝑡)
𝑘𝑜𝑛
[𝐸𝑆] =  𝐾𝑀[𝐸𝑆] 
[𝐸𝑆2] − ([𝐸𝑇] + [𝑆𝑇] + 𝐾𝑀)[𝐸𝑆] + [𝐸𝑇][𝑆𝑇] =  0 
This is a quadratic equation; the roots are calculated using: 
(−𝑏 ± √𝑏2 − 4𝑎𝑐)/2𝑎 
Substitute in  
𝑎 = 1 
𝑏 = −([𝐸𝑇] + [𝑆𝑇] + 𝐾𝑀) 
𝑐 =  [𝐸𝑇][𝑆𝑇] 
To give: 
[𝐸𝑆] =  




Then substitute into: 




To give:  
𝑣 = 𝑉𝑚𝑎𝑥  





In the equation 3A used the terms have altered to appropriate notations. F accounts 
for the baseline fluorescence. 




   
7.3.3. Derivation of equation 5,6,7 
 
Differential equations from the scheme above 
𝑑𝐴
𝑑𝑡
= −𝑘1𝐴 + 𝑘2𝐵 
𝑑𝐵
𝑑𝑡
= 𝑘1𝐴 − (𝑘2 + 𝑘3)𝐵 + 𝑘4𝐶 
𝑑𝐶
𝑑𝑡
= 𝑘3𝐵 − 𝑘4𝐶 
In matrix form: 
[
−𝑘1 𝑘2 0


























−(𝑘1 + 𝜆) 𝑘2 0
𝑘1 −(𝑘2 + 𝑘3 + 𝜆) 𝑘4
0 𝑘3 −(𝑘4 + 𝜆)
| = 0 
Divide through by -λ to give this quadratic equation 
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𝜆2 +  𝜆(𝑘1 + 𝑘2 + 𝑘3 + 𝑘4) + (𝑘1𝑘3 + 𝑘2𝑘4 + 𝑘1𝑘4) = 0 
It’s difficult to solve the quadratic but note that  
𝜆1 + 𝜆2 = 𝑘1 + 𝑘2 + 𝑘3 + 𝑘4 
𝜆1𝜆2 = 𝑘1𝑘3 + 𝑘1𝑘4 + 𝑘2𝑘4 
Interest in conditions where only one exponential is visible, this assumes that one step 
is faster than the another. If the first step is the fast step then 𝑘1+ 𝑘2 ≫ 𝑘3 + 𝑘4 
As a result 
  𝜆1+ 𝜆2 ≈ 𝜆1 ≈ 𝑘1 + 𝑘2 
This gives 
𝜆2 = 


































+ 𝑘4   
In the equation 5,6,7 used the terms have altered to appropriate notations.  
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7.4. Protein expression trials 
7.4.1. P. acnes HemHL protein expression gels 
 
7.4.2. P. acnes HemHS protein expression gels 
 
Right is in LB and 2xYT media and left is in auto induction media 
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7.4.3. P. acnes HemQL  protein expression gels 
 
7.5. Purification gels 
7.5.1. P. acnes HemQL purification gel 
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7.5.2. P. acnes HemHQ heat trials 
 
7.5.3. S. aureus HemQ purification gel 
 
 300 
7.6. Additional kinetic data 
7.6.1. Zn uncatalysed  
 


































Red line indicates assay in the presence of detergent, Black line indicates assay 
without detergent (enzyme concentration 0.2 µM, CPIII 4 µM and Fe2+ 50 µM) 
 
Static CPIII binding assay with S. aureus HemH (50 nM) monitoring tryptophan 
quenching in the presence of increasing concentrations of CPIII. The S. aureus  HemH 








7.6.3. Global fit for S.  aureus HemH and B. subtilis HemH steady 
kinetics 
B. subtilis ferrochelatase global fit  
 
Parameter Value 
kcat 0.35 ± 0.01 s-1 
KmFe 2.6 ± 0.4 µM 
KmCP 0.17 ± 0.03 µM 







S. aureus ferrochelatase global fit 
 
Parameter Value 
kcat 0.37 ± 0.02 s-1 
KmFe 1.1 ± 0.5 µM 
KmCP 0.068 ± 0.04 µM 
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